Hosts:

Official Website
2023.apvrs.org

The 16th APVRS

CONGRESS OF THE ASIA-PACIFIC VITREO-RETINA SOCIETY

APVRS 2023 HONG KONG

held in conjunction with

The 3rd Asia-Pacific Ocular Imaging Society Congress
The Asia-Pacific Society of Eye Genetics 2023 Annual Meeting
The 35th Annual Scientific Meeting
Hong Kong Ophthalmological Symposium

December 8-10, 2023

Hong Kong Convention and Exhibition Centre

FINAL PROGRAM

HOST

CO-HOST

CO-SPONSOR

APAO 2024

The 39th Asia-Pacific Academy of Ophthalmology Congress

BALI INDONESIA

In Conjunction with
The 49th Indonesian Ophthalmologists Association Annual Meeting

"BEYOND ALL LIMITS"

To know more updated information about

APAO 2024,

please subscribe to

FACEBOOK
https://www.facebook.com/APAOphth/

TWITTER
https://twitter.com/APAOphth

WECHAT
http://weixin.qq.com/r/OUiFncXEyJi3rYH_9x0r

Congress Website:
https://2024.apaophth.org/
Enquiries: secretariat@apaophth.org





EYLEA®
(aflibercept solution for injection)

INNOVATIVE MECHANISM OF ACTION

VEGF AND PlGF PLAY SIGNIFICANT ROLES IN PATHOLOGICAL ANGIOGENESIS[1,2]



In some retinal diseases, excessive activation of VEGFR1 and VEGFR2 by VEGF and PlGF contribute to vascular permeability, inflammation and neovascularisation, and **lead to PRE cell damage, vessel leakage & edema** [3-7]

EYLEA IS THE ONLY GLOBALLY APPROVED anti-VEGF THAT INHIBITS ALL VEGFR1 AND KEY VEGFR2 LIGANDS, INCLUDING VEGF AND PlGF, TO TARGET THESE DRIVERS OF RETINAL DAMAGE [1,3,8,9]

EYLEA molecule

VEGFR1 domain

VEGFR2 domain

Fc portion of IgG

EYLEA HAS THE LONGEST REPORTED INTRAOCULAR HALF-LIFE AMONG anti-VEGFs [a,10-13]

Eylea	Brolucizumab	Ranibizumab	Bevacizumab	Faricimab
				
9.1-11.0 [10,b]	5.1 [10]	7.2 [11]	9.8 [11,12]	7.5 [13,b]

Estimated human intraocular half-life, days

VEGFR1 domain

VEGFR2 domain

Fc portion of IgG

EYLEA HAS THE HIGHEST REPORTED BINDING AFFINITY TO VEGF-A COMPARED WITH OTHER anti-VEGFs [a,3,14,15]

Eylea	VEGFR1	Brolucizumab	Ranibizumab	VEGFR2	Faricimab
0.49	9.3	28.4	46	88.8	3500 [c]

Kinetic binding to the VEGF family of molecules, pM

Highest binding affinity

Eylea active substance: Aflibercept
Molecular structure is a visual for illustration purpose only.

[a] This information is from separate, independent studies, and must be interpreted carefully. No direct comparison should be made. [b] Assumes that aqueous or serum half-life is equivalent to vitreous half-life [c] Although the VEGF binding affinity for faricimab appears to be significantly weaker than that for aflibercept, these values are from different studies and cannot be directly compared However, when studied together in the same conditions, faricimab demonstrated similar VEGF-A binding affinity to ranibizumab (both k_D values=~ 3000 pM which has a binding affinity approximately 100 times weaker than that of aflibercept.

Abbreviation: DME = diabetic macular edema. Fc= fragment crystallisable. IgG = immunoglobulin G. nAMD = neovascular age related macular degeneration. PlGF = placental growth factor. RVO = retinal vein occlusion. VEGF = vascular endothelial growth factor. VEGFR= vascular endothelial growth factor receptor

Eylea Abbreviated Prescribing Information: Eylea (aflibercept) 40mg/mL solution for intravitreal injection in a vial (Please refer to the full prescribing information before prescribing) **Indication for Use:** Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to the following conditions: macular oedema secondary to retinal vein occlusion (branch or central RVO), diabetic macular oedema (DME), myopic choroidal neovascularisation (myopic CNV). **Composition:** 1mL solution for intravitreal injection contains 40 mg aflibercept. Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. **Posology and Method of Administration:** The recommended dose for Eylea is 2 mg aflibercept, equivalent to 50 microlitres. Eylea is for intravitreal injection only, please do refer to section 6.6 in the full prescribing information for step-by-step instructions for use. **Contraindications:** Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1 of the full PI; Active or suspected ocular or periocular infection; Active severe intraocular inflammation. **Warnings and Precautions: Traceability:** To improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded; **Intravitreal injection-related reactions:** Proper aseptic injection techniques must always be used when administering Eylea. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including those with Eylea. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Eylea while the intraocular pressure is ≥ 30 mmHg). **Immunogenicity:** As this is a therapeutic protein, there is a potential for immunogenicity with Eylea; **Systemic effects:** Non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition; **Populations with limited data:** There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy; **Excipients:** This medicine contains less than 1 mmol sodium (23 mg) per dosage unit; **Incompatibilities:** this medicinal product must not be mixed with other medicinal products; **Storage:** Store in a refrigerator (2°C to 8°C), do not freeze. Store in the original package in order to protect from light. The unopened vial may be stored outside the refrigerator below 25 °C for up to 24 hours. **Adverse Effects: Very common:** Visual acuity reduced, retinal haemorrhage, conjunctival haemorrhage, eye pain. **Common:** Retinal pigment epithelial tear, detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract, cataract cortical, cataract nuclear, cataract subcapsular, corneal erosion, corneal abrasion, intraocular pressure increased, vision blurred, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, lacrimation increased, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival hyperaemia, ocular hyperaemia. **For uncommon and rare adverse reactions, please refer to section 4.8 in the full prescribing information.** (2023 March) (MA-EYL-HK-0007-1) Reference cited as: Eylea 40 mg/mL solution for intravitreal injection in a vial, Hong Kong Prescribing Information (May 2021) **Eylea (aflibercept) 40mg/mL solution for injection in pre-filled syringe** (Please refer to the full prescribing information before prescribing) **Indication for Use:** Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to the following conditions: macular oedema secondary to retinal vein occlusion (branch or central RVO), diabetic macular oedema (DME), myopic choroidal neovascularisation (myopic CNV). **Composition:** 1mL solution for intravitreal injection contains 40 mg aflibercept. One pre-filled syringe contains 90 microlitres, equivalent to 3.6 mg aflibercept. **Posology and Method of Administration:** The recommended dose for Eylea is 2 mg aflibercept, equivalent to 50 microlitres. Eylea is for intravitreal injection only, please do refer to section 6.6 in the full prescribing information for step-by-step instructions for use. **Contraindications:** Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1 of the full PI; Active or suspected ocular or periocular infection; Active severe intraocular inflammation. **Warnings and Precautions: Traceability:** To improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded; **Intravitreal injection-related reactions:** Proper aseptic injection techniques must always be used when administering Eylea. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including those with Eylea. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Eylea while the intraocular pressure is ≥ 30 mmHg). **Immunogenicity:** As this is a therapeutic protein, there is a potential for immunogenicity with Eylea; **Systemic effects:** Non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition; **Populations with limited data:** There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy; **Excipients:** This medicine contains less than 1 mmol sodium (23 mg) per dosage unit; **Incompatibilities:** this medicinal product must not be mixed with other medicinal products; **Storage:** Store in a refrigerator (2°C to 8°C), do not freeze. Store in the original package in order to protect from light. The unopened vial may be stored outside the refrigerator below 25 °C for up to 24 hours. After opening the blister, proceed under aseptic conditions. **Adverse Effects: Very common:** Visual acuity reduced, retinal haemorrhage, conjunctival haemorrhage, eye pain. **Common:** Retinal pigment epithelial tear, detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract, cataract cortical, cataract nuclear, cataract subcapsular, corneal erosion, corneal abrasion, intraocular pressure increased, vision blurred, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, lacrimation increased, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival hyperaemia, ocular hyperaemia. **For uncommon and rare adverse reactions, please refer to section 4.8 in the full prescribing information.** (July 2022) (PP-M_AFL-HK-0021-1) Reference cited as: Eylea 40 mg/mL solution for injection in pre-filled syringe, Hong Kong Prescribing Information(May 2021)

Reference 1. Uemura A, et al. Prog Retin Eye Res 2021;84:100954. **2.** Van Bergen T, et al. Prog Retin Eye Res 2079;69:116-136. **3.** Papadopoulos N, et al. Angiogenesis 2012;15:171–185. **4.** Bhagat N, et al. Surv Ophthalmol 2009;54:1–32. **5.** Daruich A, et al. Prog Retin Eye Res 2018;63:20–68. **6.** Whitcup SM, et al. Int J Inflam 2013;2013:724648. 7. Kovacs K, et al. Invest Ophthalmol Vis Sci 2015;56:6523–6530 **8.** Autiero M, et al. J Thromb Haemost 2003;1:1356–1370. **9.** Fischer C, et al. Nat Rev Cancer 2008;8:942–956. **10.** Eissing T, et al. Trans Vis Sci Technol 2021; 109 **11.** Krohne TU et al. Am J Ophthalmol 2012;154:682-686 **12.** Krohne TU et al. Am J Ophthalmol 2008;146:508-512 **13.** Vabysmo US Prescribing Information 2022 **14.** Beovu FDA drug approval package 2019 **15.** Regula JT, et al. EMBO Mol Med 2016;8:1265-1288

For further prescribing information, please contact:

Bayer HealthCare Limited

14/F, Oxford House, Taikoo Place
979 King's Road, Quarry Bay, Hong Kong
Tel: (852) 8100 2755 Website: www.bayer.com

PP-EYL-HK-0306-1

EYLEA®
(aflibercept solution for injection)

offers you and your patients

GAINS BEYOND VISION

GAIN LETTERS
Robust visual gains

nAMD ALTAIR

+9.0
LETTERS

at Week 52 with proactive T&E 2-week extension [1]

DME VIVID and VISTA

+10.7
LETTERS

at Week 52 with early and intensive treatment [2]

GAIN INNOVATION
Designed to last

EYLEA® targets both VEGF and PlGF with high binding affinity and **long-lasting VEGF suppression** [3,4]

GAIN FREEDOM
Extend with confidence

The only anti-VEGF with the freedom to proactively extend intervals from q4 to q16 based on RCT data in patients with nAMD [5,6,7]

In ALTAIR, 96% of patients who achieved Q16 dosing in the 2-week extension group, remained on Q16 to the end of Year 2 [1,a]

GAIN TIME
Visual gains that last

In nAMD, gains achieved at Year 1 were **maintained up to Year 4** in both RCTs and in the real world [8,9]

In DME, initial gains were **maintained through Year 5** with fewer injections over time [10]

GAIN CONFIDENCE
Real-world outcomes you can trust

Well-established ocular and systemic safety [5]

>70
million

doses worldwide [11]

Long-term real-world outcomes similar to RCTs [8-10]

[a]Between Weeks 16 and 96, 43.1% (n=53) and 54.5% (n=67) of patients (2-week and 4-week adjustment groups, respectively) were extended to a maximum treatment interval of 16 weeks at least once. Of these patients, 96.2% of patients (n=51 of 53) in the 2-weeks adjustmen group and 77.6% of patients (n=52 of 67) in the 4-weeks adjustment group maintained a 16-week treatment interval until the end of the study.[1]

Abbreviations: CNV, choroidal neovascularisation. DME, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. PlGF, placental growth factor. RCT, randomised controlled trial. RVO, retinal vein occlusion. T&E, treat and extend. q4, every 4 weeks. q16, every 16 weeks. VEGF, vascular endothelial growth factor.

Eylea Abbreviated Prescribing Information: Eylea (aflibercept) 40mg/mL solution for intravitreal injection in a vial (Please refer to the full prescribing information before prescribing) **Indication for Use:** Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to the following conditions: macular oedema secondary to retinal vein occlusion (branch or central RVO), diabetic macular oedema (DME), myopic choroidal neovascularisation (myopic CNV). **Composition:** 1mL solution for intravitreal injection contains 40 mg aflibercept. Each vial contains 100 microlitres, equivalent to 4 mg aflibercept. **Posology and Method of Administration:** The recommended dose for Eylea is 2 mg aflibercept, equivalent to 50 microlitres. Eylea is for intravitreal injection only, please do refer to section 6.6 in the full prescribing information for step-by-step instructions for use. **Contraindications:** Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1 of the full PI; Active or suspected ocular or periocular infection; Active severe intraocular inflammation. **Warnings and Precautions: Traceability:** To improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. **Intravitreal injection-related reactions:** Proper aseptic injection techniques must always be used when administering Eylea. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including those with Eylea. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Eylea while the intraocular pressure is ≥ 30 mmHg). **Immunogenicity:** As this is a therapeutic protein, there is a potential for immunogenicity with Eylea; **Systemic effects:** Non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition; **Populations with limited data:** There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy; **Excipients:** This medicine contains less than 1 mmol sodium (23 mg) per dosage unit; **Incompatibilities:** this medicinal product must not be mixed with other medicinal products; **Storage:** Store in a refrigerator (2°C to 8°C), do not freeze. Store in the original package in order to protect from light. The unopened vial may be stored outside the refrigerator below 25 °C for up to 24 hours. **Adverse Effects: Very common:** Visual acuity reduced, retinal haemorrhage, conjunctival haemorrhage, eye pain. **Common:** Retinal pigment epithelial tear, detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract, cataract cortical, cataract nuclear, cataract subcapsular, corneal erosion, corneal abrasion, intraocular pressure increased, vision blurred, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, lacrimation increased, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival hyperaemia, ocular hyperaemia. **For uncommon and rare adverse reactions, please refer to section 4.8 in the full prescribing information.** (2023 March) (MA-EYL-HK-0007-1) Reference cited as: Eylea 40 mg/mL solution for intravitreal injection in a vial, Hong Kong Prescribing Information (May 2021) **Eylea (aflibercept) 40mg/mL solution for injection in pre-filled syringe** (Please refer to the full prescribing information before prescribing) **Indication for Use:** Eylea is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to the following conditions: macular oedema secondary to retinal vein occlusion (branch or central RVO), diabetic macular oedema (DME), myopic choroidal neovascularisation (myopic CNV). **Composition:** 1mL solution for intravitreal injection contains 40 mg aflibercept. One pre-filled syringe contains 90 microlitres, equivalent to 3.6 mg aflibercept. **Posology and Method of Administration:** The recommended dose for Eylea is 2 mg aflibercept, equivalent to 50 microlitres. Eylea is for intravitreal injection only, please do refer to section 6.6 in the full prescribing information for step-by-step instructions for use. **Contraindications:** Hypersensitivity to the active substance aflibercept or to any of the excipients listed in section 6.1 of the full PI; Active or suspected ocular or periocular infection; Active severe intraocular inflammation. **Warnings and Precautions: Traceability:** To improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded; **Intravitreal injection-related reactions:** Proper aseptic injection techniques must always be used when administering Eylea. Increases in intraocular pressure have been seen within 60 minutes of intravitreal injection, including those with Eylea. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Eylea while the intraocular pressure is ≥ 30 mmHg). **Immunogenicity:** As this is a therapeutic protein, there is a potential for immunogenicity with Eylea; **Systemic effects:** Non-ocular haemorrhages and arterial thromboembolic events have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition; **Populations with limited data:** There is only limited experience in the treatment of subjects with DME due to type I diabetes or in diabetic patients with an HbA1c over 12% or with proliferative diabetic retinopathy; **Excipients:** This medicine contains less than 1 mmol sodium (23 mg) per dosage unit; **Incompatibilities:** this medicinal product must not be mixed with other medicinal products; **Storage:** Store in a refrigerator (2°C to 8°C), do not freeze. Store in the original package in order to protect from light. The unopened vial may be stored outside the refrigerator below 25 °C for up to 24 hours. After opening the blister, proceed under aseptic conditions. **Adverse Effects: Very common:** Visual acuity reduced, retinal haemorrhage, conjunctival haemorrhage, eye pain. **Common:** Retinal pigment epithelial tear, detachment of the retinal pigment epithelium, retinal degeneration, vitreous haemorrhage, cataract, cataract cortical, cataract nuclear, cataract subcapsular, corneal erosion, corneal abrasion, intraocular pressure increased, vision blurred, vitreous floaters, vitreous detachment, injection site pain, foreign body sensation in eyes, lacrimation increased, eyelid oedema, injection site haemorrhage, punctate keratitis, conjunctival hyperaemia, ocular hyperaemia. **For uncommon and rare adverse reactions, please refer to section 4.8 in the full prescribing information.** (July 2022) (PP-M_AFL-HK-0021-1) Reference cited as: Eylea 40 mg/mL solution for injection in pre-filled syringe, Hong Kong Prescribing Information(May 2021)

References: 1. Ohji M, et al. Adv Ther 2020;37:1173–1187. **2.** Korobelnik J-F, et al. Ophthalmology 2014;121:2247–2254. **3.** Papadopoulos N, et al. Angiogenesis 2012;15:171–185. **4.** Eissing T, et al. Trans Vis Sci Technol 2021;10:9 **5.** EYLEA® (aflibercept solution for injection)Full Prescribing Information. Hong Kong 2021 **6.** Lucentis ® (ranibizumab solution for injection) SmPC. Dublin, Ireland: Novartis Europharm Limited. **7.** Beovu ® (brolucizumab solution for injection) SmPC. Dublin, Ireland: Novartis Europharm Limited. **8.** Kaiser P, et al. Ophthalmol Retina 2017;1:304–313. **9.** Lukic M, et al. Eur J Ophthalmol 2021;31:1940–1944. **10.** Wykoff CC, et al. Br J Ophthalmol 2018;102:631–636. **11.** Bayer. Data on file. 31 Aug 2023

For further prescribing information, please contact:

Bayer HealthCare Limited

14/F, Oxford House, Taikoo Place
979 King's Road, Quarry Bay, Hong Kong
Tel: (852) 8100 2755 Website: www.bayer.com

PP-EYL-HK-0305-1

STEP INTO THE FUTURE

The future of ophthalmology is closer than you think

Roche

M-HK-00001445
Valid until 31 Dec 2024 or until change is required in accordance with the regulatory requirements, whichever comes first.
Roche Hong Kong Limited | 22/F, FTLife Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong | Tel: +852 2723 2832

THE WINDOW TO CHANGE

JOIN US LIVE AT APVRS 2023

Learn about faricimab in the first line for your nAMD and DME patients

Don't miss the symposia on faricimab in DME and nAMD at APVRS 2023!

Explore the first-line use of faricimab at the Hong Kong Convention and Exhibition Centre on the 8th and 9th of December and don't miss out on the opportunity to ask our experts about both clinical trial and real-world experiences!

nAMD symposium:

Change in treatment paradigm for nAMD with faricimab: Evidence from clinical trials and real-world practice

8 December 2023 | 12:30–13:30 | Room S421

Expert panel


Chair: Prof. Timothy Lai (HK)


Dr. Adrian Koh (SG)


Asst. Prof. Tai-Chi Lin (TW)


Asst. Prof. Keiko Kataoka (JP)

DME symposium:

Change in treatment paradigm for DME with faricimab: Evidence from clinical trials and real-world practice

9 December 2023 | 12:30–13:30 | Room Hall 5G

Expert panel


Chair: Prof. Guy Chen (HK)


Assoc. Prof. Colin Tan (SG)


Dr. Mali Okada (AU)


Dr. Michael Singer (USA)

Abbreviations: Ang-2: Angiopoietin-2; APVRS: Asia-Pacific Vitreo-Retina Society; DME: Diabetic macular edema; nAMD: Neovascular age-related macular degeneration; VEGF-A: Vascular endothelial growth factor A

Roche Hong Kong Limited
22/F, FTLife Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong | Tel: +852 2723 2832

M-HK-00001446
Valid until 31 Dec 2024 or until change is required in accordance with the regulatory requirements, whichever comes first.

Shift the paradigm in the treatment of nAMD and DME with DUAL-PATHWAY INHIBITION

For VABYSMO abbreviated prescribing information, please scan the QR code. Full prescribing information upon request. The materials for VABYSMO contained in this exhibition are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to local prescribing information.

VABYSMO®
faricimab injection 6 mg

M-HK-00001444
Valid until 31 Dec 2024 or until change is required in accordance with the regulatory requirements, whichever comes first.

Roche Hong Kong Limited
22/F, FTLife Tower, 18 Sheung Yuet Road, Kowloon Bay, Hong Kong
Tel: +852 2723 2832

Seeing more
with the first
digital microscope.

ZEISS ARTEVO 800

AdVision

Every detail in your line of sight.

zeiss.com/artevo800

ZEISS

Seeing beyond

Expanding insights with ultra-wide imaging.

ZEISS CLARUS 700

Unsurpassed image quality with fluorescein angiography.

zeiss.com/clarus700

ZEISS

Seeing beyond

Alcon
BRINGS YOU THE:

#1 Phaco-Vitrectomy Console; trusted by surgeons in over 1 million procedures in 2022* [1]

Constellation® VISION SYSTEM

HYPERVIT™ DUAL BLADE VITRECTOMY PROBE

20.000 CPM vitrectomy probe featuring a beveled tip design [2]

RED DOT AWARD winner Grieshaber REFLEX™ handle**

FINESSE Reflex™ Handle

reddot winner 2022
medical devices and technology

NGENUITY® DIGITALLY ASSISTED SURGERY

Surgical integration in combination with the NGENUITY® 3D Visualization System [3-4]

FOR MORE INFORMATION
VISIT OUR WEBSITE

1. Retinal Surgical Device Market Report, Market Scope, 2022 2. Alcon Data on file (970-8120-115), Alcon Laboratories Inc; May 2017 3. Constellation® Operator's Manual, 2022 4, NGENUITY® 3D Visualization System User Guide, 2022
* Market scope estimation ** https://www.red-dot.org/project/finesse-reflex-handle-58462
Please refer to product direction for use (or operator manual) for list of indications, contraindications and warnings.

BLutein™ Dyes

The complete ophthalmic dye range designed to help free you from safety profile concerns

for staining the vitreous

for staining the ILM

for staining the ILM and ERM

for staining the anterior capsule

WITH NATURALLY SOURCED LUTEIN



» ABSORBING DAMAGING BLUE LIGHT [1,2]

» NEUTRALISING HARMFUL FREE RADICALS [3,4]

» REDUCING IATROGENIC STRESS [5]

The BLutein™ Dyes for ILM and ERM staining also contain highly pure PBB® [6-8]

- PBB® is an innovative, patented intraocular blue dye component designed to optimise safety profile, with: [6-8]

☑ 99% purity [6]	☑ Greater ILM tissue selectivity compared to BBG [7,8]	☑ Lower retinal distribution versus BBG [7,8]	☑ Minimal dye reaching inner retinal layers thus reducing risk of iatrogenic retinal damage [7,8]

References

1. Buscemi S et al., Nutrients. 2018; 10: 1321 2. Bernstein PS et al, Prog Retin Eye Res. 2016; 50: 34-66. 3. Lima VC et al., Int J Retin Vitr. 2016; 2:19. 4. Junghans A et al., Arch Biochem Biophys. 2001; 391:160-164. 5. Sasaki M et al., J Nutr Biochem. 2012; 23: 423-429 6. European Patent EP 3 692 101 B1. 7. Spadaro A et al., Frontiers Pharmacol. 2020; 11: 708. 8. Bucolo C et al., Poster #39-A0113. Presented at ARVO Annual Meeting 2019.

Please read the Instructions for Use (IFU) / Directions for Use (DFU) for important product use and safety information for BLutein™ Dyes.

Bausch & Lomb (HK) Ltd.
Suites 3901 & 3912-14, 39/F, Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. Tel: 2213 3333

HK-SU-2023-10-011

BAUSCH + LOMB
See better. Live better.

LUXSMART™

PRELOADED

PURE

Refractive Optics

HYDROPHOBIC IOL

The extended depth of focus intraocular lens for your daily range of vision

HYDROPHOBIC PRO TECHNOLOGY* PRELOADED EDOF

Scan this QR code to have additional information about LuxSmart™

* PRO TECHNOLOGY: Pure refractive Optics Technology

HK SU 2022-10-004
Bausch & Lomb (HK) Ltd.
Suites 3901 & 3912-14, 39/F., Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong Tel: +852 2213 3333

CATARACT LASER RETINA

BAUSCH+LOMB
See better. Live better.

Ocuvite® AREDS 2 FORMULA
Eye Vitamin & Mineral Supplement



Revitalizing Bright Vision Defying Macular Degeneration

Reduce risk of advanced AMD with Ocuvite® AREDS 2 Formula[1,2]

- Contains 6 essential nutrients[3]
- Golden standard ratio for eye protection[1]
- Enhanced nutrient absorption*[4]

- **Proven risk reduction** in progression to advanced AMD in **>3,500 patients**[2,6-8]
- **10 years** of sustained results with **20 years** worth of research[2,6-9]
- β-carotene free - **Safe for long-term use** without increased risk of lung cancer[3,7]

Superior bioavailability of Ocusorb® formulation for rapid replenishment of lutein and zeaxanthin status*[4]

INCREASED ABSORPTION

Lutein† 2.5x
(219.15 vs 87.01 ng/mL with reference products‡; p<0.05 [90%CI 191.97-330.44%])[4]

Zeaxanthin† 1.8x
(56.95 vs 32.55 ng/mL with reference products‡; p<0.05 [90%CI 140.70-217.50%])[4]



***** Study design: A total of 90 adults volunteers were enrolled in a randomized, double-blinded, parallel, comparative bioavailability study. Volunteers were randomly assigned to receive single dose of Ocusorb® with 10 mg lutein and 2 mg zeaxanthin or reference formulations after breakfast. The Ocusorb® and reference formulations were compared for lutein and zeaxanthin on the basis of Cmax, AUC_{0-72}, and AUC_{0-t}. † Data refers to C_{max} ‡Reference products refer to capsules which contained a blend of commercially available sampe of lutein 20% and zeaxanthin 14% to obtain the dose of 10 mg lutein and 2 mg RR-zeaxanthin per capsule.

AMD= age-related macular degeneration; AUC_{0-72}= area under the curve from 0 to 72 hours; AUC_{0-t}= area under the concentration-time curve from dosing to time; AREDS 2= Age-Related Eye Disease Study 2; CI= confidence interval; C_{max}= maximum concentration.

References: 1. Age-Related Eye Disease Study 2 Research Group. JAMA. 2013 May 15;309(19):2005-15. **2.** Bausch Health. New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression. Available at https://www.prnewswire.com/news-releases/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-age-related-macular-degeneration-progression-301288304.html. Accessed on 6 Oct 2023. **3.** Product insert of Ocuvite® AREDS 2. **4.** Kotagiri SR, et al. Ophthalmol Ther. 2022 Aug;11(4):1463-1477. **5.** Wilson LM, et al. Adv Nutr. 2021;12:2244-2254. **6.** Chew EY. Ophthalmologica. 2017;238(1-2):1-5. **7.** Chew EY, et al. JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. **8.** Age-Related Eye Disease Study Research Group. Arch Ophthalmol. 2001 Oct;119(10):1417-36. **9.** Chew EY, et al. Ophthalmology. 2013 Aug;120(8):1604-11.e4.

BAUSCH+LOMB
See better. Live better.

Bausch + Lomb (H.K.) Ltd.
Suites 3901 & 3912-14, 39/F, Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong
Tel: (+852) 2213 3333

We've got the SOLUTION

For your dry eye symptoms

The ARTELAC® range of advanced eye drops based on your needs[1-3]

Artelac Rebalance®

For providing enduring relief and protection for dry eyes caused by chronic tear dysfunction[1]

- 0.15% Hyaluronic acid[1]
- Contains Vitamin B12[1]
- Compatible with contact lens[1]
- Two months storage once opened[1]

Promotes a healthy ocular surface environment that helps protect the cornea from damage[1]

Artelac Advanced

Hyaluronic acid 0.2%

To refresh and moisturize dry eyes caused by external environmental factors*[2]

- 0.20% Hyaluronic acid[2]
- Preservative free[2]
- Single-dose unit[2]
- Suitable for wetting and rewetting contact lenses (soft and rigid)[2]

Relieves symptoms of irritated, tired, dry, even teary eyes[2]

Artelac Splash MDO®

For instantly soothing and hydrating dry eyes[3]

- 0.24% Hyaluronic acid[3]
- Preservative free multi-dose system (PFMD)[3]
- Ergonomic thumb support design[3]
- Compatible with contact lens[3]
- Six months storage once opened[3]

Provides instant moisturization for all dry eye symptoms[3]

The ARTELAC® range of advanced eye drops helps reduce symptoms of dry and irritated eyes, based on your needs[1-3].

* Such factors often include: extensive computer use, indoor controlled-air environments, insufficient blinking, cigarettes smoke, as well as windy outdoor environments.

References: 1. Product Insert of Artelac Rebalance®; **2.** Product Insert of Artelac Advanced; **3.** Product Insert of Artelac Splash MDO®.

BAUSCH + LOMB
See better. Live better.

Bausch & Lomb (Hong Kong) Limited
Suites 3901 & 3912-14, 39/F
Tower 6, The Gateway, 9 Canton Road,
Tsim Sha Tsui, Kowloon, Hong Kong
Tel: (852) 2213 3333

THE NEW DIMENSION

FULLY DIGITAL VISUALIZATION



See LUMA™

Please contact your local representative for more information on Bausch & Lomb products.

Bausch & Lomb (HK) Ltd.
Suites 3901 & 3912-14, 39/F, Tower 6, The Gateway, 9 Canton Road, Tsim Sha Tsui, Kowloon, Hong Kong. Tel: 2213 3333
HK-SU-2023-10-012

BAUSCH+LOMB
See better. Live better.



Nikon

Silverstone is the only ultra-widefield imaging device with integrated swept-source OCT. It can produce a 200° single-capture retinal image of unrivaled clarity in less than 0.5 second and enables optomap-guided OCT scanning across the retina and into the far periphery.

optos®



optomap® *color*

optomap® *af*



optomap® *fa*

optomap® *icg*



Nikon

Silverstone is the only ultra-widefield imaging device with integrated swept-source OCT. It can produce a 200° single-capture retinal image of unrivaled clarity in less than 0.5 second and enables optomap-guided OCT scanning across the retina and into the far periphery.

optos®

高視 GAUSH

SCHWIND eye-tech-solutions

SCHWIND SmartSquare

Innovative Refractive Surgery Laser Portfolio

Versatile solutions for customized refractive surgery

ATOS with SmartSight

The Latest Intelligent Femtosecond Laser

- **Automated eye tracker guided centration** including offset compensatione
- **Static cyclotorsion compensation**
- **Large flap diameter** up to 9.6 mm

AMARIS 1050RS

The Evolutionary Premium Excimer Laser

- **Short treatment times with repetition rates** up to 1,050 Hz
- **High precision through 7D eye tracking**
- **0.54 mm beam size, Super-Gaussian profile**

Global Vision HongKong Limited tracycheung@gaush.com rayckcheung@gaush.com

CONTENTS

CONTENTS

WELCOME MESSAGES

WELCOME MESSAGE

From Congress Presidents – Prof. Dennis LAM and Prof. Guy CHEN



Prof. Dennis LAM

Prof. Guy CHEN

Dear Friends and Colleagues,

It is our pleasure to invite you to the 16th Asia-Pacific Vitreo-retina Society (APVRS) Congress in Hong Kong, from December 8 – 10, 2023.

The APVRS strives to provide a platform for us to explore the latest advancements in the field, from cutting-edge surgical techniques to emerging technologies in imaging and diagnostics.

As we gather here in the bustling city of Hong Kong, we are reminded of the importance of collaboration and knowledge-sharing in advancing the field of ophthalmology. The 16th APVRS Congress represents a unique opportunity to engage with colleagues from around the world, to learn from their experiences and expertise, and to explore new ideas and innovations.

In addition, Hong Kong offers a captivating backdrop for both scientific and social endeavors. From its iconic skyline and vibrant culinary scene to its rich cultural heritage and diverse entertainment options, Hong Kong promises an unforgettable experience for all attendees. Do take the chance to make the most of your stay in Hong Kong!

We wish you all a productive and engaging congress, filled with new insights, connections, and opportunities!

With Warmest Regards,

Prof. Dennis Lam
Congress Presidents, the 16th APVRS Congress

Prof. Guy Chen

WELCOME MESSAGE

From Scientific Program Committee Chair – Prof. Paisan RUAMVIBOONSUK

Prof. Paisan RUAMVIBOONSUK

Dear Friends and Colleagues,

It is my pleasure to welcome you all to the 16th APVRS Congress.

We would like to express our greatest gratitude to everyone, especially our Scientific Program Committee members and invited faculty, who are willing to commit and take part in our scientific sessions.

Dedicated to advancing the frontiers of vitreo-retina in the Asia-Pacific region, the 16th APVRS Congress will continue providing a platform for vitreo-retinal specialists to meet and exchange expertise. This year, we have 50 invited sessions, featuring a broad range of subspecialties, addressing the emergence of certain retinal conditions and the latest discoveries and cutting-edge innovations in the vitreo-retinal field.

Together, let us explore new horizons and shape the future of vitreo-retinal care in the Asia-Pacific region. Thank you all for your warm support and participation, and we cannot wait to see you soon!

With Warmest Regards,

Prof. Paisan Ruamviboonsuk
Scientific Program Committee Chair, the 16th APVRS Congress
Scientific Secretary, Asia-Pacific Vitreo-retina Society

WELCOME MESSAGE

From Asia-Pacific Vitreo-retina Society President – Prof. Chi-Chun LAI

Prof. Chi-Chun LAI

Dear Colleagues,

On behalf of the Asia-Pacific Vitreo-retina Society (APVRS), it is my utmost pleasure to extend a warm welcome to all participants of the 16th APVRS Congress in Hong Kong, taking place from December 8 – 10, 2023.

I am thrilled that the APVRS Congress continues to serve as a vital platform for vitreo-retinal specialists to come together and explore the latest advancements in our field. It is also an exciting time for us, as we witness the end of the pandemic and return to face-to-face interactions, allowing us to reconnect, forge new connections, and foster collaborations and friendships. I am confident that the next few days will be filled with insightful discussions, meaningful networking opportunities, and memorable experiences.

We look forward to welcoming you personally to the 16th APVRS Congress in Hong Kong. Let's seize this opportunity to expand our knowledge, strengthen our professional networks, and contribute to the advancement of vitreo-retina in the Asia-Pacific region.

With Warmest Regards,

Chi-Chun Lai

Prof. Chi-Chun Lai
President, Asia-Pacific Vitreo-retina Society

WELCOME MESSAGE

From Asia-Pacific Vitreo-retina Society Secretary-General – Prof. Andrew CHANG

Prof. Andrew CHANG

Dear Friends and Colleagues,

Taking this opportunity, I would like to extend a very warm welcome to you to the 16th APVRS Congress.

On behalf of APVRS, I would like to extend our heartfelt gratitude to Prof. Dennis Lam, Prof. Guy Chen and their team for their hard work in organizing such an exemplary congress. Their leadership has made this event possible, and we are truly grateful for their contributions.

I would like to express our deepest thanks to Prof. Paisan Ruamviboonsuk, our Scientific Program Chair, Prof. Timothy Lai and Prof. Guy Chen, our Scientific Program Co-chairs, and the star-studded Scientific Program Committee. Their commitment and expertise have been invaluable in creating a world-class and compelling scientific program for this congress.

Last but not least, I would like to express our heartfelt appreciation to each and every one of you for your participation. At the time of writing, we have over 1,400 registered delegates from 40+ countries. Your presence and engagement are what make this event truly special!

Once again, a warm welcome to the 16th APVRS Congress. Let us make the most of this gathering and collectively contribute to the advancement of our field.

With Warmest Regards,

Prof. Andrew CHANG
Secretary-General, Asia-Pacific Vitreo-retina Society (APVRS)

WELCOME MESSAGE

From Asia-Pacific Ocular Imaging Society add President – Prof. Tien Yin WONG

Prof. Tien Yin WONG

The Asia-Pacific Ocular Imaging Society (APOIS) is delighted to co-host the 16th Asia-Pacific Vitreo-retina Society (APVRS) Congress. The collaboration between APOIS and APVRS is a testament to our shared commitment to advancing the field of vitreoretinal surgery and ocular imaging in the Asia-Pacific region. By combining our collective expertise, we can push the boundaries of ocular imaging and propel our field forward.

Throughout the Congress, you can look forward to an exceptional line-up of keynote speakers and renowned experts in the field of ocular imaging. Our programs will cover the latest developments in imaging techniques, novel applications of artificial intelligence, and integration of advanced technology into clinical practice, which will be instrumental in expanding your knowledge and enhancing your professional growth.

I invite you to mark your calendar for the APVRS Congress. Let us embrace this remarkable opportunity to drive innovation, share knowledge, and shape the future of our field!

Prof. Tien Yin WONG
President, The Asia-Pacific Ocular Imaging Society (APOIS)

WELCOME MESSAGE

From The College of Ophthalmologists of Hong Kong President – Dr. Emily Yeung

Dr. Emily YEUNG

It is my greatest pleasure to welcome you all to the 35th Annual Scientific Meeting of the College of Ophthalmologists of Hong Kong and the Hong Kong Ophthalmological Society which will be jointly organized with the 16th Congress of the Asia-Pacific Vitreo-retina Society and the 3rd Asia-Pacific Ocular Imaging Society Congress and the Annual Meeting of the Asia-Pacific Society of Eye Genetics.

We have an exciting lineup of speakers and presentations that will cover the latest advances in vitreo-retina, ocular imaging, eye genetics, myopia, and artificial corneas research.

It has been over four years since we joined our annual scientific meeting with other international or Asia-Pacific organizations. This meeting will provide an excellent platform for us to reconnect, share our knowledge and exchange the latest scientific developments with each other.

I would like to take this opportunity to thank all our speakers, sponsors, and attendees for their support, and participation in this meeting. I would also like to thank the organizing committee for their dedication and hard work in putting together such an excellent program.

On behalf of the College of Ophthalmologists of Hong Kong, I look forward to welcoming you all to Hong Kong and hope that you will have a productive and enjoyable meeting.

Dr. Emily Yeung
President, The College of Ophthalmologists of Hong Kong

WELCOME MESSAGE

From The Hong Kong Ophthalmological Society President – Dr. Emmy Li

Dr. Emmy LI

On behalf of the Hong Kong Ophthalmological Society, it is our great pleasure to invite you to the 35th Annual Scientific Meeting Hong Kong Ophthalmological Symposium, which will be held jointly with the 16th Congress of the Asia-Pacific Vitreo-retina Society, the 3rd Asia-Pacific Ocular Imaging Society Congress, and the Annual Scientific Meeting of the Asia-Pacific Society of Eye Genetics on December 8-10, 2023 at the Hong Kong Convention and Exhibition Center.

We sincerely hope that the ASM 2023 will continue to serve as an important platform for knowledge exchange, teaching and education, connection, and collaboration after the pandemic. Looking forward in welcoming all of you in Hong Kong. See you in December.

Dr. Emmy Li
President, The Hong Kong Ophthalmological Society (HKOS)

WELCOME MESSAGE

From Chairman of Department of Ophthalmology and Visual Sciences, Faculty of Medicine, The Chinese University of Hong Kong

Prof. Clement THAM

The 16th Congress of the Asia-Pacific Vitreo-retina Society (APVRS) will be held in conjunction with the Asia-Pacific Ocular Imaging Society (APOIS) Congress, the Annual Meeting of the Asia-Pacific Society of Eye Genetics (APSEG), and the Annual Scientific Meeting Hong Kong Ophthalmological Symposium in Hong Kong on December 8 - 10, 2023!

The Department of Ophthalmology and Visual Sciences of The Chinese University of Hong Kong is immensely honored to co-host this joint international conference in Hong Kong, along with the two ophthalmological institutions in Hong Kong: The College of Ophthalmologists of Hong Kong and the Hong Kong Ophthalmological Society.

The Congress features a most exciting scientific program with insightful presentations by distinguished and influential speakers, presenting cutting-edge ideas in the field. It will be an unparalleled opportunity for ophthalmologists to share professional expertise and experience, and to connect.

This is surely an occasion you cannot afford to miss! We in Hong Kong are very much looking forward to welcoming you to this Congress in person in December.

Prof. Clement Tham
Chairman
Department of Ophthalmology and Visual Sciences
Faculty of Medicine, The Chinese University of Hong Kong

VYZULTA™
(latanoprostene bunod ophthalmic solution),0.024%

20 YEARS
OF BREAKTHROUGH IN GLAUCOMA TREATMENT

Indication

VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular with hypertension.[1]

One molecule, two pathways

Lowers IOP by increasing outflow through both the trabecular meshwork and uveoscleral pathway[1]

Remarkable efficacy

Reduced the mean IOP up to 9.0 mmHg from baseline[2*]

Demonstrated safety

<1% discontinuation rate due to ocular adverse effects[1]

***VOYAGER study design:** a randomized, parallel-group, phase 2 study, which compared the efficacy and safety of 4 doses of VYZULTA™ and Xalatan® 0.005% in 413 patients with open-angle glaucoma or ocular hypertension. Primary endpoint was the change of mean diurnal IOP at day 28 from baseline. The mean IOP at baseline was 26.0 mmHg in the VYZULTA™ 0.024% group and 26.2 mmHg in the latanoprost 0.005% group.[2]

IOP=intraocular pressure.

References: 1. VYZULTA Hong Kong prescribing information. **2.** Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol 2015; 99(6): 738-45.

INDICATION VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular with hypertension. **DOSAGE AND AMINISTRATION** The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. Do not administer VYZULTA™ (latanoprostene bunod ophthalmic solution), 0.024% more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the intraocular pressure lowering effect. If VYZULTA™ is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five (5) minutes apart. **IMPORTANT SAFETY INFORMATION** • Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent. • Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation. • Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). VYZULTA™ should generally not be used in patients with active intraocular inflammation. • Macular edema, including cystoid macular edema, has been reported during treatment with prostaglandin analogs. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. • There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients. • Contact lenses should be removed prior to the administration of VYZULTA™ and may be reinserted 15 minutes after administration. • Most common ocular adverse reactions with incidence ≥2% are conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%), and instillation site pain (2%). Please refer to full package insert for the detail.

For healthcare professional only.
Please refer to full Prescribing Information and additional Important Safety Information for VYZULTA™.

BAUSCH + LOMB
See better. Live better.

Bausch & Lomb (H.K.) Ltd.
Suites 3901 & 3912-14, 39/F
Tower 6, The Gateway, 9 Canton Road
Tsim Sha Tsui, Kowloon, Hong Kong
Tel: (+852) 2213 3333

COUNCIL AND COMMITTEES

HOST – ASIA-PACIFIC VITREO-RETINA SOCIETY

The Asia-Pacific Vitreo-retina Society (APVRS) was founded in 2006 with the mission to assist in the development of the vitreo-retinal subspecialty in the Asia-Pacific region, to provide a platform for good integration of skills and knowledge of vitreo-retinal specialists, and to promote and disseminate eye care information about vitreo-retinal diseases and related issues to the general public.

Asia-Pacific Vitreo-retina Society Council

President
Chi-Chun LAI — Chinese Taipei

Immediate Past President
Dennis LAM — Hong Kong SAR

Secretary-General
Andrew CHANG — Australia

Vice Presidents
Timothy LAI — Hong Kong SAR
Masahito OHJI — Japan
Tien Yin WONG — Singapore

Scientific Secretary
Paisan RUAMVIBOONSUK — Thailand

Treasurer
Seung Young YU — Korea, Republic of

Councilors at-large
Marten BRELEN — Hong Kong SAR
Ian CONSTABLE — Australia
Taraprasad DAS — India
Xiaoxin LI — China
Xun XU — China

Members
Rajvardhan AZAD — India
Gemmy CHEUNG — Singapore
Kenneth FONG — Malaysia
Adrian FUNG — Australia
Tzyy-Chang HO — Chinese Taipei
Adrian KOH — Singapore
Xiaoling LIANG — China
Hiroko TERASAKI — Japan
Harvey UY — Philippines
Raymond WONG — Hong Kong SAR
Peiquan ZHAO — China

CO-HOST – ASIA-PACIFIC OCULAR IMAGING SOCIETY

Asia-Pacific Ocular Imaging Society (APOIS) is an academic, scientific and professional society that facilitates collaboration between ophthalmologists and vision scientists in the region, with a focus on development and application of ocular imaging. APOIS aims to provide a dynamic professional and educational platform for ophthalmologists and vision scientists from around the world to meet, exchange and advance knowledge in ocular imaging technology, to encourage collaborative research and clinical service projects, to assist ophthalmological colleagues to be up to date with advances in all aspects of ocular imaging, and to contribute to international development in ocular imaging.

Website: http://apois.org/

The Council

President
Tien Yin Wong (Singapore)

Vice-President
Ki Ho Park (Korea)

Secretary General
Carol Cheung (Hong Kong SAR)

Treasurer
Tommy Chan (Hong Kong SAR)

Council Members
Mingguang He (Australia)
Yogesan Kanagasingam (Australia)
Yuanbo Liang (China)
Wenbing Wei (China)
Jin Yuan (China)
Xiulan Zhang (China)
Xinyuan Zhang (China)
Timothy Lai (Hong Kong SAR)
Christopher Leung (Hong Kong SAR)
Jay Chhablani (India)
Vishali Gupta (India)
Harsha Rao (India)
Rohit Shetty (India)
Atsuya Miki (Japan)
Masahiro Miura (Japan)
Kyoko Ohno-Matsui (Japan)
Yasuo Yanagi (Japan)
Yoshiaki Yasuno (Japan)
Won Ki Lee (Korea)
Tae Woo Kim (Korea)
Rupesh Agrawal (Singapore)
Ting Aung (Singapore)
Marcus Ang (Singapore)
Gemmy Cheung (Singapore)
Leopold Schmetterer (Singapore)
Henry Shen-Lih Chen (Chinese Taipei)
Da Wen Lu (Chinese Taipei)
Yi Chun Chen (Chinese Taipei)
Paisan Ruamviboonsuk (Thailand)

CO-HOST – THE COLLEGE OF OPHTHALMOLOGISTS OF HONG KONG

香港眼科醫學院

The College of Ophthalmologists of Hong Kong was incorporated in October 1994 with the following objectives:

1. To promote for public benefit the advancement of knowledge in the field of ophthalmology
2. To promote for public benefit the standard of ophthalmic care in Hong Kong
3. To develop and maintain good practice and high professional standards of competence in the field of ophthalmology
4. To act as a consultative body for matters of educational or public interest concerning ophthalmology
5. To encourage and support training, continuing education and research in ophthalmology

Website: https://www.cohk.org.hk/

The COHK Council 2023-2024

President: Dr YEUNG Fung Yee, Emily
Vice President (Professional Affairs): Dr LAM Fung, Robert
Vice-President (General Affairs): Dr YUNG Hon Wah
Honorary Secretary: Dr CHIU Yee Hang, Thomas
Honorary Treasurer: Dr YEUNG Chun Chun, Jane
Editor-in-Chief: Dr YAM Cheuk Sing, Jason
Immediate Past President: Prof THAM Chee Yung, Clement
Council Members:
Dr AU Ka Hong, Alvin
Dr BAIG Nafees Begum
Dr CHAN, Kar Mun Carmen
Dr CHING, Hok Ying Ruby
Dr CHONG, Kam Lung Kelvin
Dr LAI, Hong Yee Connie
Dr LO Chi Fung, Ernie
Dr SHIH Kendrick Co
Dr SIN Pui Yee, Helena
Dr WONG Lai Man, Raymond
Co-opted Council Member: Dr YUEN Shi Yin, Nancy

CO-HOST – THE HONG KONG OPHTHALMOLOGICAL SOCIETY

The Hong Kong Ophthalmological Society (HKOS) was formed and registered on 16 August 1954 with Dr Dansey Browning as the first Chairman. The Society was established with the objectives to maintain and upgrade the quality of eye care in Hong Kong, and to foster brotherhood among eye care professionals serving the public in Hong Kong. Every year since 1989, the HKOS has organized the annual scientific meeting in ophthalmology, as well as other ad-hoc open lectures by internationally renowned speakers. This tradition has been carried on jointly with other health-related associations and has supported any public health talks and vision screening programs. There are at present over 300 members registered with the Society.

Website: http://www.hkos.org.hk/

The HKOS Council 2023-2024

President: Dr LI Yuen Mei, Emmy
Vice President (Internal Affairs): Dr YAM Cheuk Sing, Jason
Vice President (External Affairs): Dr CHAN Chung Yan, Tommy
Honorary Secretary: Dr NG Lap Ki, Alex
Honorary Treasurer: Dr WONG Lai Man, Raymond
Ex-offico: Dr WONG Yat Hin, Ian
Council Members:
Dr CHOW, She Wan Sharon
Dr FAN Ching Yim, Michelle
Dr FONG Cheong Yi
Dr FONG Hon Chi, Angie
Dr HO Wing Lau
Dr IU Pui Leung, Lawrence
Dr LAI Hiu Ping, Frank
Dr LEUNG Wing Yun, Joy
Dr SZETO Ka Ho, Simon
Dr WONG Wai Nam, Eva
Dr YEUNG Chun Chun, Jane

CO-HOST – DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES, FACULTY OF MEDICINE, THE CHINESE UNIVERSITY OF HONG KONG

The Department of Ophthalmology and Visual Sciences (DOVS), Faculty of Medicine, The Chinese University of Hong Kong (CUHK), founded in 1994, was the first academic ophthalmology department in Hong Kong. Now a leading ophthalmic institute in Asia, CUHK DOVS provides ophthalmic education to undergraduate and postgraduate students, delivers professional training to ophthalmology trainees and specialists from Hong Kong and overseas, and conducts clinical, basic, and epidemiological research that advances eye care to patients.

The Department consists of two main functional units: the CUHK Eye Centre and the CUHK Ophthalmic Laboratory.

The CUHK Eye Centre includes the CUHK-HKEH Private Eye Clinic which provides subspecialty-based clinical ophthalmic care to the public, the CUHK-HKEH Clinical Drug Trial Centre which is the only clinical ophthalmic research facility in Hong Kong accredited by the National Medical Products Administration (NMPA) in China, the Pao So Kok Macular Disease Treatment and Research Centre, and the Lam Kin Chung · Jet King-Shing Ho Glaucoma Treatment and Research Centre.

The CUHK Ophthalmic Laboratory includes the Lim Por-yen Eye Genetics Research Centre, The CUHK Ophthalmic Microsurgical Training Centre, as well as the clinical and visual sciences research laboratories and facilities of the Department. The Lee Wing Kit Advanced Ophthalmic Training and Education Centre (AOTEC), officially opened at Hong Kong Eye Hospital in 2012, raises the standard of CUHK ophthalmic training and education to world class.

CO-HOST – DEPARTMENT OF OPHTHALMOLOGY AND VISUAL SCIENCES, FACULTY OF MEDICINE, THE CHINESE UNIVERSITY OF HONG KONG

Prof. Clement THAM
Chairman, Department of Ophthalmology and Visual Sciences
S.H. Ho Professor of Ophthalmology and Visual Sciences

Prof. Calvin PANG
S.H. Ho Research Professor of Visual Sciences

Prof. Guy CHEN
Professor

Dr Mårten BRELÉN
Associate Professor

Dr Carol CHEUNG
Associate Professor

Dr Kelvin CHONG
Associate Professor

Dr Jason YAM
Associate Professor

Dr Poemen CHAN
Assistant Professor

Dr Simon SZETO
Assistant Professor

Dr CHU Wai Kit
Research Assistant Professor

Dr ZHANG Xiujuan
Research Assistant Professor

APVRS 2023 SCIENTIFIC PROGRAM COMMITTEE

Chair

Paisan Ruamviboonsuk (Thailand)

Co-Chair

Timothy Lai (Hong Kong SAR)

Guy Chen (Hong Kong SAR)

Symposium	International	Asia-Pacific	Local
Age-related Macular Degeneration: Wet AMD	 Neil Bressler (USA)	 Voraporn Chaikijmongkol (Thailand)	 Guy Chen
Age-related Macular Degeneration: Dry AMD	 Richard Spaide (USA)	 Kelvin Teo (Singapore)	 Ian Wong
Pachychoroid Diseases	 Timothy Lai (Hong Kong SAR)	 Shih-Jen Chen (Chinese Taipei)	 Danny Ng
Artificial Intelligence for Retinal Diseases	 Paisan Ruamviboonsuk (Thailand)	 Daniel Ting (Singapore)	 Carol Cheung

Surgical Retina: Macular Surgery	 Andrew Chang (Australia)	 Masahito Ohji (Japan)	 Guy Chen
Surgical Retina: PDR, PVR, and Others	 Gregg Kokame (USA)	 Taraprasad Das (India)	 Chi Wai Tsang
Diabetic Retinopathy (1): DME	 Tien Yin Wong (Singapore)	 Taiji Sakamoto (Japan)	 Simon Szeto
Diabetic Retinopathy (2): DR	 Judy Kim (USA)	 Adrian Koh (Singapore)	 Pui Pui Yip
High Myopia	 Kyoko Ohno-Matsui (Japan)	 Tzyy-Chang Ho (Chinese Taipei)	 Jason Yam
Innovation and Controversies in Surgical Retina	 Manish Nagpal (India)	 Kazuaki Kadonosono (Japan)	 Jason Chan
Pediatric Retina (1)	 Shunji Kusaka (Japan)	 Wei-Chi Wu (Chinese Taipei)	 Nicholas Fung
Pediatric Retina (2)	 Rajvardhan Azad (India)	 Xiaoling Liang (China)	 Callie Ko
Current Concepts in Intraocular Tumors	 J. Fernando Arevalo (USA)	 Duangnate Rojanaporn (Thailand)	 Emily Wong
Retinal Vascular Diseases	 Mark Gillies (Australia)	 Seung-Young Yu (South Korea)	 Shaheeda Mohamed

Mysterious Retina Cases	 William Mieler (USA)	 Xiaoxin Li (China)	 Fiona Luk
Uveitis (1): Applying Research Findings to Clinical Conundrums: A Clinical Case-based Symposium	 Quan Dong Nguyen (USA)	 Lyndell Lim (Australia)	 Mary Ho
Uveitis (2): Update in Uveitis	 Careen Lowder (USA)	 Harvey Uy (Philippines)	 Carmen Chan
Management of VR Complications from Anterior Segment Surgeries	 Adrian Fung (Australia)	 Peiquan Zhao (China)	 Vincent Lee
Young Ophthalmologist Symposium	 Elliott Sohn (USA)	 Anna Tan (Singapore)	 Raymond Wong
The Macula Society Sponsored Symposium on Central Serous Chorioretinopathy (CSC)	 Lihteh Wu (Costa Rica)	 Chi-Chun Lai (Chinese Taipei)	 Timothy Lai
Inherited Retinal Diseases	 Graham Holder (Singapore)	 Kyu Hyung Park (South Korea)	 Marten Brelen
Canadian VR Society Sponsored Symposium	 Wai Ching Lam (Canada)	 Xinyuan Zhang (China)	 Marten Brelen
Subthreshold Ophthalmic Laser Society (SOLS)	 Kenneth Fong (Malaysia)	 Vivek Dave (India)	 Wai Man Chan
New Translational Developments on Vitreo-retina	 Michael Chiang (USA)	 Dennis Lam (Hong Kong SAR)	 Angie Fong

APOIS Sponsored Symposium: Advanced Retinal Imaging	 SriniVas Sadda (USA)	 Hiroko Terasaki (Japan)	 Kenneth Li
APOIS Sponsored Symposium: Polypoidal Choroidal Vasculopathy (PCV)	 Gemmy Cheung (Singapore)	 Won-Ki Lee (South Korea)	 Simon Szeto
APSEG Sponsored Symposium: Gene and Cell Therapy in Retinal Diseases	 Calvin Pang (Hong Kong SAR)	 Xinyi Su (Singapore)	 Wai Kit Chu
APSEG Sponsored Symposium: Molecular Genetics in Retinal Diseases	 Govindasamy Kumaramanickavel (India)	 Ching-Yu Cheng (Singapore)	 Michael Ng
APSEG Sponsored Symposium: Genomics of Eye Diseases	 Anthony Khawaja (UK)	 Chen Zhao (China)	 Haoyu Chen
GEGC Sponsored Symposium: Global Collaboration in Eye Diseases	 Gyan 'John' Prakash (USA)	 S. Natarajan (India)	 Calvin Pang

ASM ORGANIZING COMMITTEE

Advisors:


Dr Ruby CHING


Prof Christopher LEUNG


Dr Emmy LI


Prof Calvin PANG


Prof Clement THAM


Dr Ian WONG


Dr Emily YEUNG


Prof Hunter YUEN

OC Chairman:


Dr Mårten E BRELÉN

Secretary:


Dr Simon SZETO

Treasurer:


Dr Poemen CHAN

ASM Scientific Program Committee Chair:


Dr Ian WONG

ASM Scientific Program Committee members:


Dr Tommy CHAN
(Cataract and Refractive Surgery)


Dr Alex NG
(Cataract and Refractive Surgery)


Dr Alex NG
(Cornea and External Eye Disease)


Dr Kendrick SHIH
(Cornea and External Eye Disease)


Dr Noel CHAN
(Glaucoma)


Dr Dexter LEUNG
(Glaucoma)


Carmen Chan
(Neuro-ophthalmology)


Dr Connie LAI
(Paediatric)


Dr Jason YAM
(Paediatric)


Dr Andy CHENG
(Orbits and Oculoplastics)


Dr Kelvin CHONG
(Orbits and Oculoplastics)


Prof Carmen CHAN
(Uveitis)


Dr Raymond WONG
(Uveitis)


Dr Mary HO
(General Ophthalmology)


Dr Lawrence IU
(General Ophthalmology)


Dr Frank LAI
(General Ophthalmology)


Dr Ruby CHING
(APES)


Dr Simon SZETO
(CUHK)


Prof Christopher LEUNG
(HKU)

Publication Committee:


Dr Mary HO (PIC)


Dr Mandy WONG


Dr Michelle FAN

AVIT Committee:


Dr Alvin AU (PIC)


Dr Sunny Au

Social Committee:


Dr Julia CHAN (PIC)


Dr Karen CHAN


Dr Gillian SIU

Floor Committee:

Dr Isabel LAI (PIC)



Dr Andrew MAK

Exhibition Committee:

Dr Emily WONG (PIC)

Dr Raymond WONG

Dr Tommy CHAN

Publicity Committee:

Dr Lawrence IU (PIC)

Dr Joy SEE LEUNG

Venue and Accommodation:



Dr Alex NG (PIC)

Dr Fanny YIP

APVRS 2023 ABSTRACT REVIEWING COMMITTEE

Chair:

Paisan RUAMVIBOONSUK	Thailand

Members:

Geoffrey BROADHEAD	Australia
Wai-Ching LAM	Canada
David WONG	Canada
Ling-Ping CEN	China
Haotian LIN	China
HAI LU	China
Ruifang SUI	China
Jian-Ping TONG	China
Gabriel YANG	China
Guoming ZHANG	China
Shih Jen CHEN	Chinese Taipei
San-Ni CHEN	Chinese Taipei
Tzyy-Chang HO	Chinese Taipei
Chi-Chun LAI	Chinese Taipei
Tai-Chi LIN	Chinese Taipei
Lihteh WU	Costa Rica
Marten BRELEN	Hong Kong SAR
Carmen CHAN	Hong Kong SAR
Li Jia CHEN	Hong Kong SAR
Wai Kit CHU	Hong Kong SAR
Mary HO	Hong Kong SAR
Timothy LAI	Hong Kong SAR
Michael NG	Hong Kong SAR
Chi Wai TSANG	Hong Kong SAR
Emily WONG	Hong Kong SAR
Rajvardhan AZAD	India
Shorya AZAD	India
Reema BANSAL	India
Umesh BEHERA	India
Bhuvan CHANANA	India
Taraprasad DAS	India
Vivek DAVE	India
Manish NAGPAL	India
Nishant RADKE	India
Anand RAJENDRAN	India
Pradeep SUSVAR	India
Stela VUJOSEVIC	Italy
Fumi GOMI	Japan
Yasushi IKUNO	Japan
Makoto INOUE	Japan
Hiroyuki KONDO	Japan
Shunji KUSAKA	Japan
Wataru MATSUMIYA	Japan
Yuki MORIZANE	Japan
Tomoaki MURAKAMI	Japan
Toshinori MURATA	Japan
Shintaro NAKAO	Japan
Koji NISHIGUCHI	Japan
Miho NOZAKI	Japan
Masahito OHJI	Japan
Kyoko OHNO-MATSUI	Japan
Osamu SAWADA	Japan
Koh-Hei SONODA	Japan
Hiroko TERASAKI	Japan
Akitaka TSUJIKAWA	Japan
Kenji YAMASHIRO	Japan
Yasuo YANAGI	Japan
Sohee JEON	Korea, Republic of
Min KIM	Korea, Republic of
Kiyoung KIM	Korea, Republic of
Sang Jin KIM	Korea, Republic of
Kenneth FONG	Malaysia
Manoharan SHUNMUGAM	Malaysia
Eleonore IGUBAN	Philippines
Harvey UY	Philippines
Sherman VALERO	Philippines
Tin AUNG	Singapore
Hwei Wuen CHAN	Singapore
Gemmy CHEUNG	Singapore
Shu Yen LEE	Singapore
Tyler RIM	Singapore
Anna TAN	Singapore
Kelvin TEO YI CHONG	Singapore
Andrew TSAI	Singapore
Thuss SANGUANSAK	Thailand
Tharikarn SUJIRAKUL	Thailand
Siegfried WAGNER	United Kingdom
J. Fernando AREVALO	United States
Debra GOLDSTEIN	United States
T.Y. Alvin LIU	United States
Yun LIU	United States
Nimesh PATEL	United States
Francesco PICHI	United States
Richard SPAIDE	United States

APOIS and ASMHK 2023 ABSTRACT REVIEWING COMMITTEE

APOIS reviewing committee:
Dr Henry Chen
Dr Carol Cheung
Dr Xinyuan Zhang

ASMHK 2023 reviewing committee:
Dr Tommy Chan
Dr Alex Ng
Dr Kendrick Shih
Dr Noel Chan
Dr Dexter Leung
Prof Carmen Chan
Dr Connie Lai
Dr Jason Yam
Dr Andy Cheng
Dr Kelvin Chong
Dr Raymond Wong
Dr Mary Ho
Dr Lawrence Iu
Dr Frank Lai

SECRETARIAT

APVRS Secretariat

Senior Executive Manager and Assistant Project Manager
Winnie HO

Special Appreciation for APAO Secretariat and Hong Kong Tourism Board

HONG KONG TOURISM BOARD 香港旅遊發展局

Beovu® brolucizumab

For adult patients with wet AMD[1]

THEIR VISION IS A MASTERPIECE

NOW APPROVED

In head-to-head trials vs aflibercept, Beovu®[1]:

- Demonstrated **robust vision gains**[2*]
- Outperformed aflibercept in achieving **superior fluid resolution**[1,2*†]
- Maintained a **majority of patients on a q12w** interval immediately after loading through Week 48[1]

INDICATION: Beovu® is indicated in adults for the treatment of neovascular (wet) age related macular degeneration (AMD)[1]

BEOVU® Important note: Before prescribing, consult full prescribing information. **Presentation:** Solution for injection. Each vial contains 27.6 mg of brolucizumab in 0.23 mL solution. Each pre-filled syringe contains 19.8 mg of brolucizumab in 0.165 mL solution. **Indications:** Beovu® is indicated in adults for the treatment of neovascular (wet) age related macular degeneration (AMD). **Dosage regimen and administration:** Single-use vial or single-use pre-filled syringe for intravitreal use only. Each vial or pre-filled syringe should only be used for the treatment of a single eye. Beovu® must be administered by a qualified ophthalmologist experienced in intravitreal injections. **Adults:** The recommended dose is 6 mg brolucizumab (0.05 ml solution) administered by intravitreal injection every 4 weeks (monthly) for the first 3 doses. Thereafter, the physician may individualise treatment intervals based on disease activity as assessed by visual acuity and/or anatomical parameters. A disease activity assessment is suggested 16 weeks (4 months) after treatment start. In patients without disease activity, treatment every 12 weeks (3 months) should be considered. In patients with disease activity, treatment every 8 weeks (2 months) should be considered. The physician may further individualise treatment intervals based on disease activity. If visual and anatomical outcomes indicate that the patient is not benefiting from continued treatment, Beovu® should be discontinued. **Special populations: ♦Renal impairment:** No dose adjustment is required. **♦Hepatic impairment:** No dose adjustment is required. **♦Geriatric patients:** No dose adjustment is required. **♦Paediatric patients:** Safety and efficacy have not been established. **Contraindications:** ♦Hypersensitivity to the active substance or to any of the excipients. ♦Active or suspected ocular or periocular infection. ♦Active intraocular inflammation. **Warnings and precautions: ♦Traceability:** In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. **♦Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment, retinal vasculitis, and/or retinal vascular occlusion:** Intravitreal injections, including those with Beovu®, have been associated with endophthalmitis, intraocular inflammation, traumatic cataract and retinal detachment. Proper aseptic injection techniques must always be used when administering Beovu. Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of Beovu®. In patients developing these events, treatment with Beovu® should be discontinued and the events should be promptly managed. Patients should be instructed to report any symptoms suggestive of the above mentioned events without delay. **♦Intraocular pressure increases:** Transient increases in intraocular pressure have been seen within 30 minutes of intravitreal injection with vascular endothelial growth factor (VEGF) inhibitors, including brolucizumab. Special precaution is needed in patients with poorly controlled glaucoma (do not inject Beovu® while the intraocular pressure is ≥30 mmHg). Both intraocular pressure and perfusion of the optic nerve head must be monitored and managed appropriately. **♦Bilateral treatment:** The safety and efficacy of brolucizumab administered in both eyes concurrently have not been studied. **♦Immunogenicity:** As this is a therapeutic protein, there is a potential for immunogenicity with brolucizumab. Patients should be instructed to inform their physician if they develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light. **♦Concomitant use of other anti VEGF:** There are no data available on the concomitant use of Beovu® with other anti VEGF medicinal products in the same eye. Brolucizumab should not be administered concurrently with other anti VEGF medicinal products (systemic or ocular). **♦Withholding treatment:** In intravitreal anti-VEGF treatments, the dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of: • a decrease in best corrected visual acuity (BCVA) of ≥30 letters compared with the last assessment of visual acuity; • a retinal break; • a subretinal haemorrhage involving the centre of the fovea; or, if the size of the haemorrhage is ≥50% of the total lesion area; • performed or planned intraocular surgery within the previous or next 28 days. **♦Retinal pigment epithelial tear:** Risk factors associated with the development of a retinal pigment epithelial tear after anti VEGF therapy for wet AMD include a large and/or high pigment epithelial retinal detachment. When initiating brolucizumab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears. **♦Rhegmatogenous retinal detachment or macular holes:** Treatment should be discontinued in subjects with rhegmatogenous retinal detachment or stage 3 or 4 macular holes. **♦Systemic effects following intravitreal use:** Systemic adverse events, including non ocular haemorrhages and arterial thromboembolic events, have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition. There are limited data on safety in the treatment of patients with AMD with a history of stroke, transient ischaemic attacks or myocardial infarction within the last 3 months.Caution should be exercised when treating such patients. **♦Sodium content:** This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium free'. **♦Driving and using machines:** Beovu® has a minor influence on the ability to drive and use machines due to possible temporary visual disturbances following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently. **Pregnancy, lactation, women of childbearing potential, fertility. Pregnancy:** Although the systemic exposure after ocular administration is very low, brolucizumab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus. **Lactation:** Brolucizumab is not recommended during breast feeding and breast feeding should not be started for at least one month after the last dose when stopping treatment with brolucizumab. **Women of childbearing potential:** Women of childbearing potential should use effective contraception during treatment with brolucizumab and for at least one month after the last dose when stopping treatment with brolucizumab. **Fertility:** Based on the mechanism of action of VEGF inhibitors, there is a potential risk for female reproduction, and to embryofoetal development. **Adverse drug reactions: Common (≥1/100 to <1/10):** Hypersensitivity (including urticaria, rash, pruritus, erythema), visual acuity reduced, retinal haemorrhage, uveitis, iritis, vitreous detachment, retinal tear, cataract, conjunctival haemorrhage, vitreous floaters, eye pain, intraocular pressure increase, conjunctivitis, retinal pigment epithelial tear, vision blurred, corneal abrasion, punctate keratitis. **Uncommon (≥1/1,000 to <1/100):** Blindness, endophthalmitis, retinal artery occlusion, retinal detachment, conjunctival hyperaemia, lacrimation increased, abnormal sensation in eye, detachment of retinal pigment epithelium, vitritis, anterior chamber inflammation, iridocyclitis, anterior chamber flare, corneal oedema, vitreous haemorrhage. **Frequency not known:** Retinal vasculitis, retinal vascular occlusion. **Interactions:** No interaction studies have been performed. **Packs:** Vial: Pack size of 1 vial and 1 blunt filter needle. Pre-filled syringe: Pack size of 1 pre filled syringe. Not all pack sizes may be marketed. **Legal classification:** P1S153. Ref: EU Sep 2020

The materials for Beovu® are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country/location. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC).

For Hong Kong Healthcare Professionals' reference and sole use only.

* The primary efficacy endpoint for the studies was the change from baseline in BCVA at Week 48 as measured by the ETDRS Letter Score, with the primary objective to demonstrate noninferiority of Beovu vs aflibercept.[1] † Secondary endpoint in HAWK and HARRIER, confirmatory analysis in HAWK only (1-sided P values for superiority of Beovu).[2,3]

REFERENCES: 1. Beovu Prescribing Information HK, Oct 2020. **2.** Dugel PU, Koh A, Ogura Y, et al; on behalf of the HAWK and HARRIER Study Investigators. HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. *Ophthalmology.* 2020;127(1):72-123. **3.** Data on file. RTH258-C002 Clinical Study Report. Novartis; 2018. **4.** Data on file: RTH258-C001 Clinical Study Report. Novartis; 2018.

LUCENTIS® RANIBIZUMAB

LUCENTIS®: Unsurpassed efficacy and durability in both clinical and real-world evidence



* The primary endpoint of RIVAL is the mean change in area of geographic atrophy from baseline to Month 24.[1]
† Mean final BCVA calculated for patients completing 12 months of follow-up (LUCENTIS®, n=127; aflibercept, n=121).[1]
‡ Injection number reported for Year 2 only, when all patients were treated according to a PRN regimen. In Year 1, patients received LUCENTIS® injections every 4 weeks in both treatment groups.[2]
§ The treatment regimens available for selection were monthly, PRN and Treat & Extend. In a 2013 poll of FRB investigators, 74% used Treat & Extend, 22% used PRN and 4% used monthly.[3]

LUCENTIS®
Note: Before prescribing, consult full prescribing information. **Presentation: Pre-filled syringe :** Ranibizumab. Each pre-filled syringe contains 1.65 mg of ranibizumab in 0.165 mL solution. The extractable volume of one pre-filled syringe is 0.1 ml. This provides a usable amount to deliver a single dose of 0.05 ml containing 0.5 mg ranibizumab. **Indications:** Treatment of neovascular (wet) age-related macular degeneration (AMD). Treatment of visual impairment due to diabetic macular oedema (DME). Treatment of proliferative diabetic retinopathy (PDR). Treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). Treatment of visual impairment due to choroidal neovascularisation (CNV). **Dosage and administration:** The recommended dose is 0.5 mg (0.05 mL) given as a single intravitreal injection. The interval between two doses injected into the same eye should be at least four weeks. Treatment is initiated with one injection per month until maximum visual acuity is achieved and/or there are no signs of disease activity. Thereafter, monitoring and treatment intervals should be determined by the physician and should be based on disease activity as assessed by visual acuity and/or anatomic parameters. Monitoring for disease activity may include clinical examination, functional testing or imaging techniques (e.g. optical coherence tomography or fluorescein angiography). In patients with wet AMD, DME, PDR and RVO, initially, three or more consecutive, monthly injections may be needed. The treatment of visual impairment due to CNV should be determined individually per patient based on disease activity. Some patients may only need one injection during the first 12 months; others may need more frequent treatment, including a monthly injection. For CNV secondary to pathologic myopia (PM), many patients may only need one or two injections during the first year. **treat-and-extend regimen:** While applying the treat-and-extend regimen, the treatment interval should be extended by no more than two weeks at a time for wet AMD and extended by up to one month at a time for DME. For PDR and RVO, treatment intervals may also be gradually extended, however there are insufficient data to conclude on the length of these intervals. If disease activity recurs, the treatment interval should be shortened accordingly. **Lucentis and laser photocoagulation in DME or in branch RVO:** Lucentis has been used concomitantly with laser photocoagulation in clinical studies. When given on the same day, Lucentis should be administered at least 30 minutes after laser photocoagulation. Lucentis can be administered in patients who have received previous laser photocoagulation. Lucentis must be administered by a qualified ophthalmologist using aseptic techniques. Broad-spectrum topical microbicide and anesthetic should be administered prior to the injection. Not recommended in children and adolescents. **Contraindications:** Hypersensitivity to ranibizumab or to any of the excipients, patients with active or suspected ocular or periocular infections, patients with active intraocular inflammation. **Warnings and precautions:** Intravitreal injections have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract. Therefore proper aseptic injection techniques must be used. Patients should be monitored during the week following the injection to permit early treatment if an infection occurs. Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis. Sustained IOP increases have also been reported. Intraocular pressure and the perfusion of the optic nerve head must be monitored and managed appropriately. Patients should be informed of the symptoms of these potential adverse reactions and instructed to inform their physician if they develop signs such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the Lucentis clinical trials in patients with AMD, DME, RVO and CNV and there were no major differences between the groups treated with ranibizumab compared to control. Patients with known risk factors for stroke, including history of prior stroke or transient ischemic attack should be carefully evaluated by their physicians as to whether Lucentis treatment is appropriate and the benefit outweighs the potential risk. Available data do not suggest an increased risk of systemic adverse events with bilateral treatment. As with all therapeutic proteins, there is a potential for immunogenicity with Lucentis. Lucentis has not been studied in patients with active systemic infections or in patients with concurrent eye conditions such as retinal detachment or macular hole. There are insufficient data to conclude on the effect of Lucentis in patients with RVO presenting irreversible ischaemic visual function loss. Should not be used during pregnancy unless the expected benefit outweighs the potential risk to the fetus. For women who wish to become pregnant and have been treated with ranibizumab, it is recommended to wait at least 3 months after the last dose of ranibizumab before conceiving a child; use of effective contraception is recommended for women of child-bearing potential; breast-feeding is not recommended. Following treatment patients may develop transient visual disturbances that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist. Risk factors associated with the development of a retinal pigment epithelial tear after anti-VEGF therapy for wet AMD and potentially also other forms of CNV, include a large and/or high pigment epithelial retinal detachment. When initiating ranibizumab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears. **Interactions:** No formal interaction studies have been performed. **Adverse drug reactions: Very common (≥10%):** vitritis, vitreous detachment, retinal hemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival hemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperemia, eye pruritus, intraocular pressure increased, nasopharyngitis, headache, arthralgia. **Common (1 to 10%):** hypersensitivity, retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of the retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous hemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, vision blurred, injection site hemorrhage, eye hemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema, eyelid pain, conjunctival hyperemia, urinary tract infection*, anemia, anxiety, cough, nausea, allergic reactions (rash, pruritus, urticaria, erythema), eyelid irritation. **Serious adverse events** related to intravitreal injections include endophthalmitis, blindness, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract.
observed only in the DME population
A meta-analysis of pooled safety data from completed, randomized, double masked global studies showed a higher incidence rate of non-serious, non-ocular wound infection/inflammation in DME patients treated with ranibizumab 0.5 mg (1.85/100 patient years) compared to control (0.27/100 patient years). The relationship to ranibizumab remains unknown. **Packs:** 1 pre-filled syringe per pack. **Legal Classification:** P1S153.
Ref: EU Oct 2019 + CDSv)

*The materials for Lucentis® are approved for use only in Hong Kong. Prescribing information may vary depending on local approval in each country/location. Before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SPC). For Hong Kong Healthcare Professionals' reference and sole use only.

References: 1. Gillies MC, Hunyor AP, Arnold JJ, et al. Ophthalmology. 2020;127:198-210. **2.** Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Ophthalmology. 2014;121:193-201. **3.** Gillies MC, Nguyen V, Daien V, et al. Ophthalmology. 2016;123:2545-2553. **4.** Jin KW, Kim JH, Park JY, et al. Sci Rep. 2021;11:14623. November 2016. **5.** Gillies MC, Walton RJ, Arnold et al. Ophthalmology. 2014;121:676-81. **6.** LUCENTIS® Prescribing Information HK, Oct 2019.

NOVARTIS

Novartis Pharmaceuticals (HK) Ltd
7/F, Citi Tower, One Bay East, 83 Hoi Bun Road, Kwun Tong, Kowloon, Hong Kong
Tel: (852) 2882 5222 Fax: (825) 2577 0274

CONGRESS INFORMATION

CONGRESS INFORMATION

The following information is provided to make your attendance at the 16th APVRS Congress in Hong Kong as pleasant as possible. If you have any queries during the Congress or require any assistance, please visit the Registration Desk, or email secretariat@apvrs.org, where our team will be happy to help.

EVENT NAME

The 16th APVRS Congress held in conjunction with the Asia-Pacific Ocular Imaging Society (APOIS) Congress, the Annual Meeting of the Asia-Pacific Society of Eye Genetics (APSEG), and the Annual Scientific Meeting Hong Kong Ophthalmological Symposium

CONGRESS VENUE

4/F and 5/F, Hong Kong Convention and Exhibition Centre (HKCEC), 1 Expo Drive, Wanchai, Hong Kong

REGISTRATION AND INFORMATION DESK

The Registration and Information Desk is located Hall 5FG Concourse, with the following opening hours:

Dec 8, 2023 (Fri)	07:30 – 18:30
Dec 9, 2023 (Sat)	07:30 – 18:30
Dec 10, 2023 (Sun)	07:30 – 13:45

ON-SITE PAYMENT

On-site payment with cash and credit card can be made at the Registration Desk during opening hours. Cheques are not accepted.

NAME BADGES

All delegates registered for the Congress will be issued with a name badge at the Registration Desk. This badge will be the official pass and must be worn at all times while on-site by the named delegate only.

All badges are non-transferable. Reissuing of name badges for the delegate/accompanying person will be available at the Registration Desk. An administrative fee of US$20 may be incurred for re-issuing a delegate badge.

Accompanying Persons (if any) are entitled to enter only the Exhibition Hall and Opening Ceremony of APVRS 2023.

DELEGATE BAG AND RIBBON COLLECTION

Delegates can collect delegate bags and ribbons at the Delegate Bag Pick-up Area in the Exhibition Hall.

DRESS CODE

Neat casual attire is acceptable for attendance at Congress sessions and social functions.

APVRS CONGRESS SMARTPHONE APP

The APVRS 2023 mobile app provides easy-to-use interactive capabilities to enhance your Congress experience. The app features all the scientific sessions, e-posters, video abstracts, sponsors, floor plan, and general information.

The app can be downloaded by scanning the QR codes shown below.

ANDROID IOS

You are strongly recommended to update the app regularly to keep abreast of the latest congress updates. If you need any help downloading the app and navigating its functions, please ask for assistance at the registration desk during the Congress or email secretariat@apvrs.org.

SESSION SCHEDULE

The session schedule can be found at https://2023.apvrs.org/program-schedule/. All program schedules are shown in GMT+8 (Hong Kong).

SPEAKER READY ROOM

All speakers are required to check in and upload their PowerPoint at the respective Speaker Ready Room 24 hours before their scheduled presentation. The computers in the Speaker Ready Room will have the exact same configuration as those in the session rooms.

It is imperative that you review your presentation in the Speaker Ready Room where our technicians will help resolve any compatibility and/or formatting issues.

The Speaker Ready Room will be open during the following times in S430 on the 4/F:

Dec 7, 2023 (Thu)	15:30 – 18:00
Dec 8, 2023 (Fri)	07:30 – 18:00
Dec 9, 2023 (Sat)	07:30 – 17:00
Dec 10, 2023 (Sun)	07:30 – 15:00

SCIENTIFIC POSTERS

Paper posters can be found in the Exhibition Hall.

Delegates can use the image scanner to scan the poster. They will then be directed to a recording made by the author where applicable.

E-POSTER & VIDEO PLATFORM

Delegates can view e-posters via the APVRS 2023 Congress app for smartphones. They can also visit the E-poster and Video Viewer located in the Exhibition Hall.

ABSTRACT BOOK

A PDF copy of the abstract book is available online at http://2023.apvrs.org/publications. No hard copy will be distributed. Please scan the QR code below to access the abstract book:

SPONSORED SESSIONS

Venues where sponsored sessions will be held are listed below.

Time	Session	Venue*
Dec 8, 2023 (Fri)		
12:30 - 13:30	Bayer Sponsored Symposium 1: Aflibercept: Achieving Optimal Outcomes in Retinal Diseases	Hall 5G
	Roche Sponsored Symposium 1: nAMD: Change in Treatment Paradigm for nAMD with faricimab: Evidence from Clinical Trials and Real World Practice	S421
	ZEISS Sponsored Symposium: ZEISS Retina Workflow Lunch Symposium	S426 - S427
	Topcon Sponsored Symposium: Wider Applications of Retina Imaging and Treatment	S423 - S424
Dec 9, 2023 (Sat)		
12:30 - 13:30	Bayer Sponsored Symposium 2: Maximizing Patient Outcomes in nAMD, and Can We Go Further with Disease Control?	S421
12:30 - 13:30	Roche Sponsored Symposium 2: DME: Change in Treatment Paradigm for DME with faricimab: Evidence from Clinical Trials and Real World Practice	Hall 5G
	Alcon Sponsored Symposium 1: Modern Approach to Vitrectomy Surgery	S426 - S427
	Nikon/Optos Sponsored Symposium: Advances in Ultra-widefield Multimodal Retinal Imaging	S423 - S424
Dec 10, 2023 (Sun)		
12:30 - 13:30	Alcon Sponsored Symposium 2: Alcon Vision Suite: Complete, Connected Care for VR Surgeons	S426 - S427
	Novartis Sponsored Symposium: From Past to Present: The Evolution of Retinal Disease Therapy	S423 - S424

*Please refer to the floor plan for the location of the session rooms.

ON-DEMAND

All congress materials will be on demand for viewing till April 21, 2024. Please visit https://2023.apvrs.org/program-schedule/ and select scientific sessions to view the recordings.

POLICIES

No Smoking – Smoking is strictly prohibited in all session rooms, meeting and exhibition areas. Your cooperation is appreciated.

Mobile Phones – Please respect the presenter and other delegates by ensuring that your mobile devices are put in silent mode during sessions.

Photography in the Exhibition Hall – Attendees wishing to photograph or videotape an exhibit must obtain permission from the relevant company beforehand.

Photographing or Videotaping Scientific Sessions – Photographing and/or videotaping the scientific sessions are strictly prohibited. (Permission must be obtained in advance by media representatives.)

CERTIFICATES OF ATTENDANCE

Certificates of Attendance can be downloaded through the APVRS Congress system (http://congress.apvrs.org/) after the Congress.

SOCIAL EVENTS

Opening Ceremony cum Tano Lecture and International Award Lecture

Date: Dec 8, 2023 (Fri)
Time: 13:45 – 15:00 (GMT+8)
Location: Hall 5G, 5/F, Hong Kong Convention and Exhibition Centre (HKCEC)

Constable Lecture and Dennis Lam Lecture

Date: Dec 9, 2023 (Sat)
Time: 13:45 – 15:00 (GMT+8)
Location: Hall 5G, 5/F, Hong Kong Convention and Exhibition Centre (HKCEC)

Sponsor Appreciation

Date: Dec 9, 2023 (Sat)
Time: 14:45 – 15:15 (GMT+8)
Location: Hall 5F, 5/F, Hong Kong Convention and Exhibition Centre (HKCEC)

Gala Dinner

Date: Dec 9, 2023 (Sat)
Time: 19:00 – 21:00 (GMT+8)
Location: Chancellor Room, 4/F, Hong Kong Convention and Exhibition Centre (HKCEC)

PROGRAM AT A GLANCE

PROGRAM OVERVIEW

GMT+8 (Hong Kong Time)	Dec 8 (Day 1 Friday)	Dec 9 (Day 2 Saturday)	Dec 10 (Day 3 Sunday)
08:30 - 08:45	Registration	Registration	Registration
08:45 - 09:00			
09:00 - 09:15			
09:15 - 09:30			
09:30 - 09:45			
09:45 - 10:00	**Scientific Sessions** (08:30 - 10:00)	**Scientific Sessions** (08:30 - 10:00)	**Scientific Sessions** (08:30 - 10:00)
10:00 - 10:15	Break	Break	Break
10:15 - 10:30			
10:30 - 10:45			
10:45 - 11:00			
11:00 - 11:15			
11:15 - 11:30			
11:30 - 11:45			
11:45 - 12:00	**Scientific Sessions** (10:30 - 12:00)	**Scientific Sessions** (10:30 - 12:00)	**Scientific Sessions** (10:30 - 12:00)
12:00 - 12:15	Break	Break	Break
12:15 - 12:30			
12:30 - 12:45			
12:45 - 13:00			
13:00 - 13:15			
13:15 - 13:30	**Lunch Symposiums (S)*** (12:30 - 13:30)	**Lunch Symposiums (S)*** (12:30 - 13:30)	**Lunch Symposiums (S)*** (12:30 - 13:30)
13:30 - 13:45	Break	Break	Break
13:45 - 14:00			
14:00 - 14:15			
14:15 - 14:30			
14:30 - 14:45			
14:45 - 15:00	**Opening Ceremony** **Tano Lecture** **International Award Lecture** (13:45 - 15:00)	**Constable Lecture** **Dennis Lam Lecture** (13:45 - 14:45) **Sponsor Appreciation** (14:45 - 15:15)	**Scientific Sessions** (13:45 - 15:15)
15:00 - 15:15	Break		
15:15 - 15:30			
15:30 - 15:45			
15:45 - 16:00			
16:00 - 16:15			
16:15 - 16:30			
16:30 - 16:45	**Scientific Sessions** (15:15 - 16:45)	**Scientific Sessions** (15:15 - 16:45)	
16:45 - 17:00	Break	Break	
17:00 - 17:15			
17:15 - 17:30			
17:30 - 17:45			
17:45 - 18:00			
18:00 - 18:15			
18:15 - 18:30	**Scientific Sessions** (17:00 - 18:30)	**Scientific Sessions** (17:00 - 18:30)	
18:30 - 18:45			
18:45 - 19:00			
19:00 - 19:15			
19:15 - 19:30			
19:30 - 19:45			
19:45 - 20:00			
20:00 - 20:15		**Gala Dinner** (19:00 - 21:00)	
20:15 - 20:30			
20:30 - 20:45			
20:45 - 21:00			

SCIENTIFIC SESSIONS

Day 1 - December 8, 2023 (FRIDAY)				
	Venue	Subspecialty	Type	Theme
08:30 - 10:00	S421	Retina (Surgical)	Symposium	Innovation and Controversies in Surgical Retina
	S422	Retina (Medical)	Free Paper	APVRS Rapid Fire 1 – Retina (Medical)
	S423 - S424	Retina (Medical)	Symposium	Pachychoroid Diseases
	S428	Other (General Ophthalmology)	Symposium	APMS Symposium: Myopia – Genetics, Epidemiology, Risk Factors and Animal Models
10:30 - 12:00	S421	Retina (Medical)	Symposium	Age-related Macular Degeneration: Dry AMD
	S422	Retina (Surgical)	Free Paper	APVRS Rapid Fire 2 – Retina (Surgical)
	S423 - S424	Retina (Medical)	Symposium	Subthreshold Ophthalmic Laser Society (SOLS) Sponsored Symposium
	S425	Pediatric Retina	Symposium	Pediatric Retina (1)
	S428	Other (General Ophthalmology)	Symposium	APMS Symposium 2
15:15 - 16:45	S421	Retina (Medical)	Symposium	Diabetic Retinopathy (1): DME
	S422	Translational Medicine	Symposium	APSEG Symposium: Genomics of Eye Diseases
	S423 - S424	Ocular Imaging	Symposium	APOIS-APVRS Symposium 1: Advanced Retinal Imaging
	S425	Ocular Oncology & Pathology	Symposium	Current Concepts in Intraocular Tumors
	S428	Other (General Ophthalmology)	Symposium	APMS Symposium: Updates on Refractive Surgery: SMILE and ICL
17:00 - 18:30	S421	Translational Medicine	Symposium	Artificial Intelligence for Retinal Diseases
	S422	Translational Medicine	Symposium	APSEG Symposium: Molecular Genetics in Retinal Diseases
	S423 - S424	Retina (Surgical)	Symposium	Surgical Retina: PDR, PVR, and Others
	S425	Other (General Ophthalmology)	Symposium	Young Ophthalmologist Symposium
	S428	Other (General Ophthalmology)	Symposium	APMS Symposium: Myopia Prevention and Control

Day 2 - December 9, 2023 (SATURDAY)				
	Venue	Subspecialty	Type	Theme
08:30 - 10:00	S421	Retina (Surgical)	Symposium	Surgical Retina: Macular Surgery
	S422	Ocular Imaging (APOIS)	Free Paper	APOIS Symposium 7: Rapid Fire
	S423 - S424	Retina (Medical)	Symposium	Retinal Vascular Diseases
	S425	Pediatric Retina	Symposium	Pediatric Retina (2)
	S426 - S427	Ocular Imaging	Symposium	APOIS-APVRS Symposium 2: Polypoidal Choroidal Vasculopathy (PCV)
	S428	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 1: Masterclass in Ocular Imaging
10:30 - 12:00	S421	Retina (Medical)	Symposium	Age-related Macular Degeneration: Wet AMD
	S422	Retina (Medical)	Free Paper	APVRS Rapid Fire 3 – Retina (Medical) and Ocular Oncology & Pathology
	S423 - S424	Intraocular Inflammation, Uveitis & Scleritis	Symposium	Uveitis (1): Applying Research Findings to Clinical Conundrums: A Clinical Case-based Symposium
	S425	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 4: Future of Cornea and Anterior Segment Imaging
	S426 - S427	Other (General Ophthalmology)	Symposium	APMS-APVRS Symposium: High Myopia
	S428	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 3: Artificial Intelligence and Machine Learning in Glaucoma Imaging
15:15 - 16:45	S421	Retina (Medical)	Symposium	Diabetic Retinopathy (2): DR
	S422	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 2: Advancements in OCT for Glaucoma Diagnosis and Management
	S423 - S424	Intraocular Inflammation, Uveitis & Scleritis	Symposium	Uveitis (2): Update in Uveitis
	S425	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 5: Intraoperative Imaging and New Ideas in Ocular Imaging
	S426 - S427	General Ophthalmology	Symposium	CUHK Ophthalmology 30th Anniversary Symposium
	S428	Cornea and External Eye Disease	Symposium	Cornea and External Eye Disease Symposium
17:00 - 18:30	S421	Retina (Medical)	Symposium	The Macula Society Sponsored Symposium on Central Serous Chorioretinopathy
	S422	Translational Medicine	Symposium	APSEG Symposium: Gene and Cell Therapy in Retinal Diseases
	S423 - S424	Translational Medicine	Symposium	GEGC Dr. Chi Chao Chan Symposium on Global Collaboration of Eye Diseases
	S425	Ocular Imaging (APOIS)	Symposium	APOIS Symposium 6: Innovations and Challenges in Ocular Imaging
	S428	General Ophthalmology	Symposium	APES Symposium

Day 3 - December 10, 2023 (SUNDAY)				
	Venue	Subspecialty	Type	Theme
08:00 - 09:00	S421	Other (General Ophthalmology)	Symposium	Late Breaking Keynote Symposium
08:30 - 10:00	S422	Ocular Oncology & Pathology	Free Paper	APVRS Rapid Fire 4 – Ocular Oncology & Pathology, Eye Trauma, Emergencies & Infections, General Ophthalmology and Pediatric Retina
	S423 - S424	Retina (Medical)	Symposium	Mysterious Retina Cases
	S425	Other (General Ophthalmology)	Symposium	Canadian Retina Society Sponsored Symposium: Advances in Pneumatic Retinopexy: The Expanded Indications
	S426 - S427	Orbital & Oculoplastic Surgery	Symposium	Orbital & Oculoplastic Surgery Symposium
	S428	Glaucoma	Symposium	Glaucoma Symposium
10:30 - 12:00	S422	Ocular Imaging	Free Paper	APVRS Rapid Fire 5 – Ocular Imaging, Intraocular Inflammation and Uveitis & Scleritis
	S423 - S424	Translational Medicine	Symposium	New Translational Developments in Vitreo-retina
	S425	Retina (Medical)	Symposium	Inherited Retinal Diseases
	S426 - S427	General Ophthalmology	Symposium	HKU Symposium - Diagnostic and Therapeutic Innovations From HKU Ophthalmology
	S428	General Ophthalmology	Symposium	General Ophthalmology Symposium
13:45 - 15:15	S422	Pediatric Retina	Free Paper	APVRS Rapid Fire 6 – Pediatric Retina, Translational Medicine and Ophthalmic Epidemiology
	S423 - S424	Retina (Surgical)	Symposium	Management of VR Complications from Anterior Segment Surgeries
	S426 - S427	Cataract and Refractive Surgery	Symposium	Cataract & Refractive Symposium
	S428	Paediatric & Neuro-ophthalmology	Symposium	Paediatric & Neuro-ophthalmology Symposium

FLOOR PLAN

4/F



5/F





SPECIAL LECTURES AND AWARDS

SPECIAL LECTURES

APVRS TANO LECTURE

The APVRS Tano Lecture was established in 2009 in memory of Prof. Yasuo Tano, the founding president of APVRS. Every year, the APVRS honors an individual of over 45 years of age for exemplary leadership and significant contributions in advancing the understanding, diagnosis, and treatment of vitreoretinal diseases with the APVRS Tano Lecture.

Prof. Kazuaki Kadonosono (Japan), MD

Prof. Kazuaki Kadonosono obtained his medical degree from Yokohama City University School of Medicine in Japan in 1988. Following that, he completed his residency in Ophthalmology at Yokohama City University Hospital. He then assumed the role of director of the retina department at Yokohama City University, School of Medicine, where he also served on the faculty.

His primary research focuses on advancing and evaluating innovative surgical techniques within the fields of vitreoretinal and macular surgery. Prof. Kadonosono has been actively involved in various pioneering studies pertaining to treatments for retinal diseases. He has held positions of significance, including being a member of the Board of the Japanese Ophthalmological Society (JOS), serving as the Executive Director of the Japanese Retina and Vitreous Society (JRVS), and maintaining memberships with esteemed organizations such as the American Society of Retina Specialists (ASRS), the American Academy of Ophthalmology (AAO), the Macula Society, and as an International member of Club Jules Gonin.

Currently, Prof. Kadonosono holds the position of Professor and Chair of the Department of Ophthalmology and Micro-technology at Yokohama City University. His prolific contributions extend to the publication of over two hundred papers, and he has been a sought-after participant in prestigious international conferences for decades.

Innovation of Vitrectomy Techniques and Subsequent Surgical Results

December 8 (Friday) 14:33 - 14:48 Hall 5G

Vitrectomy is an extremely innovative surgical procedure. Professor Yasuo Tano was my mentor, and although I wasn't directly taught surgical techniques by him, he kindly supported me at important points in my career. One thing he taught me that I have always kept in mind is: "Don't do things in a conventional way". Since gaining this insight, I have been inspired to develop cutting-edge surgical techniques and instruments. I'd like to introduce several surgical techniques that I've developed and discuss recent modifications and

improvements that have been made to them.

Internal limiting membrane peeling with the use of dyes is an essential surgical procedure. Since I invented this staining technique 20 years ago, I haven't changed the method I use, but recent 3D digital technology has allowed us to enhance it greatly.

Central retinal arterial occlusion is an unmet need. Cannulation with tPA using a 47-gauge needle enables re-canalization of macular vessels leading to a 60% improvement in visual acuity for patients with CRAO.

I have been engaged in developing flanged scleral suture techniques and displacement of submacular hemorrhages due to AMD.

Our group has also developed autologous retinal transplant for refractory macular hole and evaluated it to be superior to other techniques in current use.

Even more recently exosomes have proved to be a highly effective adjunct to retinal transplantation.
I'm glad I believed in the wisdom Dr. Tano passed on to me 20 years ago, and I'll continue to do things in an unconventional way.

APVRS CONSTABLE LECTURE

The APVRS Constable Lecture was established in 2016 in honor of Prof. Ian Constable, a past president of APVRS. The Constable Lecture awards individuals of 45 years or younger for outstanding contributions in advancing the understanding, diagnosis, and treatment of vitreo-retinal diseases.

Dr. Gavin Tan (Singapore), MBBS, MMed, FRCSEd, PhD

Dr. Gavin Tan is a Senior Consultant at the Surgical Retina Department of Singapore National Eye Centre (SNEC). He is an Associate Professor with the SingHealth Duke-National University of Singapore (Duke-NUS) Ophthalmology Academic Clinical Program and concurrently the Vice-Chair for Strategy and Innovation. As a clinician, he has contributed to the development of the Paediatric Vitreoretinal Service at SNEC and KK Women and Children's Hospital; and set up the first Ocular Oncology Plaque Brachytherapy Service in Singapore.

Dr. Gavin Tan has been instrumental in developing tele-ophthalmology in Singapore and the region. He set up the Singapore National Diabetic Retinopathy (DR) Telescreening Program for which he is Program Director, and developed imaging based virtual telemedicine clinics at SNEC, which were instrumental in providing high quality care for patients during the Covid pandemic.

Academic achievements

Dr. Tan has more than 100 peer reviewed publications in vitreoretinal diseases and has presented over 40 papers in local and overseas meetings. Gavin has been awarded various competitive grants for his work, totalling more than $10 million as principal investigator.

He has published widely on the epidemiology of DR in Asia (Tan, Ophth 2017). He demonstrated the cost effectiveness of non-physician graders for DR screening (Nguyen Ophth 2016), and developed an AI algorithm for DR screening (Ting Jama 2017) and showed a hybrid model of care is most cost effective (Xie, Lancet Digital health 2020). He has investigated the utility of wide field optical coherence tomography angiography of the retina and choriocapillaris in the understanding of diabetic retinopathy (Tan, Jama open 2020; Tan, BJO 2022). He has also contributed to research on the use of ocular imaging biomarkers and AI for systemic disease. (Nusinovici Sci Rep. 2021; Nusinovici, Am J Kidney Dis. 2019 Cheung Nat Biomed Eng 2020; Ting NPJ Digit Med. 2019).

Leadership

He is Head of the Ocular Diagnostics Department and SNEC Ocular Reading Centre which provides imaging reading for clinical trials internationally and training in setup of DR screening programs for countries as diverse as Vietnam to Mexico. He developed Ophthalmic Investigations Technicians (OIT) into an allied health profession in Singapore and supports training for OITs across the region. Dr. Tan is council member for the

Asia Pacific Tele-ophthalmology Society (APTOS) since 2016. He is currently Secretary of the Singapore Society of Ophthalmology (SSO) and has serve on council since 2012. He was the congress chair for APTOS meeting in Singapore 2018 and scientific program chair for Singapore-Malaysia Joint Meeting in Ophthalmology in 2020 and 2023; and 33rd APACRS-SNEC 30th Anniversary Virtual Meeting in 2021.

Contribution to the vitreoretinal subspecialty

Dr. Tan is heavily involved in the training of both medical retina and surgical retina fellows at SNEC and has trained fellows both from Singapore and internationally. He has served as course director for various imaging and retina courses and preceptorships organized by SNEC and SERI, and contributes to instructional courses, invited, and submitted programs in retina at APAO, APVRS, ASRS, Euretina, ARVO and macular society meetings. He has contributed to the WHO diabetes complications work group, the IDF clinical practice recommendations committee and the IAPD diabetic retinopathy work group.

Other achievements/awards

Dr. Tan has been recognized for his contribution to ophthalmology with the SingHealth Outstanding Clinician Researcher Award 2019, APAO Achievement Awards 2019, MOH National Clinical Excellence Awards 2019, and the APJO 2022 Asia Pacific Eye 100.

The Evolution of Multimodal Imaging in Diabetic Retinopathy

December 9 (Saturday) 13:50 - 14:05 Hall 5G

The staging of diabetic retinopathy (DR) was establish by the ETDRS study, which utilised 7-field fundus photography to grade severity which determined DR management and treatment for decades. The development of optical coherence tomography coupled with the introduction of anti-VEGF drugs revolutionised the management of diabetic macular edema. Further developments including ultra-wide field fundus photography with angiography; and optical coherence tomography angiography have also contributed to our understanding of diabetic retinopathy. There is growing evidence that deep learning can improve the interpretation of retinal imaging beyond the standard biomarkers. This lecture will cover the evolution of these imaging modalities for diabetic retinopathy and discuss how multimodal imaging and artificial intelligence will change the way we manage diabetes in the future.

APVRS DENNIS LAM LECTURE

The APVRS Dennis Lam Lecture was established in 2023 in honor of Prof Dennis Lam, APVRS Past President, Past Chairman of the Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong, and Director of the APVRS Leadership Development Program (LDP). The Dennis Lam Lecture honors individuals who have made significant contributions to VR training and education for residents, fellows, and postgraduate students, and grooming future VR leaders in the Asia-Pacific region and beyond. There are no geographic or age restrictions for the awardees of this lecture.

Neil M Bressler (USA), MD

Prof. Neil Bressler is well known throughout the Asia-Pacific region and the rest of the world in his current leadership roles as Professor of Ophthalmology at Johns Hopkins University, where he was Chief of the Retina Division for 13 years, and as the current Editor in Chief of *JAMA Ophthalmology* since 2013. Throughout his career, he has authored over 470 peer-reviewed publications, many in his role as Chair of multiple NIH-sponsored multicenter clinical trials, such as the DRCR Retina Network, that have changed practice and improved vision outcomes for leading public health problems such as diabetic retinopathy and age-related macular degeneration. Since 2003, he has served on the National Eye Institute's (NEI's) Data and Safety Monitoring Committee for intramural clinical trials at the National Institutes of Health (NIH), and has chaired this Committee for over 17 years. He also has participated on the FDA Ophthalmic Devices Panel for 23 years, and has served as the Panel's Chair 2008 – 2011 and currently chairs the Panel since 2019. Dr. Bressler also was President of the Macula Society in 2013 and 2014.

Throughout this illustrious career, he has continued to mentor individuals from the Asia-Pacific region and beyond, many of whom participated in their first multicenter clinical trials chaired by Professor Bressler and who then went on to mentor other individuals in the region and become leaders in the field of ophthalmology throughout Asia and the rest of the world. These interactions have given him the opportunity to invite early career ophthalmologists to train with him as research fellows, often for one to two years at Johns Hopkins University School of Medicine, and these individuals subsequently have published numerous peer-reviewed articles with Dr. Bressler and become leaders and mentors themselves, for example, Dr. Voraporn Chaikitmongkol from Thailand, or Dr. Daniel Ting from Singapore. Even in 2023, some of these individuals, and others, for example, Professor Xiaoyan Ding in Guangzhou, or Professor Gemmy Cheung in Singapore, collaborate in projects through formal agreements with Johns Hopkins University School of Medicine and Prof. Bressler's leadership.

Furthermore, Prof. Bressler has served as a mentor's mentor for many years at the APVRS and APAO's Leadership Development Program, where he has co-chaired with Professor Dennis Lam one of the highlights of the Program for many years, specifically, moderating a panel of leading mentors from the Asia-Pacific region and

the rest of world through a series of some of the most challenging questions for mentors and mentees in ophthalmology.

Evolution of Managing Diabetic Macular Edema in the 21st Century

December 9 (Saturday) 14:15 - 14:30 Hall 5G

Management of diabetic macular edema (DME) has evolved into the 21st century, resulting in outstanding outcomes that can improve vision or prevent vision loss and blindness. Given the public health problem of DME throughout the world, it is critical to strive to bring this management to as many people with diabetes as possible. The management is built on the foundation of laser treatment first proven effective at avoiding at least moderate vision loss in approximately 85% of treated eyes. Further improvements came with the onset of anti-vascular endothelial growth factor treatments that can result in visual acuity of 20/25 or better in over 85% of treated eyes if identified at an early stage and managed as performed in recent clinical trials, as well as imaging with optical coherence tomography and artificial intelligence assisting in the interpretation of retinal images. The challenge for the next decade will include getting access to monitoring and these treatments, when warranted, in an attempt to eliminate vision loss, including blindness, until a cure for diabetes becomes a reality. This lecture will present this evolution of managing DME as part of an educational process that hopefully can assist in these goals of eliminating vision loss from DME.

APVRS INTERNATIONAL AWARD LECTURE

The APVRS International Award Lecture was established in 2017. The International Award Lecture recognizes individuals from outside the Asia-Pacific region for outstanding contributions in advancing the understanding, diagnosis, and treatment of vitreo-retinal diseases. There is no age restriction for APVRS International Award Lecture recipients.

Jost B Jonas (Germany), MD

Jost B. Jonas, MD is a comprehensive ophthalmologist and clinical scientist.

He is Chairman of the Department of Ophthalmology of the Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg/Germany. He received his medical degree at the University of Freiburg/Germany. After attending the military service in the German Navy, he underwent his ophthalmology training at the private praxis Dres. Schmitz-Valckenberg / Brambring in Koblenz / Germany and at the University of Erlangen, Germany, where he became staff member and Vice Chairman in 1991, before he moved to the Heidelberg University in 2000.

His research interests include:

- Intravitreal application of medication as treatment of intraocular edematous, proliferative, and neovascular diseases (first descriptions of intravitreal medication (triamcinolone) for diabetic macular edema, proliferative diabetic retinopathy, retinal vein occlusions, ocular hypotony, sympathetic ophthalmia, uveitis, secondary neovascular angle glaucoma, cataract surgery);
- Process of emmetropization and myopization (including axial elongation-associated shifting of Bruch's membrane, histology of Bruch's membrane and choriocapillaris in myopia, spatial relationships of morphometric parameters; intraocular myopia-associated messenger molecules);
- Morphology of the optic nerve head (interindividual size variability of the optic disc, pseudoglaucomatous macrocups in macrodiscs, ISNT-rule, parapapillary alpha, beta, gamma and delta zones; peripapillary border tissue of the choroid and scleral flange in myopia; lamina cribrosa thickness in glaucoma and myopia), localized retinal nerve fiber layer defects;
- Ophthalmodynamometry (assessment of the retinal arterial and venous blood pressure for estimation of brain pressure, and evaluation of the retinal veinous and carotid artery status);
- Surgical aspects (intraocular foreign body removal; transpupillary silicone oil release combined with cataract surgery; topical anesthesia for glaucoma surgery; femtosecond laser-assisted penetrating keratoplasty with conical cutting edges and anti-rotational indentation spikes);

- Cerebrospinal fluid pressure in the pathogenesis of glaucomatous optic neuropathy, diabetic retinopathy and retinal vein occlusions;
- Intravitreal cell-based (drug) therapy;
- Homologous intravitreal bone-marrow transplantation;
- Retinal microglial cell system as retinal "gardeners";
- Epidemiology in ophthalmology and general medicine (including 21 population-based or community-based studies such as the Beijing Eye Study 2001, 2006, 2011; Central India Eye and Medical Study; Shandong Children Eye Study; Ural Eye and Medical Study, Ural Children Eye Study, and Ural Very Old Study).

Statistics

- H-index (Web of Science Core Collection, 16.8.23): 145
- Number of citations (Web of Science Core Collection), total: 167,186; in 2022: 27,016
- Number of SCI (PubMed) publications: 1,459

He is Honorary Member of the French Ophthalmological Society and Asia-Pacific Vitreo-retinal Society and Fellow of the Association of Research in Vision and Ophthalmology ARVO. From 2014 to 2021, he served as one of the editors-in-chief of the *British Journal of Ophthalmology*, and actually he is, second to Prof. Dennis Lam, editor-in-chief of the *Asia-Pacific Journal of Ophthalmology*. He has received the Glaucoma Award of the German Ophthalmologic Society, the Junior and Senior Award of the American Academy of Ophthalmology, the Senior Clinical Scientist Award of the World Glaucoma Association, the Prof. Robert Ritch Glaucoma Award, the International Gold Award of the Chinese Ophthalmologic Society, the Senior Award of the Asia-Pacific Academy of Ophthalmology, the International Scholar Award of the American Glaucoma Society, and the International Collaboration Award of the Beijing Municipal of Science and Technology.

Histological-Clinical Correlation and Potential Mechanism

December 8 (Friday) 14:53 - 15:08 Hall 5G

Myopic axial elongation is associated with non-pathological changes, including a decrease in photoreceptor cell and retinal pigment epithelium (RPE) cell density and retinal layer thickness, mainly in the retro-equatorial to equatorial regions; choroidal and scleral thinning pronounced at the posterior pole and least marked at the ora serrata; and a shift in Bruch's membrane opening (BMO) occurring in moderately myopic eyes and typically in the temporal/inferior direction. The BMO shift leads to an overhanging of Bruch's membrane (BM) into the nasal intrapapillary compartment and BM absence in the temporal region (i.e., parapapillary gamma zone), optic disc ovalization due to shortening of the ophthalmoscopically visible horizontal disc diameter, fovea–optic disc distance elongation, reduction in angle kappa, and straightening/stretching of the papillomacular retinal blood vessels and retinal nerve fibers. Highly myopic eyes additionally show an enlargement of all layers of the optic nerve canal, elongation and thinning of the lamina cribrosa, peripapillary scleral flange (i.e., parapapillary delta zone) and peripapillary choroidal border tissue, and development of circular parapapillary beta, gamma, and delta zone. Pathological features of high myopia include development of macular linear RPE defects (lacquer cracks), which widen to round RPE defects (patchy atrophies) with central BM defects, macular neovascularization, myopic macular retinoschisis, and glaucomatous/glaucoma-like and non-glaucomatous optic neuropathy. BM thickness is unrelated to axial length. Including the change in eye shape from a sphere in emmetropia to a prolate (rotational) ellipsoid in myopia, the features may be explained by a primary BM enlargement in the retro-equatorial/equatorial region.

APVRS TANO TRAVEL GRANTS

The APVRS Tano Travel Grants were established in memory of the Founding President of the Asia-Pacific Vitreo-retina Society (APVRS), Prof. Yasuo Tano, with the aim to provide partial travel support to young ophthalmologists in the vitreo-retina field in the Asia-Pacific region to attend the APVRS Congress. This is an integral part of APVRS's effort to further the training and education of young ophthalmologists in the Asia-Pacific region.

Abu Faisal Md Jahangir ALAM
(Bangladesh)

Chi Lik AU
(Hong Kong SAR)

Harsh H. JAIN
(India)

John Philip T. UY
(The Philippines)

Dawei YANG
(China)

INVITED SYMPOSIUMS

INVITED SYMPOSIUMS

Dec 08, 2023 (Fri)

Ocular Imaging

APOIS-APVRS Symposium 1: Advanced Retinal Imaging

Advances in retinal imaging continue to progress at a rapid pace. This symposium will include a selection of these many advances in imaging which are poised to impact the clinical practice of retina in the next few years. We will discuss topics ranging from home diagnostics to pushing the boundaries of structural resolution, and in vivo metabolic assessments to imaging in the operating room.

15:15 - 16:45 **Venue: S423-S424**
*Chair(s): Kenneth Kai Wang **LI**, Srinivas **SADDA**, Hiroko **TERASAKI***

15:15 Widefield OCT and OCT Angiography
*Hiroko **TERASAKI***

15:26 High-resolution OCT (or FLIO)
*Yoko **MIURA***

15:37 Clinical Applications of Peripheral OCT
*Srinivas **SADDA***

15:48 Inferring FA from OCTA Using AI Approaches
*Toshinori **MURATA***

15:59 Update on AI Applications in Retinal Imaging
*Carol **CHEUNG***

16:10 Progress in Home OCT
*Judy **KIM***

16:21 Intraoperative OCT and Digital Viewing
*Kenneth Kai Wang **LI***

16:32 Panel Discussion and Q&A

Ocular Oncology & Pathology

Current Concepts in Intraocular Tumors

This symposium will discuss the current state of advances to treat several intraocular tumors and management techniques, including vitreoretinal lymphoma, intra-arterial chemotherapy, retinoblastoma organoids, tebentafusp retinopathy, imaging of intraocular tumors, and retinoblastoma perspectives and treatment. Experts from around the world will discuss the impact that several ophthalmic oncology conditions have had worldwide and its current management. At the conclusion of this course, participants will understand a variety of intraocular tumors and its current management in and outside the Asia-Pacific region based on the speakers' international experience.

15:15 - 16:45 **Venue: S425**
*Chair(s): J. Fernando **AREVALO**, Duangnate **ROJANAPORN**, Emily **WONG***

15:15 Diagnosis of Vitreoretinal Lymphoma
*Qing **LI***

15:26 Is Intra-arterial Chemotherapy for Everyone? When Not to Use This Technique
*Carol **SHIELDS***

15:37 Retinoblastoma Organoids
*Duangnate **ROJANAPORN***

15:48 Tebentafusp Retinopathy
*J. Fernando **AREVALO***

15:59 Imaging of Intraocular Tumors
*Christopher **LEE***

16:10 Retinoblastoma: A Global Perspective
*Emily **WONG***

16:21 Retinoblastoma Treatment Update 2023
*Bhavna **CHAWLA***

16:32 Panel Discussion and Q&A

Other (General Ophthalmology)

Young Ophthalmologist Symposium

The program aims to give a platform for young retinal specialists to discuss, share experiences and learn from their counterparts in the region in the hope that YOs may be able to meet potential mentors and form meaningful collaborations with each other.

17:00 - 18:30 **Venue: S425**
*Chair(s): Kai Xiong **CHEONG**, Elliott **SOHN**, Anna **TAN**, Raymond **WONG***

17:00 Keynote Lecture 1
*Richard **SPAIDE***

17:11 Keynote Lecture 2
*Young Hee **YOON***

17:22 Q&A with Experts

17:30 Gameshow/Quiz

18:00 Case Presentation 1
*Shayne **TAN***

18:05 Case Presentation 2
*Ye **LI***

18:09 Case Presentation 3
*Katrina Beatrize **MANAS-LIM***

18:13 Case Presentation 4
*Christopher **GO***

Pediatric Retina

Pediatric Retina (1)

The section highlights the recent advances in pediatric retinal disorders. The latest diagnostic tools such as smartphones used for ROP diagnosis, portable OCT and biomarkers in tear fluid for ROP, ultra-widefield fluorescein angiogram in regressed ROP, genetics in FEVR, optimal treatment options for ROP, and innovative surgical techniques in handling tough pediatric retina disorders such as XLRS and MGS will be presented. After these talks, the audience will get a better idea of how this progress can help manage these challenging pediatric cases.

10:30 - 12:00 **Venue: S425**
*Chair(s): Nicholas **FUNG**, Shunji **KUSAKA**, Wei-chi **WU***

10:30 Smartphone Fundus Imaging in ROP
*Parag **SHAH***

10:40 Portable OCT in ROP
*Cagri **BESIRLI***

10:50 Management of Sight-threatening ROP
*Sanyam **BAJIMAYA***

11:00 Tear Fluid Biomarkers in ROP
*Wai-ching **LAM***

11:10 Persistent Vascular Anomalies in Children with Retinopathy of Prematurity: Ultra-widefield Fluorescein Angiography Findings until School Age
*Wei-chi **WU***

11:20 Update on Genetics of FEVR
*Hiroyuki **KONDO***

11:30 Surgical Innovation in the Pediatric Retina
*Peiquan **ZHAO***

11:40 Complicated Pediatric RD in XLRS and MGS
*Shunji **KUSAKA***

11:50 Panel Discussion and Q&A

Retina (Medical)

Pachychoroid Diseases

Pachychoroid describes a phenotype in which the structural and functional changes of the choroid play a key role in a spectrum of retinal disorders. This session will present the most recent advancements in understanding of how pachychoroid is involved in theses related retinal disorders, their clinical manifestations, treatments and outcomes.

08:30 - 10:00 **Venue: S423-S424**
*Chair(s): Shih Jen **CHEN**, Timothy **LAI**, Danny **NG***

08:30 Diagnosis of PCV: From Gold Standard to Silver Standard
*Shih Jen **CHEN***

08:38 Stress and Pachychoroid Diseases
*Fumi **GOMI***

08:48 PEHCR: A Mysterious Variant of Pachychoroid Disease
*Min **KIM***

08:58 The Role of Ang/Tie Pathway in Pachychoroid Diseases
*Timothy **LAI***

09:08 Pachychoroid in High Myopia: Thick or Thin?
*Tzyy-chang **HO***

09:16 Imaging Predictors for Treatment Response in PCV
*Colin **TAN***

09:26 Application of OCT-A in Pachychoroid Diseases
*Danny **NG***

09:36 Treatment of Pachychoroid Neovascularization: Net or Activity?
*San-ni **CHEN***

09:44 Panel Discussion and Q&A

Age-related Macular Degeneration: Dry AMD

This dry AMD session will focus on both early and advanced dry AMD (geographic atrophy). It will highlight the precursor signs of advanced AMD, the GA phenotype in an Asian population, explore the vision changes when GA occurs concurrently with nAMD and discuss new therapies and management strategies currently available.

10:30 - 12:00 **Venue: S421**
*Chair(s): Richard **SPAIDE**, Kelvin **TEO YI CHONG**, Ian **WONG***

10:30 Prevalence and Characteristics of GA in the Japanese Population
*Yasuo **YANAGI***

10:40 Pachychoroid Geographic Atrophy
*Akitaka **TSUJIKAWA***

10:50 Understanding Macular Drusen: Are They All the Same?
*Wai-ching **LAM***

11:00 Progression of Vision in Geographic Atrophy in Eyes Treated for nAMD
*Mark **GILLIES***

11:10 Panel Discussion 1

11:20 Prevention of Dry AMD
*Youxin **CHEN***

11:30 Analysis of Complement Inhibitors in the Treatment of Geographic Atrophy
*Richard **SPAIDE***

11:40 Diet and Other Lifestyle Modifications in Dry AMD Management
*Geoffrey **BROADHEAD***

11:50 Panel Discussion 2

Subthreshold Ophthalmic Laser Society (SOLS) Sponsored Symposium

Subthreshold laser remains an important treatment modality for various macular diseases. While it is not widely used, it is essential for all retinal specialists to be aware of it and its indications. This symposium will cover the history, guidelines and cases of subthreshold laser use.

10:30 - 12:00 **Venue: S423-S424**
*Chair(s): Wai Man **CHAN**, Vivek **DAVE**, Kenneth **FONG***

10:30 History of Subthreshold Laser and Its Development and Needs
*Victor **CHONG***

10:38 Protocols and Standardization of Methods for Subthreshold Laser
*Kenneth **FONG***

10:49 Subthreshold Laser for DME
*Anand **RAJENDRAN***

11:00 Subthreshold Laser for CSCR
*Lihteh **WU***

11:11 Controversies Around Use of Subthreshold Laser: Is There Still a Role for PDT Laser for CSCR?
*Marten **BRELEN***

11:22 Case Studies of Subthreshold Laser Use in Macular Diseases
*Xinyuan **ZHANG***

11:33 Sub-threshold Laser: Different Cases, Different Results
*Vivek **DAVE***

11:44 Panel Discussion and Q&A

Diabetic Retinopathy (1): DME

Diabetic macular edema (DME) is the leading cause of visual impairment in the diabetic population, affecting approximately 7% of persons with diabetes. Despite the success of anti-VEGF therapy, up to 40% of patients have suboptimal visual improvement even when receiving regular treatment. Hence, there is a need to improve prognosis determination and treatment outcomes of DME. Furthermore, there has been new research into imaging biomarkers of DME including the use of AI and deep learning models. In this symposium, we will cover the latest advances in DME, from epidemiology and retinal imaging based biomarkers to updates in treatment strategy and novel therapeutic agents.

15:15 - 16:45 **Venue: S421**
*Chair(s): Taiji **SAKAMOTO**, Simon **SZETO**, Tien Yin **WONG***

15:15 Hot Topic 1: DME Epidemiology, Risk Factors and Burden
*Zhen Ling **TEO***

15:25 Hot Topic 2: Role of Vitreous Cells in DR in Diabetes
*Shintaro **NAKAO***

15:35 Hot Topic 3: New OCT Classification of DME
*Carol **CHEUNG***

15:45 Hot Topic 4: What is the Role of OCTA, if any, in DME?
*Tomoaki **MURAKAMI***

15:55 Hot Topic 5: AI and Deep Learning in DME
*Rajiv **RAMAN***

16:05 Hot Topic 6: New Concepts in Management of DME with Current Anti-VEGF
*Neil **BRESSLER***

16:15 Hot Topic 7: Management of DME with Novel Agents
*Simon **SZETO***

16:25 Hot Topic 8: Refractory DME – What is the Role of Surgery, Cell and Gene Therapies?
*Xiaodong **SUN***

16:35 Panel Discussion and Q&A

Retina (Surgical)

Innovation and Controversies in Surgical Retina

This symposium will review new innovations and technical advances in surgical retinal diseases. The international faculty will share their perspectives on complex and difficult retinal conditions, including managing myopic macular holes, epiretinal membranes and various controversies regarding peeling ILM, flapping and using adjuncts, managing retinal folds and scleral fixated lenses. The session will also highlight emerging technology such as intraoperative OCT for pediatric cases and 3D visualization which may go a long way in improving surgical efficiency and clinical outcomes.

08:30 - 10:00 **Venue: S421**
*Chair(s): Jason Chung Kit **CHAN**, Kazuaki **KADONOSONO**, Manish **NAGPAL***

08:30 Prevention of Macular Hole Formation in MTM Surgery
*Chi-chun **LAI***

08:40 Intraoperative OCT for Pediatric Maculopathy
*Hai **LU***

08:50 Effect of Autologous Platelet Concentrate in Surgery for Recurrent Macular Holes
*Young Hee **YOON***

09:00 Enhancement of Visibility in 3D Heads-up Surgery
*Makoto **INOUE***

09:10 Scleral Fixation IOL
*David **WONG***

09:20 Controversies in Utilizing 27 Gauge Vitrectomy Systems in Vitreoretinal Surgery
*Amer **AWAN***

09:30 ERM Peeling with OCT Guide
*Yuki **MORIZANE***

09:40 Myopic Macular Holes: ILM Peel or ILM Flap?
*Shu Yen **LEE***

09:50 Panel Discussion and Q&A

Surgical Retina: PDR, PVR and Others

This session highlights advances in surgical retina with leading retina surgeons discussing techniques in the management of rhegmatogenous retinal detachment, proliferative diabetic retinopathy, epiretinal membrane and proliferative vitreoretinopathy. Current thinking about scleral buckle, surgical management of epiretinal membrane in high myopia, PDR and PVR, and a minimally invasive technique to repair retinal detachment with shallow peripheral subretinal fluid will be presented.

17:00 - 18:30 **Venue: S423-S424**
*Chair(s): Taraprasad **DAS**, Gregg **KOKAME**, Chi Wai **TSANG***

17:00 Introduction
*Taraprasad **DAS***

17:05 Repair of Rhegmatogenous Retinal Detachment: The Transition from Scleral Buckle to Pars Plana Vitrectomy
*William **MIELER***

17:12 Why Scleral Buckling Should Remain Part of Your Toolkit for Retinal Detachment Repair
*Edwin **RYAN***

17:19 Scleral Buckle: The Lost Art of Rhegmatogenous Retinal Detachment Repair
*Bhuvan **CHANANA***

17:26 Panel Discussion and Q&A

17:31 Preoperative Intravitreal Bevacizumab for TRD Secondary to PDR
*J. Fernando **AREVALO***

17:38 Panel Discussion and Q&A

17:41 Surgery in Advanced PDR
*Gopal S **PILLAI***

17:48 Panel Discussion and Q&A

17:51 Macular Epiretinal Membrane in Patients with High Myopia
*Jian-ping **TONG***

17:58 Panel Discussion and Q&A

18:01 Effectiveness of ILM Removal for Eyes with PDR and PVR
*Kazuaki **KADONOSONO***

18:08 Panel Discussion and Q&A

18:11 Laser Treatment with Minimized Eye Movement for Retinal Detachment Repair
*Gregg **KOKAME***

18:18 Panel Discussion and Q&A

18:27 Summary
*Chi Wai **TSANG***

Translational Medicine

APSEG Sponsored Symposium: Genomics of Eye Diseases

15:15 - 16:45 **Venue: S422**
*Chair(s): Tin **AUNG**, Haoyu **CHEN**, Anthony **KHAWAJA***

15:15 The Genetic Architecture of Primary Angle Closure Glaucoma
*Chiea Chuen **KHOR***

15:25 Gene-Environment Interactions in Glaucoma
*Anthony **KHAWAJA***

15:35 Clinical Relevance of Advances in Exfoliation Glaucoma Genetics
*Tin **AUNG***

15:45 Genetics of Myopia and Its Progression and Endophenotypes in Children: The Hong Kong Children Eye Genetics Study
*Li Jia **CHEN***

15:55 Update on Genetics of Age-related Macular Degeneration
*Masato **AKIYAMA***

16:05 The Genetic Landscape of Inherited Retinal Disease in Aōtearoa/New Zealand
*Andrea **VINCENT***

Artificial Intelligence for Retinal Diseases

17:00 - 18:30 **Venue: S421**
*Chair(s): Carol **CHEUNG**, Paisan **RUAMVIBOONSUK**, Daniel **TING***

17:00 Using AI to Assess DMI and How It Relates to Diabetic Retinal Disease Progression and Visual Acuity Deterioration
*Gabriel **YANG***

17:11 Development and International Validation of Custom-engineered and Code-free Deep-learning Models for Detection of Plus Disease in Retinopathy of Prematurity
*Siegfried **WAGNER***

17:22 Automatic Detection of Multiple Fundus Diseases with Deep Learning
*Ling-ping **CEN***

17:33 Generative AI and Large Language Models for Retinal Diseases
*Yun **LIU***

17:44 Prospective Prioritization of Cases for DR Screening Using DL
*Paisan **RUAMVIBOONSUK***

17:55 A Foundation Transformer for Detecting DR from Ultra-wide OCT-angiography Images
*Bin **SHENG***

18:06 Privacy-preserving AI Technology in Retinal Diseases
*Zhen Ling **TEO***

18:17 Panel Discussion and Q&A

APSEG Sponsored Symposium: Molecular Genetics in Retinal Diseases

17:00 - 18:30 **Venue: S422**
*Chair(s): Hwei Wuen **CHAN**, Govindasamy **KUMARAMANICKAVEL**, Michael **NG***

17:00 Genetics of Age-related Macular Degeneration: a GWAS and Post-GWAS Update
*Ching-yu **CHENG***

17:10 TBC
*Calvin **PANG***

17:20 TBC
*Hwei Wuen **CHAN***

17:30 TBC
*Kenji **YAMASHIRO***

17:40 Disrupted mRNA Splicing of Visual Perception Genes Causes Prpf31 Retinal Pigmentosa
*Chen **ZHAO***

17:50 Could Artificial Intelligence Algorithm Help the Genetic Studies?
*Michael **NG***

18:00 When Should an Ophthalmologist Refer a Patient for Genetic Counselling?
*Govindasamy **KUMARAMANICKAVEL***

18:10 How does Genotype Influence Clinical Presentation in Inherited Retinal Degeneration?
*Ta-ching **CHEN***

18:20 Panel Discussion and Q&A

Dec 09, 2023 (Sat)

Cornea and External Eye Disease

Cornea and External Eye Disease Symposium

15:15 - 16:45 **Venue: S428**
*Chair(s): Alex **NG**, Kendrick **SHIH***

15:15 DMEK in Asian Eyes
*Marcus **ANG***

15:35 CMV Anterior Uveitis, from Diagnosis to Management
*Ka Wai **KAM***

15:55 Topography Guided PRK and CXL for Keratoconus
*Arthur Chak-kwan **CHENG***

16:15 Q&A

16:22 Free Paper - *Lycium barbarum* Polysaccharide Promotes Corneal Re-epithelialization After Alkaline Injury
*Ho Lam **WONG***

16:29 Free Paper - Ocular Surface Changes After Periocular Steroid Injection to the Levator Palpebrae Superioris-Superior Rectus Complex and Lacrimal Gland for Eyelid Retraction, Swelling and Lateral Flare
*Yan Tung Abbie **TANG***

16:36 Free Paper - Probiotics Pretreatment Attenuates Impaired Corneal Re-epithelialization in Diabetic Mice Through Amelioration of T cell Immunity and Remodulation of the Intestinal Microbiome
*Kendrick **SHIH***

16:43 Q&A

General Ophthalmology

CUHK Ophthalmology 30th Anniversary Symposium

15:15 - 16:45 **Venue: S426-S427**
*Chair(s): Calvin **PANG**, Simon **SZETO***

15:15 Welcome Speech and Update on Research from CUHK DOVS
*Clement **THAM***

15:25 Endoscopic Orbital Surgery: The Good, The Bad and The Future
*Kelvin Kam-lung **CHONG***

15:35 The Hong Kong Children Eye Genetic Study
*Li Jia **CHEN***

15:45 Novel Surgical Techniques for Dislocated Intraocular Lenses
*Haoyu **CHEN***

15:55 Low Concentration Atropine for Myopia Control and Prevention
*Jason **YAM***

16:05 Predicting Response of Anti-Vascular Endothelial Growth Factor Therapy in Eyes with Diabetic Macular Edema using Deep-Leaning based OCT image analysis: A Multi-Center Study
*Carol **CHEUNG***

16:15 Basic Laboratory and Transnational Research at CUHK Ophthalmology and Visual Sciences
*Wai Kit **CHU***

16:30 Flipped Classroom, Case-Based Learning, Virtual Teaching and Service Learning in Ophthalmology for medical students
*Poemen **CHAN***

16:45 Panel Discussion and Q&A

APES Symposium

17:00 - 18:30 **Venue: S428**
*Chair(s): Ruby **CHING***

17:00 Introduction
*Ruby **CHING***

17:03 Principles of Medical Negligence
*Sau Man Barbara **TAM***

17:28 Spectrum of Eye Complaint Cases
*Marcus **MARCET***

17:53 Legal Eyes
*Bernard **MURPHY***

Intraocular Inflammation, Uveitis & Scleritis

Uveitis (1): Applying Research Findings to Clinical Conundrums: A Clinical Case-based Symposium

This symposium applies the latest in research and registry findings to clinical challenges in uveitis management, ranging from applications of multimodal imaging in diagnostic challenges, how to manage difficult presentations of vitritis, VKH and vitreoretinal lymphoma (VRL) to emerging new treatments for uveitic macular edema and persistent noninfectious uveitis. To round off the symposium, local and regional experiences in health economics with respect to new pharmaceuticals will also be presented and discussed.

10:30 - 12:00 **Venue: S423-S424**
*Chair(s): Mary **HO**, Lyndell **LIM**, Quan Dong **NGUYEN***

10:30 Gathering the Evidence: How Multimodal Imaging Can Help in Trying to Distinguish Acute Infectious vs Non-infectious Causes of Acute Uveitis Presentations
*Alessandro **INVERNIZZI***

10:39 Uveitis Registry in China and Its Application
*Peizeng **YANG***

10:48 VRL: Diagnosis (MyD88 and Others) and the Need for the International PVRL Registry
*Sarah **COUPLAND***

10:57 Managing Uveitic Macular Edema: From What We Have Learned in Previous Trials to the Most Recent Developments in Therapy (Topical, Suprachoroidal, Intraocular)
*Christopher **OR***

11:06 Assessment of Vitritis in Eyes with Uveitis Using Optical Coherence Tomography
*Wataru **MATSUMIYA***

11:15 Potential Role of IL-17 Inhibitor and JAK Inhibitors in the Management of Non-infectious Uveitis: From Previous Experiences to Current Clinical Trials
*Mark **DACEY***

11:24 Local Challenges in the Management of Uveitis: Lessons Learned from Healthcare Economics and Pharmaceutical Developments
*Carmen **CHAN***

11:33 Panel Discussion and Q&A

Uveitis (2): Updates in Uveitis

In this session, international uveitis experts will talk about both clinical and research aspects

of uveitis diagnosis and management. Clinical topics will include innovative applications of imaging tools in uveitis especially for sarcoidosis, the optimal use of local vs systemic therapy for uveitis treatment, surgical complications associated with uveitis and strategies to improve vitrectomy outcomes in uveitic eyes. The session will also provide insights into the recent developments in uveitis research, including proteomics, and explore the potential benefits of a uveitis registry.

15:15 - 16:45 **Venue: S423-S424**
*Chair(s): Carmen **CHAN**, Careen **LOWDER**, Harvey **UY***

15:15 Imaging in Uveitis: Unusual Applications of the Usual Tools
*Francesco **PICHI***

15:25 Imaging in Sarcoidosis
*Careen **LOWDER***

15:35 Proteomics in Uveitis
*Reema **BANSAL***

15:45 Treating Uveitis: Local vs Systemic Therapy
*Debra **GOLDSTEIN***

15:55 Surgical Complications of Uveitis
*Phoebe **LIN***

16:05 Optimizing Pars Plana Vitrectomy Outcomes in Uveitic Eyes
*Harvey **UY***

16:15 Uveitis Registry: A Portal for Uveitis Education, Research and Collaboration
*Rupesh **AGRAWAL***

16:35 Recent Developments in Uveitis Research
*Peizeng **YANG***

16:45 Panel Discussion and Q&A

Ocular Imaging (APOIS)

APOIS Symposium 1: Masterclass in Ocular Imaging

08:30 - 10:00 **Venue: S428**
*Chair(s): Carol **CHEUNG**, Ki Ho **PARK**, Tien Yin **WONG***

08:30 Central Serous Chorioretinopathy, a Disease Revealed by Ocular Imaging
*Richard **SPAIDE***

09:00 Deep Learning in OCTA
*Yali **JIA***

09:30 Advances in Ocular Imaging in Glaucoma with Myopia
*Ki Ho **PARK***

APOIS Symposium 4: Future of Cornea and Anterior Segment Imaging

10:30 - 12:00 **Venue: S425**
*Chair(s): Marcus **ANG**, Ka Wai **KAM**, Alvin **YOUNG***

10:30 Comprehensive Evaluation of the Cornea Endothelium
*Marcus **ANG***

10:40 Role of Imaging in Infectious Keratitis
*Stephanie **WATSON***

10:50 The Power of in vivo Confocal Microscopy and OCT Corneal Epithelial Mapping in the Management of Corneal Diseases
*Wei-lin **CHEN***

11:00 The Use of Ultrasound Biomicroscopy in Corneal Clinic
*On Heong **LIEW***

11:10 Application of Scheimpflug imaging in Corneal Diseases & Cataracts
*Ka Wai **KAM***

11:20 The Application of In-vivo Confocal Microscopy in Corneal Diseases and as a Window into Systemic Diseases
*Yu Chi **LIU***

11:30 TBC
*Hun **LEE***

APOIS Symposium 3: Artificial Intelligence and Machine Learning in Glaucoma Imaging

10:30 - 12:00 **Venue: S428**
*Chair(s): Tin **AUNG**, Robert **CHANG**, Xiulan **ZHANG***

10:30 Future of Angle Assessment Utilizing AI
*Tin **AUNG***

10:43 3D OCT-based Ultrafast Generation of Visual Field
*Xiulan **ZHANG***

10:56 Using Deep Learning-based Retinal Vessel Caliber Analysis to Assess Normal Tension Glaucoma Progression
*Carol **CHEUNG***

11:09 Enhancing Angle Closure Detection and Evaluation Using OCT and AI
*Benjamin **XU***

11:22 Harnessing AI and Biomechanics for Glaucoma Care
*Michael **GIRARD***

11:35 When Will We See an Approved AI Algorithm for Glaucoma Imaging?
*Robert **CHANG***

11:48 Federated Learning for Ophthalmology: Opportunities and Challenges
*Emma Anran **RAN***

APOIS Symposium 2: Advancements in OCT for Glaucoma Diagnosis and Management

15:15 - 16:45 **Venue: S422**
*Chair(s): Michael **GIRARD**, Christopher **LEUNG**, Mingzhi **ZHANG***

15:15 Patterns of RNFL Defects in Advanced Glaucoma - Lessons from RNFL Optical Texture Analysis
*Christopher **LEUNG***

15:25 Geometric Deep Learning in Glaucoma - A New Approach to Exploit Complex 3D Structural Data
*Michael **GIRARD***

15:35 OCT Technique for Glaucoma Management
*Chun **ZHANG***

15:45 Retinal Nerve Fiber Bundle Analysis in Myopic Eyes: Individualized Patterns and Intraocular Symmetry
*Qiu **KUNLIANG***

15:55 Structural Variations in Lamina Cribrosa and Neural Canal Across Glaucoma, Myopia, and Healthy Eyes
*Xiaofei **WANG***

16:05 Implementation of Deep Learning for Evaluation of Glaucoma with RNFL Optical Texture Analysis (ROTA)
*Alexander **LAM***

16:15 Panel Discussion and Q&A

APOIS Symposium 5: Intraoperative Imaging and New Ideas in Ocular Imaging

15:15 - 16:45 **Venue: S425**
*Chair(s): Rupesh **AGRAWAL**, Julia Y.Y. **CHAN**, Haotian **LIN***

15:15 Smartphone-based Self-screening for Ophthalmic Diseases
*Haotian **LIN***

15:23 Special Indications of ASOCT in the Management of Corneal Diseases
*Julia Y.Y. **CHAN***

15:31 Image Guided System in Anterior Segment Surgery
*Vanissa **CHOW***

15:39 Comprehensive Ocular Imaging Network (COIN)
*Rupesh **AGRAWAL***

15:47 Clinical Integration Challenges in Advanced Ophthalmic Technologies
*M. Ali **NASSERI***

15:55 Harnessing the Power of Retinal Images by Deep Learning to Predict Aging
*Ching-yu **CHENG***

16:03 iOCT in VR Surgery: Where Does it Help Me?
*Vivek **DAVE***

16:11 TBC
*S. **NATARAJAN***

16:19 Future Applications of Robotics in Intraocular Procedures
*Li **ZHANG***

16:27 Image-guided Ocular Robotic Surgeries
*Kai **HUANG***

16:35 Panel Discussion and Q&A

APOIS Symposium 6: Innovations and Challenges in Ocular Imaging

17:00 - 18:30 **Venue: S425**
*Chair(s): Mingguang **HE**, Paisan **RUAMVIBOONSUK**, Yih Chung **THAM***

17:00 Hardware + Software + AI Enables Self-testing Eye Disease Screening
*Mingguang **HE***

17:10 Is AI in Ophthalmology Really Cost-effective?
*Paisan **RUAMVIBOONSUK***

17:20 How May Generative AI Make a Difference in Disease Diagnosis?
*Danli **SHI***

17:30 Harnessing the Power of Large Language Models in Advanced Retinal Imaging: The Future is Here
*Yih Chung **THAM***

17:40 Big Data and AI Enable Research and Better Patient Care
*Kang **ZHANG***

17:50 Deep Learning Enables Super-resolution Enhancement of OCT-angiogram
*Hao **CHEN***

18:00 3D Reconstruction: Deep Diving into High Myopia Eye Sub-profiling
*Yaxing **WANG***

18:10 Reti-CVD: From Code to Commercialization
*Tyler **RIM***

18:20 Panel Discussion and Q&A

Ocular Imaging

APOIS-APVRS Symposium 2: Polypoidal Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD) and pachychoroid spectrum disease, characterized by nodular dilation of type 1 neovascular network. Up to 50% of nAMD phenotypes in Asians can be accounted for by PCV. Traditionally, the diagnosis and treatment planning of PCV depend on indocyanine green angiography (ICGA), which is gradually replaced by optical coherence tomography (OCT) features instead. Furthermore, there is new research on using novel retinal imaging techniques to better elucidate the pathogenesis of this complex disease. In this symposium, we will cover the latest advances in PCV imaging, from OCT angiography to choroidal imaging, and their relevance in the diagnosis and management of PCV.

08:30 - 10:00 **Venue: S426-S427**
*Chair(s): Gemmy **CHEUNG**, Won Ki **LEE**, Simon **SZETO***

08:30 Choroidal Vascularity in PCV Updates
*Taiji **SAKAMOTO***

08:42 UWF ICGA-guided SS-OCT Findings for Choroidal Changes in Patients with Pachychoroid Spectrum Disease
*Sohee **JEON***

08:54 Scleral Thickness in PCV and Pachychoroid Diseases
Hideki ***KOIZUMI***

09:06 3D OCTA Study of PCV Complex
Kelvin ***TEO YI CHONG***

09:18 Technical Tips on Evaluating the Choroid
Ruikang ***WANG***

09:30 Pachydrusen and PCV: Systematic or Opportunistic Findings?
Paisan ***RUAMVIBOONSUK***

09:42 Panel Discussion and Q&A

Other (General Ophthalmology)

APMS-APVRS Symposium: High Myopia

Myopia and high myopia have been increasing worldwide. In this session, global experts will present the latest updates on managing complications of high myopia, including macular neovascularization and traction maculopathy. They will discuss the potential benefits of novel red light therapy in preserving ocular circulation to prevent vision-threatening issues. Additionally, advancements in ocular imaging and the study of inherited eye diseases will be showcased in this session.

10:30 - 12:00 **Venue: S426-S427**
Chair(s): Tzyy-chang ***HO****, Kyoko* ***OHNO-MATSUI****, Jason* ***YAM***

10:30 Myopia and Inherited Retinal Disease: What's the Connection?
Beau ***FENNER***

10:40 Management of Myopic MNV
Timothy ***LAI***

10:50 Concerning Surgery of Myopic Maculopathy
Chi-chun ***LAI***

11:00 3D Long-shaft and Low Toxicity Chromovitrectomy in Highly Myopic Eyes
Tzyy-chang ***HO***

11:10 Long-term Surgical Outcome of MTM
Tomonari ***TAKAHASHI***

11:20 Scleral Imaging of DSM
Tae ***IGARASHI-YOKOI***

11:30 Vitreous Hemorrhage and Myopia in Infants
Jianhong ***LIANG***

11:40 Effect of Red-Light Therapy on Retinal and Choroidal Blood Perfusion in Myopic Children
Junwen ***ZENG***

11:50 Panel Discussion and Q&A

Pediatric Retina

Pediatric Retina (2)

Pediatric retina is diverse and entails a group of diseases which are often seen in our practice. Beginning from ocular trauma which is very frequent in today's world of rapid industrialization to retinopathy of prematurity which manifests early after birth, pediatric retina is truly a challenging area. Retinoblastoma is yet another disease which has seen revolutionary changes in its diagnostics and management logistics. FEVR in recent years has been defined more clearly and assumed importance in view of its long-term implications on vision. Pediatric retinal detachments are a long-time bug bear for retinal surgeons and with newer technology their management has been highly productive in terms of final visual outcome. This session will offer a panorama of scientific presentations to benefit the august audience.

08:30 - 10:00 **Venue: S425**
Chair(s): Rajvardhan ***AZAD****, Xiaoling* ***LIANG,*** *Chun* ***Yue****, Andrew* ***MAK***

08:30 Early Detection of Visual Impairment in Young Children Using a Smartphone-based Deep Learning System
Haotian ***LIN***

08:40 25G PPV in Iridofundal Coloboma with Retinal Detachment: An Ambispective Study
*Shorya **AZAD***

08:50 Hypoxia-inducible Factor Stabilization and Biomarkers in Prevention of ROP
*Guoming **ZHANG***

09:00 Anti-VEGF in ROP: Which, When, Where and How Much?
*Rajvardhan **AZAD***

09:08 Traumatic Pediatric Retinal Detachment: Epidemiology Definition, Clinical Picture and Management Outcome
*Jin **MA***

09:18 FEVR: Classifications and Management
*Xiaoyan **DING***

09:28 Retinoblastoma: Multimodal Approach to Treatment
*Bhavna **CHAWLA***

09:38 Management Outcome in Coats Disease
*Tingyi **LIANG***

09:48 Panel Discussion and Q&A

Retina (Medical)

Retinal Vascular Diseases

08:30 - 10:00 **Venue: S423-S424**
*Chair(s): Mark **GILLIES**, Shaheeda **MOHAMED**, Seung-young **YU***

08:30 Wide-field Retinal Angiography
*Stela **VUJOSEVIC***

08:40 Retinal Non-perfusion in Diabetic Retinopathy: Clinical Application of OCTA
*Kiyoung **KIM***

08:50 OCT-angiography Based Artificial Intelligence-inferred Fluorescein Angiography for Leakage Detection
*Toshinori **MURATA***

09:00 Real World Outcomes of Treatment of RVO from FRB!
*Louise **OTOOLE***

09:10 Dual Ang 2 and VEGF Inhibition for RVO
*Timothy **LAI***

09:20 OCT Angiography-guided Laser Photocoagulation for Refractory Macular Edema
*Miho **NOZAKI***

09:30 Brolucizumab in Pachychoroid Disease
*Raja **NARAYANAN***

09:40 Phase 3 Studies of the CNTF Implant for Macular Telangiectasia Type 2
*Mark **GILLIES***

09:50 Panel Discussion and Q&A

Age-related Macular Degeneration: Wet AMD

This session will provide an update on some of the newest, clinically relevant topics regarding the management of the neovascular (wet) form of age-related macular degeneration (AMD). Following a review of the global public health burden of this major cause of blindness, the biologic variability of this disease will be highlighted, including polypoidal choroidal vasculopathy (PCV), inadequate responses, local challenges in Hong Kong and real-world data from Australia, use of AI, and new anti-VEGF agents including biosimilars.

10:30 - 12:00 **Venue: S421**
*Chair(s): Neil **BRESSLER**, Voraporn **CHAIKITMONGKOL**, Li Jia **CHEN***

10:30 Introduction
*Neil **BRESSLER***

10:32 Global Public Health Burden of Neovascular AMD
*Emily **CHEW***

10:40 Complete Polypoidal Regression and Its Potential Clinical Relevance in Polypoidal Choroidal Vasculopathy
*Voraporn **CHAIKITMONGKOL***

10:48 Defining and Managing Inadequate Treatment Response in Neovascular AMD
*Geoffrey **BROADHEAD***

10:56 Does Faricimab or High Dose Aflibercept Have Greater Durability than Aflibercept?
*Gemmy **CHEUNG***

11:04 Biosimilars in Neovascular AMD
*Neil **BRESSLER***

11:12 Potential Use of AI to Manage Neovascular AMD
*T. Y. Alvin **LIU***

11:20 Management of Neovascular AMD in Hong Kong: Local Challenges
*Mary **HO***

11:28 Real World Data on Neovascular AMD Treatment: Fight Retinal Blindness! Registry
*Mark **GILLIES***

11:36 Panel Discussion and Q&A

Diabetic Retinopathy (2): DR

Diabetic retinopathy remains one of the leading causes of blindness in the world, including the Asia-Pacific. This symposium highlights the latest developments in diagnosis and treatment of diabetic macular edema (DME) and diabetic retinopathy. Advancements in retinal imaging have improved our ability to detect and predict prognosis of patients with diabetic retinopathy. These OCT biomarkers play an important role in tailoring our treatments to those who are most likely to benefit from them. Wide-field imaging and angiography now provide us with invaluable information about peripheral pathology and perfusion. Panretinal laser photocoagulation has been the standard of care for proliferative diabetic retinopathy (PDR) for decades, but the the efficacy and safety of anti-VEGF treatment for PDR has given physicians a viable choice of one or both of these therapeutic strategies. We will examine the factors and clinical situations that determine which treatment is appropriate. Recently approved therapeutic molecules have greatly increased our armamentarium of treatments for DME. The evidence supporting these newer treatments will be reviewed and discussed. Despite these advances, there remains a significant proportion of patients who do not respond adequately to existing treatments. It is important to define response and our strategies for dealing with these difficult cases. Surgical techniques for treating diabetic retinopathy have improved considerably with new techniques and technologies making a significant difference in outcomes. We then close the symposium with a look into the future, in treating macular ischemia. Join us for this exciting program.

15:15 - 16:45 **Venue: S421**
*Chair(s): Judy **KIM**, Adrian **KOH**, Pui Pui **YIP***

15:15 OCT Biomarkers and Prognostic Factors of Diabetic Retinopathy
*Seung-young **YU***

15:25 Advances in Retinal Imaging: OCT Angiography, Wide Field Fundus Photography and Angiography: Which Do I Use and When?
*Anna **TAN***

15:35 Anti-VEGF vs PRP for Proliferative Diabetic Retinopathy?
*Judy **KIM***

15:45 Latest Evidence in the Management of DME
*Adrian **KOH***

15:55 Anti-VEGF Non-responders: How Do We Define Them, How Can We Manage Them?
*Adrian **FUNG***

16:05 Latest Surgical Techniques in Management of Proliferative Diabetic Retinopathy
*San-ni **CHEN***

16:15 Therapy in Development for Diabetic Macular Ischemia
*Quan Dong **NGUYEN***

16:25 Panel Discussion and Q&A

The Macula Society Sponsored Symposium on Central Serous Chorioretinopathy

In this symposium sponsored by The Macula Society, experts from around the world will present on the latest developments in various aspects of central serous chorioretinopathy (CSC). Topics will include the latest hypothesis on the pathophysiology of CSC, advancements in imaging of CSC such as adaptive optics and OCT deep learning analysis, and management of CSC with sub-threshold laser, medical treatment and photodynamic therapy. The session will conclude with a panel discussion.

17:00 - 18:30 **Venue: S421**
*Chair(s): Chi-chun **LAI**, Timothy **LAI**, Lihteh **WU***

17:00 Pathophysiology in CSCR
*Richard **SPAIDE***

17:10 Adaptive Optics in CSCR
*J. Fernando **AREVALO***

17:20 Subthreshold Laser for CSCR
*Stela **VUJOSEVIC***

17:30 Scleral Thickness in CSCR
*Hideki **KOIZUMI***

17:40 Neovascular CSC
*Won Ki **LEE***

17:50 Photodynamic Therapy for CSC
*Simon **SZETO***

18:00 Deep Learning Analysis of OCT in CSC
*Jiwon **BAEK***

18:10 Medical Treatment for CSC
*Shih Jen **CHEN***

18:20 Panel Discussion

Retina (Surgical)

Surgical Retina: Macular Surgery

This symposium will cover challenging surgeries for macular pathology. These include how to avoid and manage complications in macular membrane surgery, techniques to repair macular holes in high myopia and retinal detachment, tips in the surgical management of macular hemorrhage and diabetic maculopathy. The cutting-edge advances in gene therapy and techniques for intraoperative OCT will be presented.

08:30 - 10:00 **Venue: S421**
*Chair(s): Andrew **CHANG**, Li Jia **CHEN**, Masahito **OHJI***

08:30 Macular Surgery in Extreme Myopia
*Hua **YAN***

08:38 Removal of Subfoveal Perfluorocarbon Liquid
*Haoyu **CHEN***

08:46 Sub-macula Gene Therapy: Surgical Approaches, Drug Loss and Functional Recovery
*Matthew **SIMUNOVIC***

08:54 Subretinal rTPA for Submacular Hemorrhage
*Thuss **SANGUANSAK***

09:02 Complications of Macular Membrane Peeling Surgery
*Andrew **CHANG***

09:10 Implications of Vitreomacular Interface in Management of Diabetic Maculopathy
*Vivek **DAVE***

09:18 Surgical Options for Macular Hole Retinal Detachment
*Osamu **SAWADA***

09:26 Rotational Internal Limiting Membrane Flap Technique to Promote Foveal Regeneration in Macular Hole Repair
*Peiquan **ZHAO***

09:35 Intraoperative OCT for Vitreomaculopathy Surgery
*Hiroyuki **KONDO***

09:43 Panel Discussion and Q&A

Translational Medicine

APSEG Sponsored Symposium: Gene and Cell Therapy in Retinal Diseases

17:00 - 18:30 **Venue: S422**
*Chair(s): Wai Kit **CHU**, Xinyi **SU**, Chen **ZHAO***

17:00 Transplantation of Human iPSC-Derived Microglia into the Mouse Retina
*Wei **LI***

17:10 Transplantation of Chemically Induced Pluripotent Stem Cell-Derived Retinal Cells in rd Mice
*Zi-bing **JIN***

17:20 TBC
*Francine **BEHAR-COHEN***

17:30 Umbilical Cord Blood Exosomes in Glaucoma Treatment
*Wai Kit **CHU***

17:40 TBC
*Xinyi **SU***

17:50 NIH Phase I/II RPE-STEM Trial Update
*Kapil **BHARTI***

18:00 iPS-based Retinal Cell Therapy
*Yasuo **KURIMOTO***

18:10 Challenges in Surgical Placement of Donor RPE in RPE Transplant
*Lingam **GOPAL***

18:20 Panel Discussion and Q&A

GEGC Dr. Chi Chao Chan Symposium on Global Collaboration of Eye Research

17:00 - 18:30 **Venue: S423-S424**
*Chair(s): S. **NATARAJAN**, Calvin **PANG**, Gyan (john) **PRAKASH***

17:00 Overview of Global Collaboration of Eye Research
*Gyan (John) **PRAKASH***

17:05 Global Collaboration in Eye Genetics
*Calvin **PANG***

17:10 Navigating the Challenges of Leading Large Multicenter Clinical Studies
*Emily **CHEW***

17:20 Through a Clear Lens – A Case of Vision Research Collaboration
*Wei **LI***

17:30 Light Therapy for Myopia Control: A Technology from China to Global
*Mingguang **HE***

17:40 Ocular Imaging Standards to Support Collaboration
*Michael **CHIANG***

17:50 Panel Discussion and Q&A

18:00 Global Collaboration of Eye Research: Personal Experience
*Chi-chao **CHAN***

18:10 TBC
*Erika **ELVANDER***

18:15 Panel Discussion and Q&A

Dec 10, 2023 (Sun)

Cataract and Refractive Surgery

Cataract and Refractive Symposium

13:45 - 15:15 **Venue: S426-S427**
*Chair(s): Tommy **CHAN**, George **CHENG**, Alex **NG***

13:45 Management of Difficult Complications of LVC Using Trans-epithelial PTK
*Zheng **WANG***

14:05 Use of Multifocal Lens in Cataract Surgery
*Tommy **CHAN***

14:25 Applying Corneal Imaging in Biometry
*Alex **NG***

14:45 Free Paper - Clinical Outcome of Phacoemulsification Combined with Intraocular Lens Implantation for Primary Angle Closure/Glaucoma (PAC/PACG) with Cataract
*Yuan **HE***

14:52 Free Paper - A Prospective Study of Vivity and Vivity Toric IOL in Taiwan: Preliminary Results and Analysis
*Tzu-te **HU***

14:59 Free Paper - Comparative Evaluation of the Techniques of Sutureless Scleral Fixation of Posterior Chamber Intaocular lenses (SF-IOLs) with and Without Fibrin Glue
*Shachi **SRIVASTAVA***

15:06 Panel Discussion and Q&A

General Ophthalmology

HKU Symposium - Diagnostic and Therapeutic Innovations from HKU Ophthalmology

10:30 - 12:00 **Venue: S426-S427**
*Chair(s): Christopher **LEUNG**, Kendrick **SHIH***

10:30 Use of a Deep Learning Model to Detect Microvascular Abnormalities in Early Diabetic Retinopathy
*Angie **FONG***

10:40 The Use of Artificial Intelligence in Enhancing Triage of Patients Presenting with Chronic Visual Loss
*Kendrick **SHIH***

10:50 Deleted in Liver Cancer 2 (DLC2) and RhoA/ROCK Signaling Pathway in Corneal Nerve Injury after Chronic Hyperglycemia
*Amy Cheuk Yin **LO***

11:00 Identifying RNFL Defects with ROTA in Ocular Hypertension
*Clarice **SU***

11:10 High-Performance Oil Absorption Material for Tackling the Residual Silicone Oil in Vitreoretinal Surgery
*Joseph Yau Kei **CHAN***

11:20 Treatment of Recalcitrant Age Related Macular Degeneration using Brolucizumab – One Year Results from a Randomized Controlled Switched Study
*Nicholas **FUNG***

11:30 Ocular Graft-versus-Host Diseases in Hong Kong: Population-Based Studies
*Allie **LEE***

11:40 Can We Detect Progression in Advanced Glaucoma? Lessons from RNFL Optical Texture Analysis
*Christopher **LEUNG***

11:50 Panel Discussion and Q&A

General Ophthalmology Symposium

10:30 - 12:00 **Venue: S428**
*Chair(s): Mary **HO**, Lawrence **IU**, Frank **LAI***

10:30 Management of Loose Zonules
*Ka Wai **KAM***

10:50 Management of Complicated Cataract
*Chi Lik **AU***

11:10 What's New in Optic Neuritis
*Chun Yue Andrew **MAK***

11:30 Free Paper - A Clinical Comparative Study between Foldable Capsular Buckle Pressing and Conventional Scleral Buckling in the Treatment of Rhegmatogenous Retinal Detachment
*Cheng **LI***

11:37 Free Paper - Paediatric- Versus Adult-onset Thyroid Eye Disease: Difference in Clinical Presentations
*Lorraine **SIU***

11:44 Free Paper - Low Clinical Activity Score Thyroid Eye Disease: Review of 1439 Patients from a Tertiary Center in Hong Kong
*Nicole **WONG***

11:51 Panel Discussion and Q&A

Glaucoma

Glaucoma Symposium

08:30 - 10:00 **Venue: S428**
*Chair(s): Noel **CHAN**, Dexter **LEUNG***

08:30 Understanding Structure-Function Relationship in Glaucoma Care
*Ki Ho **PARK***

08:50 IOP Control & PACG Progression: What We Have Learnt from the CUPAL Study
*Clement **THAM***

09:10 The HKU x Orbis AI-ROTA Glaucoma Screening Project - An Update
*Christopher **LEUNG***

09:30 Free Paper - Multimodal Machine Learning Using Visual Fields and Peripapillary Circular OCT Scans in Detection of Glaucomatous Optic Neuropathy
*Deming **WANG***

09:37 Free Paper - Establishment of Primary Angle-Closure Glaucoma Screening Models Based on Artificial Intelligence Algorithm
*Ziwei **FU***

09:44 Free Paper - Macular Ganglion Cell Complex Layer Thickness Measured with Spectral-domain OCT in a Large Population-based Cohort Study
*Jian **WU***

09:51 Panel Discussion and Q&A

Orbital & Oculoplastic Surgery

Orbital & Oculoplastic Surgery symposium

08:30 - 10:00 **Venue: S426-S427**
*Chair(s): Andy **CHENG**, George **CHENG**, Kelvin Kam-lung **CHONG***

08:30 TONES/Management of Orbital Vascular Malformation - The HKEH Experience
*Yuen Ting Tracy **KWOK***

08:45 Dacryoendoscopy - The NTEC Experience
*Joyce **CHIN***

09:00 IgG4ROD - A Territory-wide Study
*Ka Hei Kenneth **LAI***

09:15 Free Paper - Radiological Outcomes of Periocular Steroid Injection to the Levator Palpabrae Superioris- Superior Rectus Complex and Lacrimal Gland
*Ting Hei **TSANG***

09:22 Free Paper - Thyroid Eye Disease: A Territory-wide Epidemiological Study From 2000-2017 in Hong Kong with 123,889 Autoimmune Thyroid Disease Patients
*Wai Chak **CHOY***

09:29 Free Paper - 3D Printing Patient-specific Implant for Orbital Fracture Reconstruction
*Ka Hei Catherine **LAM***

09:36 Free Paper - Testing Color Vision in Dysthyroid Optic Neuropathy – A Prospective Comparative Study
*Siu Yan **CHAN***

09:43 Free Paper - Correlations of Magnetic Resonance Imaging (MRI) Parameters with Clinical Activity Score (CAS) in Thyroid Eye Disease (TED): A Systematic Review and Meta-Analysis
*Sin Ki **YEUNG***

09:50 Panel Discussion and Q&A

Other (General Ophthalmology)

Late Breaking Keynote Symposium

This symposium aims to share the latest results of important research or clinical trials on vitreoretinal diseases, conducted in the Asia-Pacific region or elsewhere, which may have major impacts on the management of these diseases in the near future.

08:00 - 09:00 **Venue: S421**
*Chair(s): Andrew **CHANG**, Li Jia **CHEN**, Paisan **RUAMVIBOONSUK***

08:00 Two Phase 3 Controlled Clinical Trials in Macular Telangiectasia Type 2 (mac tel) Using the CNTF Implant
*Emily **CHEW***

08:08 Intravitreal Aflibercept 8 mg in Patients with PCV: 96 Week Subgroup Analysis from Phase 3 PULSAR Trial
*Tien Yin **WONG***

08:16 New Data from a Home OCT Study for nAMD
*Judy **KIM***

08:24 Endophthalmitis Management Study – A Multi-Center Prospective Randomized Clinical Trial on Post Cataract Endophthalmitis Management in India
*Taraprasad **DAS***

08:32 Update on Avacincaptad Pegol – What's the Latest?
*Lihteh **WU***

08:40 Comparison of Clinical Outcomes of 10,000 versus 20,000 Cuts-Per-Minute 25-gauge Beveled-Tip Vitrectomy Probes, A RCT
*Harvey **UY***

08:48 High Macular Leakage is Associated with Elevated Ang-2-related Proteins and Immune Regulators at Baseline, which Were Reduced Following Treatment with Faricimab
*Stela **VUJOSEVIC***

Canadian Retina Society Sponsored Symposium: Advances in Pneumatic Retinopexy: The Expanded Indications

Pneumatic retinopexy (PR) was first introduced as an outpatient procedure by Hilton and Grizard (1986) to treat selected cases of rhegmatogenous retinal detachment. In Canada, pneumatic retinopexy is a common procedure with a high rate of success. With increased expertise, indications have expanded to include detachment with multiple breaks, optic nerve associated detachment, displacement of submacular hemorrhage, pediatric detachments and so on. Our Canadian experts will share their knowledge, experiences and the tips and tricks for a successful pneumatic retinopexy in expanded indications.

08:30 - 10:00 **Venue: S425**
*Chair(s): Bernard **HURLEY**, Wai-ching **LAM***

08:30 Pneumatic Displacement of Submacular Hemorrhage: Techniques and Tips for a Better Outcome
*Wai-ching **LAM***

08:40 Pneumatic Retinopexy for Optic Nerve Pits
*Bernard **HURLEY***

08:50 Pneumatics for VMT/Macular Holes or Management of Pneumatics (Post Op Scenarios, Complications, etc.)
*Arif **SAMAD***

09:00 Vitreous Imaging, The New Frontier
*David **WONG***

09:10 Pneumatic Retinopexy in Pediatric Patients
*Peter **KERTES***

09:20 Mechanisms in Retinal Detachment Repair: Novel Insights from Multimodal Imaging Lead to Innovations in Management
*Rajeev **MUNI***

09:30 Tips and Tricks for a Successful Pneumatic
*Sherman **VALERO***

09:40 How to Manage Pneumatic Complications
*Jeffrey **LIM***

09:50 Panel Discussion and Q&A

Pediatric and Neuro-ophthalmology

Pediatric and Neuro-ophthalmology Symposium

13:45 - 15:15 **Venue: S428**
*Chair(s): Carmen **CHAN**, Connie **LAI**, Jason **YAM***

13:45 Neuro-ophthalmology: Textbook vs Reality
*Noel **CHAN***

14:05 Peering into Children's Eyes
*Christopher **GO***

14:25 Long-term Complications of Childhood Myopia
*Andrew **TSAI***

14:45 Free Paper - Randomized Controlled Trial Comparing the Efficacy and Safety of Mydriatic Microdrops over Standard Dose Mydriatics for Pupil Dilation in Retinopathy of Prematurity Examination
*Evelyn **LU***

14:52 Free Paper - Pediatric Trans-scleral Intraocular Lens Fixation: Retrospective Single Centre Outcomes
*Kiran **KEDARISETTI***

14:59 Free Paper - Early Initiation of Systemic Immunosuppressants for Non-infective Anterior Uveitis in Paediatric Ptients
*Hiu Ching Kristy **YIM***

15:06 Panel Discussion and Q&A

Retina (Medical)

Mysterious Retina Cases

Cases will be presented and discussed by the invited speakers and panelists. The cases have only been seen by the individual presenter. Discussions will center around the work up of the patient, use of multimodal imaging and ancillary testing, generation of a differential diagnosis, followed by the correct diagnosis, and finally then by the appropriate management and outcome. Audience participation will be encouraged. This should provide a learning environment for everyone.

08:30 - 10:00 **Venue: S423-S424**
*Chair(s): Xiaoxin **LI**, Fiona **LUK**, William **MIELER***

08:30 Mysterious Retina Case 1
*Tharikarn **SUJIRAKUL***

08:40 Mysterious Retina Case 2
*Simon **SZETO***

08:50 Mysterious Retina Case 3
*Angie **FONG***

09:00 Mysterious Retina Case 4
*Xiaoxin **LI***

09:10 Mysterious Retina Case 5
*William **MIELER***

09:20 Mysterious Retina Case 6
*Min **KIM***

09:30 Mysterious Retina Case 7
*Manoharan **SHUNMUGAM***

09:40 Mysterious Retina Case 8
*Suqin **YU***

09:50 Panel Discussion and Q&A

Inherited Retinal Diseases

The "Inherited Retinal Diseases" symposium session brings together experts in the field to discuss groundbreaking research and advancements in the understanding and treatment of these conditions. The talks will cover a diverse range of topics, including the use of non-standard ERGs to enhance phenotyping accuracy, distinguishing between IRD and AIR, the crucial role of electrophysiology in unraveling cone dysfunction syndromes, insights into ABCA4 related diseases, and the phase 2 data from the Botaretigene study. Additionally, the session will delve into the evaluation of Tinlarebant's effects on Stargardt disease based on promising results from a phase 1b/2 study, and share experiences in establishing the first IRD service in Singapore. Attendees can expect a comprehensive overview of the latest advancements in inherited retinal diseases and their potential impact on diagnosis and treatment strategies.

10:30 - 12:00 **Venue: S425**
*Chair(s): Marten **BRELEN**, Graham **HOLDER**, Kyu-hyung **PARK***

10:30 Improving Accuracy of Phenotyping with Non-standard ERGs
*Graham **HOLDER***

10:40 Is It IRD or AIR (Autoimmune Retinopathy)?
*Tharikarn **SUJIRAKUL***

10:50 The Role or Electrophysiology in Unravelling the Cone Dysfunction Syndromes
*John **GRIGG***

11:00 ABCA4 Related Diseases
*Kaoru **FUJINAMI***

11:10 Phase 2 Data from the Botaretigene Study
*Adrian **KOH***

11:20 Evaluating the Effect of Tinlarebant in Subjects with Stargardt Disease in a Global Phase 3 Study Following Promising Results from the Phase 1b/2 Study
*Ruifang **SUI***

11:30 Experiences of Starting the First IRD Service in Singapore
*Hwei Wuen **CHAN***

11:40 Clinical Characteristics and Disease Progression of Retinitis Pigmentosa Associated with PDE6B Mutation in Korean Patients
*Joo Yong **LEE***

11:50 Panel Discussion and Q&A

Retina (Surgical)

Management of VR Complications from Anterior Segment Surgeries

This interactive symposium will discuss vitreoretinal surgical complications arising from anterior segment surgery, including dropped lens, IOL complications, endophthalmitis, CMO, suprachoroidal hemorrhage, keratoprosthesis, glaucoma and UGH syndrome. Risk factors, diagnosis and management will be covered. Expert speakers from around the APAC region will be in attendance and audience participation will be encouraged.

13:45 - 15:15 **Venue: S423-S424**
*Chair(s): Adrian **FUNG**, Vincent **LEE**, Peiquan **ZHAO***

13:45 Dropped Nucleus
Min ***KIM***

13:55 Management of IOL Complications
Nimesh ***PATEL***

14:05 Endophthalmitis
Vivek ***DAVE***

14:15 Pseudophakic Cystoid Macular Edema
Yi-ting ***HSIEH***

14:25 Suprachoroidal Hemorrhage after Cataract Surgery
Simon ***SZETO***

14:35 Vitrectomy in the Setting of Corneal Opacification
Gavin ***TAN***

14:45 Management of Lens-induced Glaucoma Related to Anterior Segment Surgeries
Peiquan ***ZHAO***

14:55 Uveitis-Glaucoma-Hyphema (UGH) Syndrome
Sebastian ***WALDSTEIN***

15:05 Panel Discussion and Q&A

Translational Medicine

New Translational Developments in Vitreoretina

10:30 - 12:00 **Venue: S423-S424**
Chair(s): Michael ***CHIANG****, Angie* ***FONG****, Dennis* ***LAM***

10:30 Early Diagnosis of Alzheimer's Disease through Ophthalmic Investigation and AI
Carol ***CHEUNG***

10:42 AMD Supplement: Latest Development
Emily ***CHEW***

10:54 Eye GPT
Daniel ***TING***

11:06 PEG-arginase: A Potential Novel New Drug to Treat Diabetic Proliferative Retinopathy
Dennis ***LAM***

11:18 Discussion of Future Directions in Clinical Care and Research
Michael ***CHIANG***

11:30 Retinal Prostheses: The History and The Future
Penelope ***ALLEN***

11:42 Panel Discussion and Q&A

Nikon

APVRS 2023 HONG KONG

optos®



Saturday

December 9th 12:30 – 13:30

Venue : S423-S424

Optos / Nikon Sponsored Lunch Symposium

Advances in Ultra-widefield Multimodal Retinal Imaging

SPEAKER

Adrian H.C. Koh, MD, Assoc Professor

Senior Consultant, Eye & Retina Surgeons, Singapore

The Role of Ultra-Widefield Imaging in the Management of Retinal Degenerations

MODERATOR & SPEAKER

SriniVas R. Sadda, MD, Professor

Director, Artificial Intelligence & Imaging Research,
Doheny Eye Institute and Professor of Ophthalmology at UCLA, USA

Clinical Applications of Ultra-Widefield Imaging and Peripheral OCT

SUBMITTED SYMPOSIUMS

BEST ABSTRACT AWARDS

The Best Abstract Awards are presented to outstanding abstract(s) in the submitted program.

Best Free Paper Award

Andrew CHANG
Australia

Stanley POH
Singapore

Michael SINGER
United States

Wei-Chi WU
Chinese Taipei

Yahan YANG
China

Best Poster Award

Yi JIANG
China

Min KIM
Republic of Korea

Brijesh TAKKAR
India

Raymond WONG
Hong Kong SAR

Pingting ZHONG
China

Best E-poster Award

Choi Mun CHAN
Singapore

Jing FENG
China

Andrew MIHALACHE
Canada

Zhen Ling TEO
Singapore

Jim XIE
Canada

Best Video Award



Jinghua LIU
China

Anjali MAHESHWARI
India

Obuli N
India

Veer SINGH
India

Shishir VERGHESE
India

FREE PAPERS

Dec 08, 2023 (Fri)

Retina (Medical)

Rapid Fire 1 - Retina (Medical)

08:30 - 10:00 **Venue: S422**

08:30 6-month Outcomes of Switching from Aflibercept to Faricimab in Refractory Cases of Neovascular Age-related Macular Degeneration
*Keiko **KATAOKA***

08:36 Concurrent Autoimmune Retinopathy and Myasthenia Gravis with/without Thymoma
*Ping **FEI***

08:42 Cord Lining Induced Pluripotent Stem Cell-derived Retinal Pigment Epithelium: A Novel Source for Cell Therapy for Age-related Macular Degeneration
*Mayuri **BHARGAVA***

08:48 Association Between Choroidal Thickness and Age-related Macular Degeneration Severity: Meta-analysis from the Asian Eye Epidemiology Consortium
*Kai Xiong **CHEONG***

08:54 Influence of Carotid Endarterectomy on Choroidal and Choriocapillaris Perfusion Study
*Sandy Wenting **ZHOU***

09:00 Effects of Physical Activity and Inactivity on Retinal Vessel Caliber of Children: The Hong Kong Children Eye Study
*Vincent **YUEN***

09:06 Real-world Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study
*Michael **SINGER***

09:12 Preliminary Results of an AAV Gene Therapy Trial on X-linked Retinitis Pigmentosa Caused by Mutations in Retinitis Pigmentosa GTPase Regulator
*Ruifang **SUI***

09:18 Exudative Age-related Macular Degeneration Events in the OAKS and DERBY Clinical Trials and the GALE Open-label Extension of Pegcetacoplan in Geographic Atrophy
*Andrew **CHANG***

09:24 Faricimab Treatment Outcomes with Extended Dosing and Potential for Q20W Intervals in DME: A Post Hoc Analysis of the Phase 3 YOSEMITE/RHINE Trials
*Yi-ting **HSIEH***

09:30 Electrophysiological and Visual Parameter Changes in Retinitis Pigmentosa Patients Undergoing Autologous Platelet-rich Plasma Therapy
*Perwez **KHAN***

09:36 Efficacy, Durability and Safety of Faricimab in DME: 1-year Results From China Subpopulation of Phase 3 RHINE Trial
*Xiaodong **SUN***

09:42 Efficacy, Durability and Safety of Faricimab in nAMD: 48-Week Results From the China Subpopulation of Phase 3 LUCERNE
*Youxin **CHEN***

Retina (Surgical)

Rapid Fire 2 - Retina (Surgical)

10:30 - 12:00 **Venue: S422**

10:30 Utilization of 3D Magnetic Resonance Imaging in Perioperative Assessment for Patients Undergoing Surgery for Myopic Traction Maculopathy
*Pradeep **SUSVAR***

10:39 Predictive Factors and Visual Outcomes After Immediate Pars Plana Vitrectomy for Posteriorly Dislocated Lens Fragments During Complicated Phacoemulsification Surgery
*Aditya **KELKAR***

10:48 Predicting Spontaneous Vitreomacular Traction Release Versus Macular Hole Formation in the Fellow Eyes of Patients Treated for Full-thickness Macular Holes
*Jehwi **JEON***

10:57 Staged Versus Combined Surgical Approach for Patients with Concomitant Cataract and Epiretinal Membrane: A Randomized Controlled Trial
*Danny **CHEUNG***

11:06 Rise in Intraocular Pressure in Elevator Travel After Vitreoretinal Surgery with Gas Tamponade
*Po Yin **WONG***

11:15 Evaluating an Optical Coherence Tomography Test for Retinal Detachment: The PReDiCT (Prediction of Retinal Detachment from retinal Irregularity with OCT) Study
*Stewart **LAKE***

11:24 Clinical Settings and Outcomes of Silicone Oil Removal: A Big Data Study of 11,934 Eyes
*Vivek **DAVE***

11:33 Efficacy and Safety of Macular Hole Repair by Pars Plana Vitrectomy without Endotamponade
*Amy Hiu Ying **YU***

11:42 Quantitative Optical Coherence Tomography Angiography Parameter Changes in Post-treatment Endophthalmitis
*John Philip **UY***

11:51 Long-term Mortality of Patients Requiring Pars Plana Vitrectomy for Diabetic Tractional Retinal Detachment: A 10-year Study from Hong Kong
*Yee Yan **CHAN***

Dec 09, 2023 (Sat)

Ocular Imaging (APOIS)

APOIS Symposium 7: Rapid Fire

08:30 - 10:00 **Venue: S422**

08:30 Ocular Factors of Fractal Dimension and Blood Vessel Tortuosity Derived from OCTA in a Healthy Chinese Population
*Yunhe **SONG***

08:38 Classification of Visual Field Abnormalities in Highly Myopic Eyes without Pathologic Change
*Fengbin **LIN***

08:46 Developing a Privacy-preserving Deep Learning Model for Glaucoma Detection: A Multi-Center Study with Federated Learning
*Emma Anran **RAN***

08:54 Translation of Color Fundus Photography into High-resolution Indocyanine Green Angiography Image
*Danli **SHI***

09:02 Deep Learning-based System for Assessing Conjunctival Injection and Subconjunctival Hemorrhage in Red Eye
*Pak Wing **CHIU***

09:10 High Myopia Normative Database of Peripapillary Retinal Nerve Fiber Layer Thickness to Detect Myopic Glaucoma in a Chinese Population
*Yunhe **SONG***

09:18 VisionFM: Towards a Generalist AI Foundation Model in Ophthalmology
*Jian **WU***

09:26 Automated Machine Learning for Anterior Segment Optical Coherence Tomography Image Quality Control
*Chak Fung **NG***

09:34 Using Deep Learning to Assess Image Quality of 3D Macular Scans from Spectral-domain Optical Coherence Tomography
*Ziqi **TANG***

09:42 Postural Changes in Retinal Vascular Parameters and Risk of Diabetic Retinopathy Progression: A Prospective Cohort Study
*Truong **NGUYEN***

09:50 Early Rate of Change in Circumpapillary Vessel Density is Associated with Normal Tension Glaucoma Progression: An Optical Coherence Tomography Angiography Longitudinal Study
*Ruyue **SHEN***

Retina (Medical)

Rapid Fire 3 - Retina (Medical) and Ocular Oncology & Pathology

10:30 - 12:00 **Venue: S422**

10:30 Long-term Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-related Macular Degeneration: Results from the Portal 5-year Subgroup Analysis
*Gemmy **CHEUNG***

10:36 Extended Treatment Outcomes and the Potential for Q20W Dosing with Faricimab in Neovascular Age-related Macular Degeneration: A Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials
*Adrian **KOH***

10:42 Real-world Efficacy and Safety of Faricimab in Neovascular Age-related Macular Degeneration: The TRUCKEE Study
*Michael **SINGER***

10:48 Aflibercept 8 mg in Patients with Neovascular Age-related Macular Degeneration: Phase 3 PULSAR Trial 96-week Results
*Tien Yin **WONG***

10:54 Biomarkers for Vascular Stability Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition with Faricimab in Phase 3 Trials in DME
*Colin **TAN***

11:00 Predicting the Need for Diabetic Macular Edema Treatment from Photographic Screening in the Singapore Integrated Diabetic Retinopathy Programme
*Stanley **POH***

11:06 Greater Reduction in Pigment Epithelial Detachment Size with Faricimab vs Aflibercept During Head-to-head Dosing in Patients with Neovascular Age-related Macular Degeneration
Timothy ***LAI***

11:12 Choroidal Vascularity Index as Biomarker to Predict the Response to Anti-vascular Endothelial Growth Factor of Pachychoroid and Nonpachychoroid Polypoidal Choroidal Vasculopathy
Yue ***ZHANG***

11:18 Plasma Apolipoproteins and Their Ratios as Novel Biomarkers for Type 2 Diabetes Mellitus and Diabetic Retinopathy
Xinyuan ***ZHANG***

11:24 Port Delivery System with Ranibizumab in Diabetic Macular Edema: Primary Analysis and Patient Preference Results of the Phase 3 Pagoda Trial
Timothy ***LAI***

11:30 Genotype and Phenotype Correlation in Leber Congenital Amaurosis Patients from a Tertiary Eye Care Center
Abhishek ***UPADHYAYA***

11:36 Preliminary Results of the Longitudinal, Non-interventional Study of Real-world Outcomes for Brolucizumab in Wet Age-related Macular Degeneration in Malaysia
Mae-lynn ***BASTION***

11:42 Comprehensive Multifactor System of Uveal Melanoma Metastatic Risk Prognosis
Ilia ***LEVASHOV***

Dec 10, 2023 (Sun)

Ocular Imaging

Rapid Fire 5 - Ocular Imaging, Intraocular Inflammation and Uveitis & Scleritis

10:30 - 12:00 **Venue: S422**

10:30 The Role and Mechanism of M-MDSCs/PMN-MDSCs in Experimental Autoimmune Uveitis
Caiyun ***YOU***

10:37 Vogt-Koyanagi-Harada Disease in Pediatric, Adult, and Elderly: Clinical Characteristics and Visual Outcomes
Weiting ***LIAO***

10:44 Examination of Galactomannan Levels in the Intraocular Fluid to Assist the Diagnosis of Aspergillus Endophthalmitis
Ting ***YU***

10:51 Using 3D-MRI Imaging to Quantitatively Analyze the Shape of Eyeballs with High Myopia and to Investigate Relationships Between Myopic Traction Maculopathy and Posterior Staphyloma
Xi ***CHEN***

10:58 Three-dimensional Choroidal Characteristics in 4 Subtypes of Central Serous Chorioretinopathy Using Swept-source Optical Coherence Tomography Angiography
Yue ***ZHANG***

11:05 Global Ocular Deformation in Pathologic Myopia
Shida ***CHEN***

11:12 Using 3D Deep Learning for Classification of Multiple Retinal Diseases on Optical Coherence Tomography Images
Ziqi ***TANG***

11:19 Association of Deep-learning Based Retinal Vessel Caliber Measurements with the Incidence of Cardiovascular Disease
Yiu Lun ***WONG***

11:26 Predicting Response to Anti-vascular Endothelial Growth Factor Therapy in Eyes with Diabetic Macular Edema Using Deep-Leaning Based OCT Image Analysis: A Multicenter Study
Gabriel ***YANG***

11:33 Performance of Artificial Intelligence in Detecting Diabetic Macular Edema from Optical Coherence Tomography and Fundus Photography Images: A Systematic Review and Meta-Analysis
Ching ***LAM***

11:40 Factors Affecting Clinical Outcomes in Polypoidal Choroidal Vasculopathy
Dominic ***TING***

11:47 Characteristics of Geographic Atrophy in Korean Patients with Dry Age-related Macular Degeneration: Incidence, Phenotypes, and Risk Factors for Fast Progression
Ye Eun ***HAN***

Ocular Oncology & Pathology

Rapid Fire 4 - Ocular Oncology & Pathology, Eye Trauma, Emergencies & Infections, General Ophthalmology and Pediatric Retina

08:30 - 10:00 **Venue: S422**

08:30 Effect of Intravitreal Bevacizumab on the Sequelae of Posterior Segment Open Globe Injuries: A Prospective Randomized Pilot Trial
Vivek ***DAVE***

08:39 Parasitic Eye Diseases: Nuances of Rapid Detection, Management Approach, and Outcome in a Tertiary Eye Care Center
Manabjyoti ***BARMAN***

08:48 Combined Ruthenium-106 Plaque Brachytherapy and Transpupillary Thermotherapy in Thick Choroidal Melanoma
Neiwete ***LOMI***

08:57 Ruthenium-106 Plaque Brachytherapy for 1-eyed Retinoblastoma Recalcitrant to Chemotherapy
Neiwete ***LOMI***

09:06 Clinicopathological Study of the Polypoidal Lesions of Polypoidal Choroidal Vasculopathy
Guangfeng ***LIU***

09:15 Role of Combined Systemic Chemotherapy and Periocular Topotecan in Advanced Intraocular Retinoblastoma
Antriksh ***WAHI***

09:24 Efficacy of Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitor in Treating Choroidal Metastasis from EGFR Mutated Non-small-cell Lung Cancer
Arnold ***CHEE***

09:33 Conbercept Versus Laser Therapy for the Treatment of Infants with Zone II Retinopathy of Prematurity
*Yong **CHENG***

09:42 Comparison of Flanged Intrascleral Intraocular Lens Fixation Versus Iris Claw Intraocular Lens Fixation: A Retrospective Study
*Harsh **JAIN***

09:51 Non-contact Ultra-widefield Swept Source Optical Coherence Tomography Biomarkers Could Predict Treatment Response to Intravitreal Anti-vascular Endothelial Growth Factor in Aggressive Retinopathy of Prematurity
*Akash **BELENJE***

Pediatric Retina

Rapid Fire 6 - Pediatric Retina, Translational Medicine and Ophthalmic Epidemiology

13:45 - 15:15 **Venue: S422**

13:45 Spatial Technology Assessment of Green Space Exposure and Myopia
*Yahan **YANG***

13:51 Efficacy of Intravitreal Bevacizumab as Monotherapy for Treatment of Aggressive Retinopathy of Prematurity
*Bhavik **PANCHAL***

13:57 Dry Lensectomy-assisted Lensectomy in the Management of End-stage Pediatric Vitreoretinopathy Complicated with Severe Anterior Segment Abnormalities
*Jie **PENG***

14:03 Vascular Development Analysis: A Study of Tertiary Anti-vascular Endothelial Growth Factor Therapy After Second Reactivation of Retinopathy of Prematurity
*Xuerui **ZHANG***

14:09 2-year Outcomes from FIREFLEYE Next, a Prospective Follow-up Study to Evaluate Long-term Efficacy and Safety of Patients Treated with Intravitreal Aflibercept or Laser Photocoagulation for Retinopathy of Prematurity in the FIREFLEYE Study
*Wei-chi **WU***

14:15 Downregulation of Tear Fluid Apolipoprotein A4 as a Potential Biomarker for Retinopathy of Prematurity
*Alicia **LIU***

14:21 The Clinical Effect of Conbercept and Ranibizumab Treatment of Familial Exudative Vitreoretinopathy of Stage 2
*Li **NAN***

14:27 Utility of 3D-display Surgical Videos for Better Educational Effects in Pediatric Persistent Fetal Vasculature for Ophthalmologists
*Jinghua **LIU***

14:33 A Retrospective Analysis of Ultra-Widefield Photograph Documentation of Retinopathy of Prematurity at a Tertiary Eye Care Outpatient Setup
*Sushma **JAYANNA***

14:39 Temporal Retinal Vessel Angle as a Novel Clinical Marker in FEVR
*Christopher **GO***

14:45 Surgical Treatment for Familial Exudative Vitreoretinopathy in Children Complicated with Tractional Epiretinal Membrane
*Jing **MA***

14:51 Delayed Inflammation and Immune Rejection of Xeno-transplanted Human iPSC-RPE Monolayers in Non-human Primates
*Zengping **LIU***

14:57 AMDGD: A Comprehensive Database Provides Landscape Genetic Variation Information for Age-related Macular Degeneration
*Dongyue **WANG***

POSTERS

Cataract and Refractive Surgery

Poster No.: EX1-131
Causes of Day-of-surgery Cancellation of Elective Cataract Surgery in Hong Kong
*First Author: Cheuk Lam **LEE***
*Co-Author(s): Jonathan **CHAN***

Poster No.: EX1-132
Innovative Modifications in the Yamane Technique for Intra-scleral Fixation of IOL: A Case Series
*First Author: Gajendra **CHAWLA***
*Co-Author(s): Neha **BIJLANI***

Poster No.: EX1-133
Intracameral Use of Moxifloxacin Eye Drops After Phacoemulsification and Foldable Intraocular Lens Implantation Surgery
*First Author: Nilutpal **BORAH***

Poster No.: EX1-134
Late-onset Bilateral Methicillin Resistant Staphylococcus aureus Keratitis After Small Incision Lenticule Extraction
*First Author: Timothy Pak Ho **LIN***
*Co-Author(s): Vanissa **CHOW***

Poster No.: EX1-135
Scleral-fixated Aniridia Intraocular Lenses in Severely Traumatized Eyes and Congenital Aniridia Eyes
*First Author: Raj Shri **HIRAWAT***
*Co-Author(s): Nagesha **CHOKKAHALLI***

Cornea and External Eye Disease

Poster No.: EX1-136
A Glance at Self and Medical Professional-based Disease Management of MGD-related DED Patients in Hong Kong
*First Author: Charlotte Yi-sum **POON***
*Co-Author(s): Hoi Ying Emily **CHAN**, Zhichao **HU**, Kam Lung **CHONG** , Xu Lin **LIAO**, Yiu Man **WONG***

Poster No.: EX1-137
Correlation Between Tear Film Lipid Quality and Meibomian Gland Dropout in Mild to Moderate Meibomian Gland Dysfunction
*First Author: Yiu Man **WONG***
*Co-Author(s): Kam Lung **CHONG**, Zhichao **HU**, Xu Lin **LIAO**, Andre **MA**, Weng Chi Stella **SIO***

Poster No.: EX1-138
Correlation of Lid Margin Abnormalities with Meibomian Gland Dysfunction Severity
*First Author: Chak Fung **NG***
*Co-Author(s): Tsun **CHIU**, Zhichao **HU**, Chong **KAM LUNG**, Jake **SEBASTIAN**, Weng Chi Stella **SIO***

Poster No.: EX1-139
Dense Endothelial Deposit and Anterior Capsular Cataract: Effect of 23-year Chlorpromazine Use on the Anterior Segment
*First Author: Julia Y.Y. **CHAN***
*Co-Author(s): Vanissa **CHOW***

Poster No.: EX1-140
Dry Eye Disease Questionnaires in Patients with Mild to Moderate Meibomian Gland Dysfunction
*First Author: Zhichao **HU***
*Co-Author(s): Eric Ka Ho **CHOY**, Chong **KAM LUNG**, Man Wai **KWOK**, Yingsi **LUO**, Yiu Man **WONG***

Poster No.: EX1-141
Epidemiology and Etiological Analysis of Keratitis in Northwest China
*First Author: Ying **LIU***
*Co-Author(s): Ping **GE**, Jie **YANG**, Xiangxiang **YANG***

Poster No.: EX1-142
Impact of Secondhand Smoking on Dry Eye Prevalence and Severity: A Population-based Study in Hong Kong
*First Author: Anakin Chu Kwan **LAI***
*Co-Author(s): Jordy **LAU**, Kendrick **SHIH**, Po Yin **WU***

Poster No.: EX1-143
Lifestyle and Medical History as Potential Risk Factors of Mild to Moderate Meibomian Gland Dysfunction
*First Author: Hoi Ying Emily **CHAN***
*Co-Author(s): Kelvin Kam-lung **CHONG**, Zhichao **HU**, Charlie **NG**, Yui Cheung **NG**, Jake **SEBASTIAN***

Poster No.: EX1-144
Ocular Surface Changes in Post Laser-assisted In Situ Keratomileusis Eyes
*First Author: Tsun **CHIU***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kelvin Kam-lung **CHONG**, Kenneth **LAI**, Yiu Man **WONG***

Poster No.: EX1-145
The Effects of Screen Time, Sleep, and Stress on Dry Eye Disease During the COVID-19 Pandemic
*First Author: June Oi Yau **WONG***
*Co-Author(s): Kelvin Kam-lung **CHONG**, Xu Lin **LIAO**, Calvin **PANG**, Clement **THAM**, Arthur Chun Chi **WONG***

Poster No.: EX1-146
Update on Advancements in Conventional and Novel Treatment Approaches in Moderate to Severe Dry Eye Disease
*First Author: Carolyn Yu Tung **WONG***
*Co-Author(s): Justin Man Kit **TONG***

Eye Trauma, Emergencies & Infections

Poster No.: EX1-001
A Curious Case of Endogenous Fungal Endophthalmitis with Novel Pathogen Presenting in Acute Angle Closure
*First Author: Jeremy **WILLIAMSON***
*Co-Author(s): Joseph **PARK**, Richard **SARAFIAN***

Poster No.: EX1-002
Clinical Features of Novel Coronavirus Infection Associated Acute Macular Neuroretinopathy
*First Author: Yusheng **ZHONG***
*Co-Author(s): Yong **CHENG**, Tong **QIAN***

Poster No.: EX1-003
Globe Perforation from Metallic Foreign Body with an Irreparable Posterior Scleral Exit Wound, Good Outcome Following Staged Surgery: A Case Report
*First Author: Bashajan **ALI***
*Co-Author(s): Benjamin **CHANG**, Siddharth **SUBRAMANI***

Poster No.: EX1-004
Risk Factors for Band Keratopathy in Aphakic Eyes with Silicone Oil Tamponade for Open-globe Injuries: A Multicenter Case-control Study
*First Author: Mengyu **LIAO***

Poster No.: EX1-005
Through the Microscope: An Insight into the Histopathological Features of Fungal Panophthalmitis
*First Author: Amber **DUBEY***
*Co-Author(s): Dipankar **DAS***

Poster No.: EX1-006
Triamcinolone to Prevent Traumatic Proliferative Vitreoretinopathy in Open Globe Injury
*First Author: Hua **YAN***

Poster No.: EX1-007
Unmasking the Culprit: Post-traumatic Late-onset Chronic Angle Recession Glaucoma Masked by a Concurrent Rhegmatogenous Retinal Detachment
*First Author: Cherry Vhie **ORTEGA***

General Ophthalmology

Poster No.: EX1-147
Are Endocrinologists' Grading of Referable Diabetic Retinopathy More Trustworthy than an Artificial Intelligence System?
*First Author: Chi Lik **AU***
*Co-Author(s): Steffi Shing Yee **CHONG**, Callie **KO**, George Tsz Ho **SHUM***

Poster No.: EX1-148
Clinical Application of Pupillometry in Ocular Disorders: A Systematic Review
*First Author: Suet Man **LI***
*Co-Author(s): Kam Lung **CHONG** , Kenneth **LAI**, Chen Hui **TANG**, Yifei **YANG***

Poster No.: EX1-149
Comparing Biomechanically Corrected Intraocular Pressure by Corvis ST with Intraocular Pressure by iCare IC200 Across Axial Lengths
*First Author: Adrian **WONG***
*Co-Author(s): Jordy **LAU**, Kendrick **SHIH***

Poster No.: EX1-150
Global Prevalence of Orbital and Eyelid Tumors and Projection of Prevalence Through 2045: A Systematic Review and Meta-analysis
*First Author: Ho Ting **MAK***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kam Lung **CHONG**, Ka Hei Kenneth **LAI**, Kei Hei **LAI**, Calvin C. P. **PANG***

Poster No.: EX1-151
Lens Power and Associated Factors in Non-human Primate Subjects: A Cross-sectional Study
*First Author: Hongyi **LIU***
*Co-Author(s): Jian **WU***

Poster No.: EX1-152
Normative Profile of Retinal Nerve Fiber Layer Thickness and Lamina Cribrosa-related Parameters in a Healthy Non-glaucoma Cynomolgus Monkey Colony
*First Author: Jian **WU***
*Co-Author(s): Hongyi **LIU***

Poster No.: EX1-153
Performance of a Novel Large Language Model Framework in Ophthalmology Examinations: An Evaluation with 4,898 Questions
*First Author: Wai Chak **CHOY***
*Co-Author(s): Carmen K. M. **CHAN**, Kam Lung Kelvin **CHONG**, Calvin **PANG**, Wilson **YIP***

Poster No.: EX1-154
Refractive Outcome and Keratometry of a Keratoconus Cornea After Cross-linking Associated Endothelial Damage
*First Author: Hong Nien **LEE***

Poster No.: EX1-155
What Can GPT-4 Do for Diagnosing Rare Eye Diseases? A Pilot Study
*First Author: Xiaoyan **HU***
*Co-Author(s): Carmen K. M. **CHAN**, Truong **NGUYEN**, Emma Anran **RAN**, Simon **SZETO***

Glaucoma

Poster No.: EX1-156
A Multicenter Clinical Study of the Automated Fundus Screening Algorithm
*First Author: Jiaxuan **JIANG***

Poster No.: EX1-157
Association of Foveal Avascular Zone Area with Structural and Functional Progression in Glaucoma Patients
*First Author: Yinhang **ZHANG***
*Co-Author(s): Fei **LI**, Xiulan **ZHANG***

Poster No.: EX1-158
Development and Clinical Deployment of a Smartphone-based Visual Field Deep Learning System for Glaucoma Detection
*First Author: Zefeng **YANG***
*Co-Author(s): Fei **LI**, Xiulan **ZHANG***

Poster No.: EX1-159
Impact of Postoperative Choroidal Detachment on Trabeculectomy Outcomes: A 4-Year Comparative Study
*First Author: Nader **MASSIRI***
*Co-Author(s): Kavousnezhad **SARA**, Kourosh **SHEIBANI**, Maryam **YADGARI***

Poster No.: EX1-160
Optic Nerve Head Abnormalities in Non-pathologic High Myopia and the Relationship with Visual Field
*First Author: Jingwen **JIANG***
*Co-Author(s): Xiulan **ZHANG***

Poster No.: EX1-161
Pretreatment with Frequent Topical Betamethasone in Ahmed Glaucoma Valve Implantation
*First Author: Nader **MASSIRI***
*Co-Author(s): Kavousnezhad **SARA**, Kourosh **SHEIBANI**, Maryam **YADGARI***

Poster No.: EX1-162
Real-world Study on Ocular Surface Condition in Patients with Primary Angle Closure and Primary Angle-Closure Glaucoma Before Treatment
*First Author: Jie **YANG***

Poster No.: EX1-163
Single-cell Transcriptomic Atlas of Aging Macaque Ocular Outflow Tissues
*First Author: Jian **WU***
*Co-Author(s): Hongyi **LIU**, Ningli **WANG***

Poster No.: EX1-164
The Effect of Early Post Trabeculectomy Bleb Leakage on Surgical Outcome: A Prospective Cohort Study
*First Author: Maryam **YADGARI***
*Co-Author(s): Kavousnezhad **SARA**, Kourosh **SHEIBANI**, Nader **MASSIRI***

Poster No.: EX1-165
The Effect of the Hypertensive Phase on the Long-term Outcomes of Ahmed Glaucoma Valve Implantation
*First Author: Nader **MASSIRI***
*Co-Author(s): Kavousnezhad **SARA**, Kourosh **SHEIBANI**, Maryam **YADGARI***

Poster No.: EX1-166
The Role of Primary Needle Revision After Ahmed Glaucoma Valve Implantation
*First Author: Maryam **YADGARI***
*Co-Author(s): Kavousnezhad **SARA**, Kourosh **SHEIBANI**, Nader **MASSIRI***

Intraocular Inflammation, Uveitis & Scleritis

Poster No.: EX1-008
Analysis of Clinical Significance of Positive IGRA Test in Uveitis Patients
*First Author: Minwoo **LEE***
*Co-Author(s): Hyun Goo **KANG***

Poster No.: EX1-009
Azathioprine-induced Alopecia Totalis as an Early Marker of Pancytopenia in Uveitis: A Rare Case
*First Author: Reema **BANSAL***
*Co-Author(s): Prabal **BARMAN**, Sabia **HANDA**, Ankur **JINDAL***

Poster No.: EX1-010
Choroidal Thickness Changes Determined by EDI-OCT in Patients with Unilateral CMV Anterior Uveitis
*First Author: Oyunzaya **LUVSANTSEREN***

Poster No.: EX1-011
Clinical Characteristics of Syphilitic Uveitis at a Referral Hospital in Japan
*First Author: Wataru **MATSUMIYA***
*Co-Author(s): Naoki **FUKUSHIMA**, Sentaro **KUSUHARA**, Makoto **NAKAMURA**, Rei **SOTANI***

Poster No.: EX1-012
Clinical Features, Long-term Outcomes, and Prognostic Factors of Eales' Disease in Korean Patients
*First Author: Min **KIM***
*Co-Author(s): Youngje **CHOI**, Seung Min **LEE***

Poster No.: EX1-013
Clinical Outcomes in Managing Macular Edema in Patients with Non-infectious Uveitis Treated with Suprachoroidal Injections of Triamcinolone Acetonide Suspension: A Post-hoc Analysis of a Phase III Study
*First Author: Raymond **WONG***
*Co-Author(s): Jackie **KAM**, Barry **KAPIK**, Qing **LIU**, Eddy **WU***

Poster No.: EX1-014
Development and Validation of Novel Retina Biomarkers and Artificial Intelligence Models for Behçet Disease Uveitis Prediction
*First Author: Ao **LU***
*Co-Author(s): Keyan **LI**, Guannan **SU**, Peizeng **YANG**, Xinle **ZHANG***

Poster No.: EX1-015
Enigmatic Subretinal Lesion Presenting with Bullous Retinal Detachment and Its Management
*First Author: Raj Shri **HIRAWAT***
*Co-Author(s): Nagesha **CHOKKAHALLI**, Prakhar **SINGHAI***

Poster No.: EX1-016
Evaluating Intravitreal Dexamethasone Implants in Non-infectious Uveitis
*First Author: Ayushi **CHOUDHARY***
*Co-Author(s): Ankush **KAWALI**, Padmamalini **MAHENDRADAS**, Aditya **PATIL**, Radhika **SRIRAM***

Poster No.: EX1-017
Managing Vogt-Koyanagi-Harada Syndrome with Human Immunodeficiency Virus: A Dual Battle Between Immunosuppression and Immune Support
*First Author: Twinkey **BHUTIA***
*Co-Author(s): Manabjyoti **BARMAN**, Subham **SINHA ROY***

Poster No.: EX1-018
Ocular Manifestations and Diagnosis of Tuberculosis Involving the Uvea: A Case Series
*First Author: Rachel **CHEUNG***
*Co-Author(s): Stephanie **POON**, Jennifer **TSUI***

Poster No.: EX1-019
Revealing Academic Evolution and Frontier Pattern in the Field of Uveitis Using Bibliometric Analysis, Natural Language Processing, and Machine Learning
*First Author: Ao **LU***
*Co-Author(s): Keyan **LI**, Guannan **SU**, Peizeng **YANG***

Poster No.: EX1-020
Suprachoroidal Injections of Triamcinolone Acetonide Suspension in Patients with Non-infectious Uveitis Complicated by Macular Edema: First in Asia Real-world Case Report
*First Author: Chun Sum **PANG***
*Co-Author(s): Nicholas **FUNG**, Jackie **KAM**, Qing **LIU**, Eddy **WU***

Poster No.: EX1-021
'Juxtapapillary' Serpiginous-like Choroiditis: A Distinct and New Phenotype of Ocular Tuberculosis Predisposing to Anterior Scleritis
*First Author: Reema **BANSAL***
*Co-Author(s): Amod **GUPTA**, Vishali **GUPTA***

Ocular Imaging (APOIS)

Poster No.: EX1-167
Are Current Data Augmentation Approaches for Ophthalmological Imaging Model Refinement Truly Results-reassuring and Applicability-beneficial?
*First Author: Carolyn Yu Tung **WONG***
*Co-Author(s): Pearse **KEANE**, Timing **LIU**, Ciara **O'BYRNE**, Priyal **TARIBAGIL***

Poster No.: EX1-168
Assessment of Mild Cognitive Impairment via a Retinal Imaging-based Deep Learning Model
*First Author: Yau Ho Herbert **HUI***
*Co-Author(s): Carol **CHEUNG**, Xiao Yan **HU**, Vincent **MOK**, Emma Anran **RAN***

Poster No.: EX1-169
Association Between Alzheimer's Disease and Artificial Intelligence-based Glaucomatous Optic Neuropathy Score
*First Author: Victor **CHAN***
*Co-Author(s): Christopher Li-hsian **CHEN**, Vincent **MOK**, An Ran **RAN**, Xi **WANG***

Poster No.: EX1-170
Code-free Deep Learning for Angle Closure Detection in Anterior Segment Optical Coherence Tomography Images
*First Author: Hin Yin **CHAN***
*Co-Author(s): Eric Ka Ho **CHOY**, Chak Fung **NG**, Ruyue **SHEN**, Clement **THAM***

Poster No.: EX1-171
Comparison of Bleb Morphologies Between Phacoemulsification Combined with Ex-PRESS Minishunt Implantation, Phacotrabeculectomy, and Trabeculectomy Alone: A 2-year Retrospective In Vivo Confocal Microscopy Study
*First Author: Hongyang **ZHANG***
*Co-Author(s): Yuqiao **ZHANG***

Poster No.: EX1-172
Comparison of Image Quality of Retinal Photographs Captured by 2 Non-mydriatic Fundus Cameras
*First Author: Anni **LING***
*Co-Author(s): An Ran **RAN**, Kaiser **SHAM***

Poster No.: EX1-173
Complications of Retinal Racemose Hemangioma
*First Author: Xuejiao **QIN***
*Co-Author(s): Yanyan **CUI**, Shaohua **LIU***

Poster No.: EX1-174
In Vivo Confocal Microscopy Predicts Cytomegalovirus as the Cause of Chronic or Recurrent Anterior Uveitis Among Chinese
*First Author: Stephanie Hiu-wai **KWOK***
*Co-Author(s): Ka Wai **KAM**, Eugenie **MOK**, Alvin **YOUNG***

Poster No.: EX1-175
Incremental Training for Multi-modality Imaging in Anterior Chamber Angle Classification Using Automated Machine Learning
*First Author: Eric Ka Ho **CHOY***
*Co-Author(s): Hin Yin **CHAN**, Anni Annie **LING**, Chak Fung **NG**, Ruyue **SHEN***

Poster No.: EX1-176
Investigating the Utility of Anterior Chamber Depth and Axial Length Thresholds in Predicting Anatomical Angle Closure in Chinese Patients
*First Author: Yik Tsz **LAM***
*Co-Author(s): Jordy **LAU**, Kendrick **SHIH***

Poster No.: EX1-177
OCT Biomarkers in Retinal Vein Occlusion Associated Macular Edema After Anti-VEGF Injection
*First Author: Kin **TSANG***
*Co-Author(s): Vivian Wing Ki **HUI**, Shaheeda **MOHAMED**, Simon **SZETO***

Poster No.: EX1-178
Reference-based Super-resolution Framework for Enhancing Image Quality of OCT Angiography Images with Low Resolution
*First Author: Dawei **YANG***
*Co-Author(s): Hao **CHEN**, Yuyan **RUAN**, Simon **SZETO**, Ziqi **TANG***

Poster No.: EX1-179
Repeatability, Interocular Correlation, and Agreement of Optic Nerve Head Vessel Density in Healthy Eyes: A Swept-source Optical Coherence Tomography Angiography Study
*First Author: Danqi **FANG***
*Co-Author(s): Haoyu **CHEN**, Carol **CHEUNG**, Xiaoting **MAI**, Dawei **YANG***

Poster No.: EX1-180
Structural and Functional Analysis of Multiple Subretinal Fluid Blebs After Successful Surgery for Rhegmatogenous Retinal Detachment
*First Author: Yingchao **WANG***
*Co-Author(s): Kangjie **KONG**, Yingqin **NI**, Sisi **XU***

Poster No.: EX1-181
Tackling Imbalanced Datasets for Vision-threatening Diabetic Retinopathy Detection via New Deep Learning Methods
*First Author: Shu Yi **ZHANG***
*Co-Author(s): Xiaoyan **HU**, An Ran **RAN**, Simon **SZETO**, Da Wei **YANG***

Poster No.: EX1-182
Ultrasound Biomarkers: Contrast Enhanced Ultrasound and Nakagami Imaging to Differentiate Benign and Malignant Choroidal Tumors
*First Author: Vishal **RAVAL***
*Co-Author(s): Karla **MERCADO-SHEKHAR**, Himanshu **SHEKHAR***

Poster No.: EX1-183
Uncertainty-inspired Open Set Learning for Retinal Anomaly Identification
*First Author: Haoyu **CHEN***
*Co-Author(s): Xinjian **CHEN**, Huazhu **FU**, Tian **LIN**, Meng **WANG***

Ocular Imaging

Poster No.: EX1-022
Association of Neuroretinal Rim Width and Diabetic Retinal Neurodegeneration in Patients with Diabetes
*First Author: Truong **NGUYEN***
*Co-Author(s): Simon **SZETO**, Dawei **YANG**, Ziqi **TANG***

Poster No.: EX1-023
Choroidal Structural Analysis Using Optical Coherence Tomography in Macular Telangiectasia Type 2 with and without Choroidal Neovascular Membrane
*First Author: Ayushi **CHOUDHARY***
*Co-Author(s): Rupesh **AGRAWAL**, Santosh **GOPIKRISHNA GADDE**, Chaitra **JAYADEV**, Gaurang **SEHGAL***

Poster No.: EX1-024
Clinical and Structural Progression of Macular Telangiectasia Type 2 in Thai Patients
*First Author: Nattha **MEECHAREON***

Poster No.: EX1-025
Evaluation of Peripheral Retinal Degeneration Using Ultra-widefield Swept Source Optical Coherence Tomography
*First Author: Ayushi **AGARWAL***
*Co-Author(s): Shorya **AZAD**, Rohan **CHAWLA**, Vinod **KUMAR**, Nawazish **SHAIKH**, Pradeep **VENKATESH***

Poster No.: EX1-026
Microvasculature and Structural Changes of Optic Disc in Pachychoroid Spectrum Disease
*First Author: Tae Rim **KIM***
*Co-Author(s): Eung-suk **KIM**, Kiyoung **KIM**, Jong Beom **PARK**, Seung-young **YU***

Poster No.: EX1-027
Multicolor Imaging Features of Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
*First Author: Dominic **TING***

Poster No.: EX1-028
Multimodal Imaging Analysis for Eyes with Autosomal Recessive Bestrophinopathy
*First Author: Masahiro **MIURA***
*Co-Author(s): Shinnosuke **AZUMA**, Shuhei **KAMEYA**, Shuichi **MAKITA**, Kazushige **TSUNODA**, Yoshiaki **YASUNO***

Poster No.: EX1-029
Myopia and Its Associations Between Axial Length and Optical Coherence Tomography Angiography Biomarkers
*First Author: Jessica **LAU***
*Co-Author(s): Mingming **ZHU***

Poster No.: EX1-030
Optical Coherence Tomography Assessment of Vitreous Opacities and Their Correlation with Retinal Breaks
*First Author: Suklengmung **BURAGOHAIN***
*Co-Author(s): Priyank **BHOLA**, Subham **SINHA ROY***

Poster No.: EX1-031
Outcomes of Switching to Brolucizumab in Eyes with Neovascular Age-related Macular Degeneration
*First Author: Seungyeon **LEE***
*Co-Author(s): Eung-suk **KIM**, Kiyoung **KIM**, Jong Beom **PARK**, Seung-young **YU***

Poster No.: EX1-032
Prediction of Treatment Response in Center-involved Diabetic Macular Edema Using a Deep Learning Approach Based on Optical Coherence Tomography
*First Author: Thanaporn **KRITFUANGFOO***
*Co-Author(s): Tharikarn **SUJIRAKUL**, Sipat **TRIUKOSE***

Poster No.: EX1-033
Vortex Vein Drainage System in Healthy Chinese People Using Ultra-widefield Optical Coherence Tomography Angiography
*First Author: Zhonghua **LUO***

Ocular Oncology & Pathology

Poster No.: EX1-034
A Case Report of Metastatic Thyroid Follicular Carcinoma Masquerading as Primary Lacrimal Gland Tumor
*First Author: Ana Camille **SANCHEZ***
*Co-Author(s): Sandra **WORAK***

Poster No.: EX1-035
A Rare Case of Neoplastic Masquerade Syndrome with Neovascular Glaucoma in Metastatic Lung Adenocarcinoma
*First Author: Hong Nien **LEE***
*Co-Author(s): M. Farahi Syazani **AB HALIM***

Poster No.: EX1-036
Bilateral Diffuse Uveal Melanocytic Proliferation: A Case Report and Review of the Literature
*First Author: Ye **LI***
*Co-Author(s): Thomas **CAMPBELL**, Andrew **ROWLANDS***

Poster No.: EX1-037
Differentiation of Choroidal Metastasis from Primary Cancer Sites: A Multimodal Imaging Study
*First Author: Anjali **MAHESHWARI***
*Co-Author(s): Vishal **RAVAL***

Poster No.: EX1-038
Effect of Geography on Eye Care Access Among Retinoblastoma Patients in the Philippines
*First Author: Roland Joseph **TAN***
*Co-Author(s): Aldous Dominic **CABANLAS**, Josemaria **CASTRO**, Kimberley Amanda **COMIA**, Mara Augustine **GALANG***

Poster No.: EX1-039
Episcleral Plaque Radiotherapy as Salvage Treatment for Retinoblastoma Following Intravenous Chemotherapy
*First Author: Vishal **RAVAL***
*Co-Author(s): Swathi **KALIKI**, Vijay Anand **REDDY***

Poster No.: EX1-040
Ocular Manifestations of Patients with Mature T/NK-cell Lymphomas
*First Author: Ping **FEI***
*Co-Author(s): Peiquan **ZHAO***

Poster No.: EX1-041
Predictive Potential of the Aqueous Humor Proteome for Metastasis in Uveal Melanoma
*First Author: Liya **XU***

Poster No.: EX1-042
Role of 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Uveal Melanoma: A Prospective Interventional Study
*First Author: Anchal **GERA***
*Co-Author(s): Rohan **CHAWLA**, Seema **KASHYAP**, Neiwete **LOMI**, Radhika **TANDON**, Rakesh **KUMAR***

Ophthalmic Epidemiology

Poster No.: EX1-043
A Comparison of Retinoblastoma Cases in the Philippines from 2010-2015 to 2016-2020
*First Author: Roland Joseph **TAN***
*Co-Author(s): Beltran Alexis **ACLAN**, Charmaine Grace **CABEBE**, Jayson **SO**, Adriel Vincent **TE***

Poster No.: EX1-044
Metabolomic Phenotyping of Obesity for Profiling Cardiovascular and Ocular Disease Outcomes
*First Author: Pingting **ZHONG***

Orbital & Oculoplastic Surgery

Poster No.: EX1-184
Case of Nasopharyngeal Carcinoma Presenting with Acute Loss of Vision
*First Author: Yi Han **LAU***
*Co-Author(s): Wing Man **HO**, Kwok Foo Nelson **YIP**, Kenneth Kai Wang **LI***

Poster No.: EX1-185
Clinical and Radiological Outcomes of Double Versus Triple Therapy in the Treatment of Dysthyroid Optic Neuropathy
*First Author: Weng Chi Stella **SIO***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kam Lung, Kelvin **CHONG**, Jake Uy **SEBASTIAN**, Kenneth Ka Hei **LAI***

Poster No.: EX1-186
Dacryoendoscopy in Patients with Lacrimal Duct Obstruction: A Systematic Review
*First Author: Nicole Tsz Yan **WONG***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kelvin **CHONG**, Jake **SEBASTIAN**, Kenneth Ka Hei **LAI***

Poster No.: EX1-187
Efficacy and Safety of Early Orbital Radiotherapy with Combined Immunosuppression in Moderate-severe Active Thyroid Eye Disease
*First Author: Hong Yu Ryan **FONG***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Karen **CHAN**, Kelvin **CHONG**, Kenneth Ka Hei **LAI***

Poster No.: EX1-188
Humphrey Visual Field Defects in Dysthyroid Optic Neuropathy
*First Author: Charlie **NG***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kam Lung **CHONG**, Ka Hei Kenneth **LAI**, Jake **SEBASTIAN***

Poster No.: EX1-189
Inferior Rectus Myositis After Orbital Fracture Repair with a Medpor Implant in a 38-year-old Chinese Male
*First Author: Ting Hei **TSANG***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kelvin Kam-lung **CHONG**, Ka Hei Kenneth **LAI**, Jake **SEBASTIAN***

Poster No.: EX1-190
Investigating the Pattern and Satisfaction of Online Information Seeking of Thyroid Eye Disease Patients
*First Author: Chun Hei Thomas **LO***
*Co-Author(s): Kelvin Kam-lung **CHONG**, Wing Sum Glodia **MUN**, Chun Hei Ryan **TANG***

Poster No.: EX1-191
Orbital Recurrence of Uveal Melanoma: 7 Years After Enucleation
*First Author: Agnes **HO***

Poster No.: EX1-192
Periorbital Mixed Tumor: The Cutaneous Counterpart of Pleomorphic Adenoma
*First Author: Shui King **TSOI***
*Co-Author(s): Chun Wah Matthew **LAM**, Hunter **YUEN***

Poster No.: EX1-193
Quality of Life Assessments in Patients with Dysthyroid Optic Neuropathy: A Cross-sectional Comparative Study
*First Author: Eric Ka Ho **CHOY***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kelvin Kam-lung **CHONG**, Kenneth **LAI**, Calvin C. P. **PANG***

Poster No.: EX1-194
Squamous Cell Carcinoma of the Caruncle
*First Author: Ming Kei **PANG***

Poster No.: EX1-195
Survey of Dysthyroid Optic Neuropathy Management Among Orbital and Oculoplastic Surgeons in Hong Kong
*First Author: Pui Yu Vienna **LEI***
*Co-Author(s): Fatema Mohamed Ali Abdulla **ALJUFAIRI**, Kelvin **CHONG**, Kenneth **LAI**, Jake Uy **SEBASTIAN***

Poster No.: EX1-196
Transorbital Decompression of Traumatic Superior Orbital Fissure Syndrome: A Case Report
*First Author: Jason **WONG***
*Co-Author(s): Fatema **ALJUFAIRI**, Kelvin **CHONG**, Kenneth **LAI***

Poster No.: EX1-197
Treatment of Orbital Lymphatic Malformations with Oral Sirolimus Therapy Alone
*First Author: Yik To **HO***
*Co-Author(s): Hunter **YUEN***

Other (General Ophthalmology)

Poster No.: EX1-045
Big Challenges in a Small Eye: Management of Secondary Angle Closure Glaucoma and Aqueous Misdirection in a Nanophthalmic Patient, a Case Report
*First Author: Cherry Vhie **ORTEGA***

Poster No.: EX1-046
Codeless Methodologies in Artificial Intelligence: A Study on Transfer Learning and Automated Machine Learning Applications Within the Ophthalmological Domain
*First Author: Suklengmung **BURAGOHAIN***
*Co-Author(s): Harsha **BHATTACHARJEE**, Henal **JAVERI**, Subham **SINHA ROY***

Poster No.: EX1-047
Comparison of Different Topical Anesthetics for Intravitreal Injections: A Randomized Crossover Clinical Trial
*First Author: Jeffrey **LO***
*Co-Author(s): Christopher **GO**, Wai-ching **LAM**, Veronica **LI***

Poster No.: EX1-048
Comparison of Visual Field 24-2 and 24-2C Test Grids for Chloroquine/Hydroxychloroquine Retinopathy Patients and High-risk Patients
*First Author: Chananchida **WONGWACHIRA***
*Co-Author(s): Sunee **CHANSANGPETCH**, Wijak **KONGWATTANON**, Anita **MANASSAKORN**, Kitiya **RATANAWONGPHAIBUL**, Disorn **SUWAJANAKORN***

Poster No.: EX1-049
Learnings and Challenges in Smartphone Fundus Photography! 2-year Journey of a New VR Surgeon
*First Author: Harshit **VAIDYA***

Poster No.: EX1-050
Practice Profile and Geographical Distribution of Ophthalmologists in the Philippines
*First Author: Roland Joseph **TAN***
*Co-Author(s): Maria Victoria **RONDARIS**, Roseny Mae **SINGSON***

Poster No.: EX1-051
Pupillometry Findings in Patients with IgG4-related Ophthalmic Disease: A Case Series Study
*First Author: Pok Yiu Angus **LEUNG***
*Co-Author(s): Kam Lung **CHONG**, Kenneth **LAI**, Chen Hui **TANG**, Yifei **YANG***

Paediatric and Neuro Ophthalmology

Poster No.: EX1-198
Complete Ophthalmoplegia in Herpes Zoster Ophthalmicus
*First Author: Natalie **CHAU***
*Co-Author(s): Stephanie Wing Ki **YUK***

Poster No.: EX1-199
Walker-Warburg Syndrome: Eye Manifestations, Diagnostic and Management Challenges: A Case Report
*First Author: Chun Sum **PANG***
*Co-Author(s): Connie **LAI***

Pediatric Retina

Poster No.: EX1-052
A Case Report of Late-onset Retinoblastoma Presenting Atypically as Secondary Angle Closure Glaucoma
*First Author: Ana Camille **SANCHEZ***
*Co-Author(s): Ricardo **VENTURA**, Sandra **WORAK***

Poster No.: EX1-053
Bilateral Total Cataract After Ranibizumab Injection for Aggressive Retinopathy of Prematurity
*First Author: Ayushi **SINHA***
*Co-Author(s): Parijat **CHANDRA**, Sindhuja **K**, Vanathi **M***

Poster No.: EX1-054
Clinical Efficacy of Intravitreal Injection of Leizumab in the Treatment of Neonatal Familial Exudative Vitreoretinopathy of Stage 2
*First Author: Li **NAN***

Poster No.: EX1-055
Congenital Retinoschisis in Children: Influence of Presenting Age on Anatomical and Visual Outcomes
*First Author: Anjali **MAHESHWARI***
*Co-Author(s): Akash **BELENJE**, Subhadra **JALALI***

Poster No.: EX1-056
Heads-up 3-dimensional Visualization System and Integrated Intraoperative Optical Coherence Tomography in Infantile Vitreoretinal Surgeries
*First Author: Akash **BELENJE***
*Co-Author(s): Subhadra **JALALI**, Brijesh **TAKKAR***

Poster No.: EX1-057
Intravitreal Bevacizumab and Laser Treatment of Aggressive Retinopathy of Prematurity: Long-term Study in Eastern India
*First Author: Nilutpal **BORAH***

Poster No.: EX1-058
Lucky to be Born Premature
*First Author: Haemoglobin **PARIDA***
*Co-Author(s): Renu **PUTHENVILAYIL RAJAN***

Poster No.: EX1-059
Retinopathy as an Initial Sign of Hereditary Immunological Diseases
*First Author: Yingwei **WANG***
*Co-Author(s): Qingjiong **ZHANG***

Poster No.: EX1-060
Retinopathy of Prematurity Computerized Screening and Monitoring Systems in a Tertiary Hospital in Ilocos Norte, Philippines
*First Author: Edlyn **NARAVAL***
*Co-Author(s): Moida Via **CAYABYAB**, Rocamia **FERMIN**, Maria Fe **NAVARRETE**, Jennifer Joy **SANTOS-RAYOS***

Poster No.: EX1-061
The Clinical and Genetic Characteristics of Chinese Children with Stickler Syndrome Associated with COL2A1 Variants
*First Author: Yi **JIANG***
*Co-Author(s): Qingjiong **ZHANG***

Poster No.: EX1-062
Tsp-1+ Microglia Attenuate Retinal Neovascularization by Maintaining the Expression of Smad3 in Endothelial Cells Through Exosomes with Decreased miR-27a-5p
*First Author: Qian **LUO***
*Co-Author(s): Yan **LI**, Jin **QIU**, Keming **YU**, Jing **ZHUANG**, Zihua **JIANG***

Retina (Medical)

Poster No.: EX1-063
3 + Treat-and-extend Versus 3 + Pro Re Nata Regimen Intravitreal Conbercept Injections for Neovascular Age-related Macular Degeneration: Results from COCOA, a Prospective, Open-label, Multicenter, Randomized Phase IV Clinical Trial
*First Author: Mingwei **ZHAO***
*Co-Author(s): Yaoyao **SUN***

Poster No.: EX1-064
3-year Follow-up of Intravitreal Bevacizumab for Vitreous Hemorrhage in Proliferative Diabetic Retinopathy
*First Author: Junwoo **LEE***
*Co-Author(s): Kiyoung **KIM**, Jong Beom **PARK**, Seung-young **YU***

Poster No.: EX1-065
3-year Outcomes of Polypoidal Choroidal Vasculopathy Treatment According to Early Polypoidal Regression: Characteristics of Polypoidal Lesions on Swept-source Optical Coherence Tomography Angiography
*First Author: Jong Beom **PARK***
*Co-Author(s): Eung-suk **KIM**, Kiyoung **KIM**, Junwoo **LEE**, Seung-young **YU***

Poster No.: EX1-066
A Large Case Series of Hemi-retinal Vein Occlusion: Profile of a Rare Condition with Associated Morbidities
*First Author: Brijesh **TAKKAR***
*Co-Author(s): Anthony Vipin **DAS**, Yogita **KADAM**, Raja **NARAYANAN**, Sirisha **SENTHIL**, Pratima **THAKUR***

Poster No.: EX1-067
A New Systemic Marker for Diabetic Retinopathy: Serum VEGF
*First Author: Gaurang **SEHGAL***
*Co-Author(s): Nikhil **GOPALAKRISHNAN**, Chaitra **JAYADEV**, Priyanka **GANDHI***

Poster No.: EX1-068
A Rare Disease with Maculopathy and Multisystem Involvement
*First Author: Wei Kiong **NGO***
*Co-Author(s): Karen **CHIA**, Graham E. **HOLDER**, Adrian **KOH**, Augustinus **LAUDE**, Melissa **TIEN***

Poster No.: EX1-069
Assessing the Efficacy and Durability of Faricimab in Patients Currently Treated for Neovascular Age-related Macular Degeneration: The FURGGHORN Study
*First Author: Thomas **HONG***
*Co-Author(s): Andrew **CHANG**, Gerald **LIEW**, Hemal **MEHTA**, Long **PHAN**, James **WONG***

Poster No.: EX1-070
Baseline Demographic, Clinical, and Multimodal Imaging Features of Young Patients with Type 2 Macular Telangiectasia
*First Author: Nikitha **GURRAM***
*Co-Author(s): Raja **NARAYANAN**, Ramesh **VENKATESH**, Sumant Vinayak **SHARMA***

Poster No.: EX1-071
Central Retinal Artery Occlusion After COVID-19 Vaccination: A Multicenter Retrospective Cohort Study
*First Author: Paul Ho Man **LEUNG***
*Co-Author(s): Chi Lik **AU***

Poster No.: EX1-072
Clinical Characteristics of Peripheral Exudative Hemorrhagic Chorioretinopathy in Asian Patients
*First Author: Min **KIM***
*Co-Author(s): Youngje **CHOI**, Hansang **LEE***

Poster No.: EX1-073
Clinical Features of Retinopathy After Cardiopulmonary Resuscitation
*First Author: Su Hwan **PARK***
*Co-Author(s): Seung Min **LEE***

Poster No.: EX1-074
Endogenous Endophthalmitis Following Methicillin-sensitive *Staphylococcus aureus* Recurrent Psoas Abscess: Pars Plana Vitrectomy or Conservative Management?
*First Author: Reema **BANSAL***
*Co-Author(s): Uday **TEKCHANDANI***

Poster No.: EX1-075
Evaluation of Peripheral Visual Field in Late-stage Retinal Degenerative Diseases Using Goldmann Perimetry and Full-field Stimulus Testing
*First Author: Daiki **SAKAI***
*Co-Author(s): Yasuhiko **HIRAMI**, Yasuo **KURIMOTO**, Tadao **MAEDA**, Michiko **MANDAI**, Midori **YAMAMOTO***

Poster No.: EX1-076
Evaluation of Treatment Outcomes of Polypoidal Choroidal Vasculopathy Subtypes in a Multicenter Randomized Controlled Clinical Trial
*First Author: Colin **TAN***

Poster No.: EX1-077
Factors Determining Timing of First Recurrence After 3 Loading Aflibercept Injections in Newly Diagnosed Neovascular Age-related Macular Degeneration
*First Author: Sang Hyeok **LEE***
*Co-Author(s): Mee Yon **LEE***

Poster No.: EX1-078
Faricimab in Neovascular Age-related Macular Degeneration: Malaysian Real-world Experience: The FAME Study
*First Author: Manoharan **SHUNMUGAM***
*Co-Author(s): Kenneth **FONG**, Ling **KIET PHANG**, Jun Quan **LEONG**, Hon Seng **WONG**, Wilson **WONG JUN JIE***

Poster No.: EX1-079
Features of Diabetic Choroidopathy and Risk Factor Analysis
*First Author: Sungyeon **JUN***
*Co-Author(s): Don Il **HAM***

Poster No.: EX1-080
Fibrinous Central Serous Chorioretinopathy with Serous Retinal Detachment
*First Author: Ye **LI***
*Co-Author(s): Warren **APEL***

Poster No.: EX1-081
Fixed Quarterly Dosing of Aflibercept After Loading Doses in Neovascular Age-related Macular Degeneration in Hong Kong
*First Author: Daniel Ho Tak **WONG***
*Co-Author(s): Kenneth Kai Wang **LI***

Poster No.: EX1-082
Internal Limiting Membrane Detachment in Acute Central Retinal Artery Occlusion: A Case Series
*First Author: Chitaranjan **MISHRA***
*Co-Author(s): Naresh **KANNAN**, Kim **RAMASAMY***

Poster No.: EX1-083
Intravitreal Anit-vascular Endothelial Growth Factor: Its Effects on Corneal Endothelial Cell Count and Central Corneal Thickness in Phakic and Pseudophakic Eyes in an Indian Population
*First Author: Shaibaan **MULLA***

Poster No.: EX1-084
Normative Data for Perfusion Density of the Superficial and Deep Capillary Plexuses Using Optical Coherence Tomography Angiography in Filipino Adults in a Tertiary Hospital
*First Author: Anne Therese **ESTANISLAO***
*Co-Author(s): Ricardo Tobias **PAPA**, John Philip **UY***

Poster No.: EX1-085
OCT Features of Disease Activity After Initial Treatment of Neovascular Age-related Macular Degeneration
*First Author: Colin **TAN***

Poster No.: EX1-086
Optic Disc Edema After Injection of Brolucizumab for Polypoidal Choroidal Vasculopathy
*First Author: Verghese **JOSEPH***
*Co-Author(s): Shishir **VERGHESE***

Poster No.: EX1-087
Pilot Study Comparing Serum and Vitreous Biomarkers in Type 1 and Type 2 Diabetes Mellitus with Diabetic Retinopathy
*First Author: Shorya **AZAD***
*Co-Author(s): Vineet **BATWANI**, Rohan **CHAWLA**, Nawazish **SHAIKH**, Pradeep **VENKATESH***

Poster No.: EX1-088
Ponatinib Induced Bilateral Neurosensory Retinal Detachment in a Patient with Chronic Myelogenous Leukemia
*First Author: Katrina Beatrize **MANAS-LIM***
*Co-Author(s): Fabian Arnel **DE JESUS**, Darby **SANTIAGO**, Ino Paul Racho **VILLACASTIN***

Poster No.: EX1-089
Post Hoc Analysis of Rhine/Yosemite Trials on Macular Leakage in DME with Faricimab vs Aflibercept
*First Author: Nicholas **FUNG***
*Co-Author(s): Roger **GOLDBERG**, Florie **MAR**, Eric **NUDLEMAN**, Sobha **SIVAPRASAD**, Tracey **WANG***

Poster No.: EX1-090
Rarity Redefined: Atypical Optic Neuritis as the Chief Presenting Feature of Testicular Malignancy: Rare Case Report with Review of Literature
*First Author: Shaibaan **MULLA***

Poster No.: EX1-091
Retina Evaluation of Everest Summiteers to Find Any Retinal Changes in the Highest Altitude on Earth
*First Author: Kaushick **BISWAS***

Poster No.: EX1-092
Retinal Morphological and Choroidal Vascular Characteristics of Dome-shaped Macula and Inferior Staphyloma Complicated by Subretinal Detachment
*First Author: Jeeyun **AHN***
*Co-Author(s): Kwangsic **JOO**, Min Seok **KIM**, Jeong Hyun **LEE**, Joo Young **SHIN**, Se Joon **WOO***

Poster No.: EX1-093
Safety and Efficacy of a New Intravitreal Ranibizumab Biosimilar in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration Patients: An Indian Study
*First Author: Kaushick **BISWAS***

Poster No.: EX1-094
Switching to Brolucizumab for Refractory Neovascular Age-related Macular Degeneration in Real-world Experience: A Systematic Review
*First Author: Andi **NADHIRA***
*Co-Author(s): Ari **DJATIKUSUMO**, Andi **VICTOR***

Poster No.: EX1-095
The Effect of Prophylactic Prostaglandin Analogue or Topical Beta Blocker Versus Placebo on Changes in Intraocular Pressure During Repeated Intravitreal Injection
*First Author: Nicholas **FUNG***
*Co-Author(s): Tiffany **CHAN**, Phoebe **LAM**, Wai Ching **LAM**, Stephanie **POON**, Mingming **ZHU***

Poster No.: EX1-096
Treatment of Polypoidal Choroidal Vasculopathy Using Standard and Reduced-fluence Photodynamic Therapy
*First Author: Isaac **CHAY***
*Co-Author(s): Colin **TAN***

Poster No.: EX1-097
Treatment of Recalcitrant nCNV Using Brolocizumab with a Novel Treat and Extend Protocol: A Randomized Controlled Study
*First Author: Nicholas **FUNG***
*Co-Author(s): Timothy **LAI**, Wai Ching **LAM***

Retina (Surgical)

Poster No.: EX1-099
A Common Surgery for an Uncommon Problem: Surgical Management of Myopic Traction Maculopathy
*First Author: Wai Yan **LAM***
*Co-Author(s): Qing **LI**, Wai-ching **LAM***

Poster No.: EX1-100
A Retrospective Study of Risk Factors for Rebleeding After Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage
*First Author: Jennifer **HUNG***

Poster No.: EX1-101
Assessing the Effectiveness and Outcomes of Nd:Yag Laser Hyaloidotomy for Premacular Subhyaloid Hemorrhage: Insights from a Study of 41 Eyes
*First Author: Deepak **KHADKA***
*Co-Author(s): Sanyam **BAJIMAYA**, Bijay **KHATRI**, Eli **PRADHAN**, Anand Kumar Sharma **SHARMA**, Raba **THAPA***

Poster No.: EX1-102
Bidirectional Dimples After Internal Limiting Membrane Peeling for a Macular Hole
*First Author: Jaeryung **OH***
*Co-Author(s): So Min **AHN**, Youngho **KIM**, Myung-sun **SONG**, Ariunaa **TOGLOOM**, Cheolmin **YUN***

Poster No.: EX1-103
Clareon Intraocular Lens Stability in Vitrectomy Patients: Clove Study
*First Author: Jeffrey **LO***
*Co-Author(s): Nicholas **FUNG**, Mehnaz **QUDDUS**, Stephanie Wing Ki **YUK***

Poster No.: EX1-104
Clinical Outcome of Tractional Lamellar Macular Hole Treated by Pars Plana Vitrectomy
*First Author: Xien **LU***
*Co-Author(s): Makoto **INOUE**, Tomoka **ISHIDA**, Akira **KANAI**, Takashi **KOTO**, Jun **TAKEUCHI***

Poster No.: EX1-105
Clinical Outcomes of Flowchart-based Treatment Algorithm of Submacular Hemorrhage
*First Author: Kshitiz **KUMAR***

Poster No.: EX1-106
Comparison of Clinical Outcomes of 10,000 Versus 20,000 Cuts-per-minute, 25-gauge, Beveled-tip Vitrectomy Probes
*First Author: Harvey **UY***
*Co-Author(s): Jose Carlo **ARTIAGA**, Pik Sha **CHAN***

Poster No.: EX1-098
Comparison of Surgical Performances and Ergonomics between using Digitally Assisted Vitreoretinal Surgery System and Standard Operating Microscope
*First Author: Jin Young **KIM***
*Co-Author(s): Jae Rock **DO**, Yong Koo **KANG**, Yumin **KIM**, Dong Ho **PARK**, Jae Pil **SHIN***

Poster No.: EX1-107
Cryotherapy Versus Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery: A Systematic Review
*First Author: Richardo **RUSLI***
*Co-Author(s): Graecia **BUNGARAN**, Beatrice **POLUAN**, Eugeni Jr **SUMANTI**, Salam **SURBAKTI***

Poster No.: EX1-108
Different Outcome of Chronic Central Serous Chorioretinopathy After Novel Low Power Mode Laser: Fundus Fluorescein Angiography Evaluation, A Case Series
*First Author: Annisak **FITRIYANA***
*Co-Author(s): Grimaldi **IHSAN**, Arief **KARTASASMITA**, Rova **VIRGANA**, Made Indra **WIDYANATHA**, Erwin **ISKANDAR***

Poster No.: EX1-109
Efficacy of Scleral Patch Graft in Optic Disc Pit Maculopathy: A Retrospective Analysis
*First Author: Muthukrishnan **VALLINAYAGAM***
*Co-Author(s): Avik **DEY SARKAR**, Naresh **KANNAN***

Poster No.: EX1-110
Epiretinal Membrane Removal with Foveal-sparing Internal Limiting Membrane Peeling vs Complete Internal Limiting Membrane Peeling (Preliminary Study)
*First Author: Alexey **ZHURAVLEV***
*Co-Author(s): Anton **KOLESNIK**, Svetlana **KOLESNIK**, Alexander **SHPAK**, Elena **ZINYCH***

Poster No.: EX1-111
Exploring Diversity in Clinical Presentation and Difficulties in Treating Symptomatic Retinal Artery Macroaneurysm: An Experience with 21 Eyes
*First Author: Deepak **KHADKA***
*Co-Author(s): Bijay **KHATRI***

Poster No.: EX1-112
Human Amniotic Membranes in the Management of Postoperative Suprachoroidal Silicone Oil Migration with Severe Proliferative Vitreoretinopathy: A Novel Approach
*First Author: Shu-chun **KUO***
*Co-Author(s): Chia-yi **LEE**, Chenghao **SUNG***

Poster No.: EX1-113
Investigation of Perfluorocarbon Liquid Evaporation Rate by Air Infusion in an In-vitro Vitrectomy Model
*First Author: Wang Yee **CHU***
*Co-Author(s): Joseph Yau Kei **CHAN**, Ying **CHEN**, Zhongdui **LONG***

Poster No.: EX1-114
Long-term Surgical Outcomes of 25-gauge Microincision Vitrectomy Surgery in Eyes with Coloboma Associated Retinal Detachment
*First Author: Sravani **YARRARAPU***
*Co-Author(s): Shorya **AZAD**, Rohan **CHAWLA**, Nawazish **SHAIKH**, Pradeep **VENKATESH***

Poster No.: EX1-115
Novel Low Power Mode Laser in the Management of Chronic Central Serous Chorioretinopathy: Time to Gain Momentum
*First Author: Annisak **FITRIYANA***
*Co-Author(s): Grimaldi **IHSAN**, Arief **KARTASASMITA**, Rova **VIRGANA**, Made Indra **WIDYANATHA**, Erwin **ISKANDAR***

Poster No.: EX1-116
Outcomes of Microincision Pars Plana Vitrectomy in Rhegmatogenous Retinal Detachment at a Tertiary Eye Care Center in Nepal
*First Author: Santosh **SUBEDI***
*Co-Author(s): Sanyam **BAJIMAYA**, Govinda **PAUDYAL**, Eli **PRADHAN**, Sanjita **SHARMA**, Raba **THAPA***

Poster No.: EX1-117
Performance, Safety, and Efficiency Comparison Between 20,000 and 10,000 Cuts Per Minute Vitrectomy Using a 27G Cutter in Rhegmatogenous Retinal Detachment: A Prospective Randomized Controlled Study
*First Author: Yu-te **HUANG***
*Co-Author(s): San-ni **CHEN**, Ming-chieh **HSIEH**, I **WANG***

Poster No.: EX1-118
Residual Silicone Oil Does Exist After Conventional Silicone Oil Removal Procedures
*First Author: Anakin Chu Kwan **LAI***
*Co-Author(s): Yau Kei **CHAN**, Ying **CHEN**, Kenneth Kai Wang **LI***

Poster No.: EX1-119
Soft Peeling for Vitreoretinal Membrane
*First Author: Po-kang **LIN***

Poster No.: EX1-120
Surgical Management Under Lincoff Rule of a Retinal Detachment with No Obvious Tear: Case Report
*First Author: Yuanfei **ZHU***
*Co-Author(s): Tie Ying **ZHAO***

Poster No.: EX1-121
Surgical Outcome for Degenerative Lamellar Macular Hole
*First Author: Akira **KANAI***
*Co-Author(s): Makoto **INOUE**, Tomoka **ISHIDA**, Takashi **KOTO**, Xien **LU**, Jun **TAKEUCHI***

Poster No.: EX1-122
Surgical Removal of Subfoveal Choroidal Neovascular Membrane in Age-related Macular Degeneration: A Retrospective Analysis
*First Author: Muthukrishnan **VALLINAYAGAM***

Poster No.: EX1-123
Temporary Vision Loss and Iatrogenic Retinal Holes After Inadvertent Globe Penetration During Retrobulbar Anesthesia for Routine Cataract Surgery: A Case Report
*First Author: Leandrea Mae **NOLLORA***
*Co-Author(s): Peter Vincent **CO**, Nilo Vincent **FLORCRUZ**, Robert William **KING**, Paul **SIOPONGCO***

Poster No.: EX1-124
The Dazzling Posterior Capsular Opacification: Post Silicone Oil Removal
*First Author: Subham **SINHA ROY***
*Co-Author(s): Twinkey **BHUTIA**, Suklengmung **BURAGOHAIN**, Amber **DUBEY***

Poster No.: EX1-125
Unveiling a Rare Ophthalmic Enigma: Choroidal Neovascular Membrane in Vitrectomized Aphakic Eye with Retino-choroidal Coloboma
*First Author: Twinkey **BHUTIA***
*Co-Author(s): Manabjyoti **BARMAN***

Poster No.: EX1-126
Vitrectomy with Subretinal Injection of Recombinant Tissue Plasminogen Activator for Submacular Hemorrhage with or without Vitreous Hemorrhage
*First Author: Haoyu **CHEN***
*Co-Author(s): Tingkun **SHI**, Jing **WEN***

Translational Medicine

Poster No.: EX1-127
Can Code-free Deep Learning Replace Traditional Deep Learning? A Look at Screening, Treatment Planning, Surgical Training, Innovative Research, and Hospital Resource Management
*First Author: Carolyn Yu Tung **WONG***
*Co-Author(s): Fares **ANTAKI**, Pearse **KEANE**, Timing **LIU**, Ciara **O'BYRNE**, Priyal **TARIBAGIL***

Poster No.: EX1-128
Light-induced Sericin Hydrogel Injected into the Anterior Chamber of Mice with Chronic Ocular Hypertension Efficacy, Medication Sensitivity, and Material Safety
*First Author: Li **LIAO***
*Co-Author(s): Xuanchu **DUAN**, Yang **ZHAO***

Poster No.: EX1-129
RIP3-mediated Microglial Necroptosis Promotes Neuroinflammation in the Early Stages of Diabetic Retinopathy
*First Author: Zijing **HUANG***

Poster No.: EX1-130
Sustained Release of Glial Cell-derived Neurotrophic Factor Secreted from Terminable Cell-encapsulating Collagen-alginate Composite Encapsulated Cell Therapy Gel as a Therapy for Retinal Degenerative Diseases
*First Author: Tingyu **HU***
*Co-Author(s): Joseph Yau Kei **CHAN**, Amy Cheuk Yin **LO**, Wai Ching **LAM**, Brian Ka Cheung **TAM***

E-POSTERS

Cataract and Refractive Surgery

Efficacy of Ultrawide Field Scanning Confocal Laser-based Red-free Imaging in Detecting Retinal Vascular Changes in Retinopathy of Prematurity
First Author: Sushma ***JAYANNA***
Co-Author(s): Tapas ***PADHI****, Miloni* ***SHAH***

Surgical Outcomes and Complications Following Sutureless Intrascleral Intraocular Lens Fixation: 7-year Experience with the Yamane Technique
First Author: Mun Wai ***LEE***

Eye Trauma, Emergencies & Infections

A Case Series of Complicated Cataract Management in Northern Territory, Australia
First Author: Christopher ***GO***
Co-Author(s): Susith ***KULASEKARA****, Ario* ***WILSON-POGMORE***

Analysis of Penetrating Ocular Injuries with Intraocular Foreign Bodies: Variations in Clinical Manifestations and Outcomes
First Author: Bhavik ***PANCHAL***
Co-Author(s): Naveen ***K.****, Avinash* ***PATHENGAY****, Rudvij* ***PANDYA***

Neurologic and Systemic Complications of Herpes Zoster Ophthalmicus
First Author: Gillian Louise ***SAQUIAN***
Co-Author(s): Charmaine ***ANG****, Fatima* ***REGALA***

Pars Plana Vitrectomy and Globe Rupture Repair Surgery to Extricate Intraocular Artificial Christmas Tree Remnant
First Author: Graecia ***BUNGARAN***
Co-Author(s): Zev ***PANKA****, Richardo* ***RUSLI****, Eugeni Jr* ***SUMANTI****, Priscillia* ***TONDOLAMBUNG****, Dyana* ***WATANIA***

Salvaging Vision in Perforating Ocular Trauma with Tractional Retinal Detachment
First Author: Kumudini ***SUBEDI***
Co-Author(s): Raghunandan ***BYANJU***

Glaucoma

Combined Phacoemulsification and Endoscopic Cyclophotocoagulation versus Phacoemulsification Alone in the Treatment of Glaucoma
First Author: Hsuan-en ***HUANG***
Co-Author(s): Hung-ju ***CHEN***

Intraocular Inflammation, Uveitis & Scleritis

A Case of Acute Foveolitis as the Presenting Manifestation of Life-threatening Invasive Group B *Streptococcus* Disease
First Author: Xin ***WEI***
Co-Author(s): Su Ling ***HO***

An Unforeseen Encounter: A Diagnosis of VKH-like Syndrome in a BRAF Mutant Metastatic Melanoma Patient Treated with Dabrafenib and Trametinib
First Author: Cadric ***GUNARATNAM***
Co-Author(s): Michael ***HOGDEN***

Novel CAPN5 Mutation Within the Regulatory Domain of Calpain-5 is Associated with Early-onset Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy
First Author: Ma. Patricia ***RIEGO DE DIOS***
Co-Author(s): Christine Marie Kara ***GOZALI-AGAS****, Manuel Benjamin* ***IBANEZ***

Pediatric Uveitis: Prevalence, Demographics, and Treatment Outcomes in a Tertiary Eye Center
First Author: Mei Kwan ***YIU***
Co-Author(s): Mary ***HO****, Wilson* ***YIP****, Alvin* ***YOUNG****, Grace* ***YUNG***

Vogt-Koyanagi-Harada-like Uveitis Induced by Darafinib Plus Trimetinib: A Report of Two Cases
First Author: Liangqi ***FENG***
Co-Author(s): Jie ***HU****, Meng* ***XUAN***

Ocular Imaging

A Comparison of Choroidal Imaging Biomarkers between Simple and Complex Central Serous Chorioretinopathy
*First Author: Arman **ZARNEGAR***
*Co-Author(s): Selina **CHANG**, Jay **CHHABLANI**, Joshua **ONG**, Elham **SADEGHI**, Amrish **SELVAM***

A Longitudinal Study of Pigment Epithelial Detachment Morphology and Outcomes in Central Serous Chorioretinopathy
*First Author: Arman **ZARNEGAR***
*Co-Author(s): Selina **CHANG**, Jay **CHHABLANI**, Razeen **KHAN**, Joshua **ONG**, Sanya **YADAV***

Anterior Scleral Thickness in Myopic Eyes and Its Association with Ocular Parameters
*First Author: Sang Woo **PARK***
*Co-Author(s): Mi-sun **SUNG***

Artificial Intelligence for Predicting the Development of Epiretinal Membrane
*First Author: Yi-ting **HSIEH***

Association of Intravenous Fluorescein Angiography and Adaptive Optics Imaging in Diabetic Retinopathy: A Prospective Case Series
*First Author: Ryan **HUANG***
*Co-Author(s): Andrew **MIHALACHE**, Rajeev **MUNI**, Marko M. **POPOVIC**, Peng **YAN***

FN-OCT: Disease Detection Algorithm for Retinal Optical Coherence Tomography Based on a Fusion Network
*First Author: Jing **FENG***

Longitudinal Outcomes of Optic Nerve Stroke with and without Optic Disc Drusen
*First Author: Xia **GONG***
*Co-Author(s): Yaping **LIAO**, Sangeethabalasri **PUGAZHENDHI**, Sophia **WANG**, Miaomiao **YU**, Ping **ZHU***

Multimodal Imaging in a Mac Tel 2 Latin American Cohort
*First Author: Lihteh **WU***
*Co-Author(s): Genesis **CHEN**, Andres **LASAVE**, Carolina **POZZONI***

Optical Coherence Tomography Angiography Evaluation of the Macular Vasculature
*First Author: Isaac **CHAY***
*Co-Author(s): Colin **TAN***

Quantitative Retinal and Choriocapillaris Blood Flow Assessment Using OCTA in Healthy Korean Subjects
*First Author: Young Hwan **JEONG***
*Co-Author(s): Iksoo **BYON***

Ultra-widefield Optical Coherence Tomography in a Patient with Acute Retinal Necrosis
*First Author: Hae Jung **SUN***
*Co-Author(s): Suk Min **HAN**, Juno **KIM***

Variation of Optical Coherence Tomography Angiography Parameters with Severity of Diabetic Retinopathy
*First Author: Isaac **CHAY***

Ocular Oncology & Pathology

A Novel Germline RB1 Mutation in Filipino Identical Twins with Bilateral Retinoblastoma
*First Author: Josept Mari **POBLETE***

Bilateral Coats-like Vasoproliferative Retinal Tumor in a 12-year-old Filipino with Retinitis Pigmentosa Fundus in the Left Eye and Leukocoria in the Right Eye
*First Author: Darby **SANTIAGO***
*Co-Author(s): Zadkiel **VELASQUEZ***

Diagnostic Methods for Primary Vitreoretinal Lymphoma: A Systematic Review
*First Author: Ryan **HUANG***
*Co-Author(s): Peter **KERTES**, Andrew **MIHALACHE**, Rajeev **MUNI**, Marko M. **POPOVIC***

Genetic Study of Sight-threatening Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes
*First Author: Chi Lik **AU***
*Co-Author(s): Yu-yan Chloe **CHEUNG**, Callie **KO**, Chi-ho Paul **LEE***

Management of Unilateral Advanced Retinoblastoma
*First Author: Allyson **FACUNDO***

Recurrent Orbital Retinoblastoma After Partial Exenteration with Central Nervous System Metastasis Mimicking Oreseptal Cellulitis: A Case Report
*First Author: Patharika **NAVAPATHANAPONG***
*Co-Author(s): Chaiwat **APHIVATANASIRI**, Nipaporn **TEWATTANARAT**, Phanthipha **WONGWAI***

Tangled: A Case Report on Periorbital Arteriovenous Malformation Treated with Triamcinolone Injection and Excision
*First Author: Gillian Louise **SAQUIAN***
*Co-Author(s): Marco **TUMALAD**, Sandra **WORAK***

Ophthalmic Epidemiology

A Validation Study of a Novel Diabetic Retinopathy Awareness and Practice Assessment Filipino Questionnaire
*First Author: Maria Christine **DY***

Association Between Social Determinants of Health and Incidence of Age-related Macular Degeneration in the National Health Interview Survey: A Population-based, Cross-sectional Analysis
*First Author: Nikhil S. **PATIL***
*Co-Author(s): Radha **KOHLY**, Andrew **MIHALACHE**, Rajeev **MUNI**, Marko M. **POPOVIC**, Jim **XIE***

Association Between Sociodemographic Factors and Glaucoma in the National Health Interview Survey: A Population-based, Cross-sectional Analysis
*First Author: Jim **XIE***
*Co-Author(s): Radha **KOHLY**, Rajeev **MUNI**, Nikhil S. **PATIL**, Matt **SCHLENKER***

Association Between Sociodemographic, Clinical Access, and Regional Factors with Diabetic Retinopathy in the National Health Interview Survey: A Cross-sectional, Population-based Analysis
*First Author: Michele **ZAMAN***
*Co-Author(s): Lana **MOAYAD**, Nikhil S. **PATIL**, Jim **XIE**, Chris **ZAJNER***

Genomics of Inherited Retinal Dystrophies in Malays and Indians Within a Singapore Cohort
*First Author: Choi Mun **CHAN***
*Co-Author(s): Yasmin **BYLSTRA**, Beau **FENNER**, Sylvia **KAM**, Ranjana **MATHUR**, Tien En **TAN***

Normative Data and Associations of Optical Coherence Tomography Angiography Measurements of the Macula: The Singapore Malay Eye Study
*First Author: Zhen Ling **TEO***

Physical and Psychosocial Challenges as Predictors of Vision Difficulty in Children: A Nationally Representative Survey Analysis
*First Author: Andrew **MIHALACHE***
*Co-Author(s): Ryan S. **HUANG**, Radha P. **KOHLY**, Rajeev **MUNI**, Nikhil S. **PATIL**, Marko **POPOVIC***

Prevalence and Risk Factors of Presbyopia in Fujian Eye Study
*First Author: Yang **LI***
*Co-Author(s): Qinrui **HU**, Xiaoxin **LI**, Bin **WANG***

Other (General Ophthalmology)

A Case of Sudden Bilateral Vision Loss: Unravelling Complex Clinical Course
*First Author: Ricko Wai Leung **WONG***

Defeat the Enemy: A Case of Sino-orbital Mucormycosis with Optic Neuropathy
*First Author: Dalal **MAHGOUB***
*Co-Author(s): Hussein **ALHUTTAITTAWI**, Zunaina **EMBONG**, Anas **MUSA**, Wan Hazabbah **WAN HITAM***

Google Bard Artificial Intelligence Chatbot Performance in Ophthalmology Knowledge Assessment
*First Author: Andrew **MIHALACHE***
*Co-Author(s): Peter **KERTES**, Rajeev **MUNI**, Nikhil S. **PATIL**, Marko **POPOVIC***

Observational Study of Fundus Outcomes in a Real-world Population with Suspected POAG and Myopia
*First Author: Yao **LU***

Pediatric Retina

Twin Pregnancy: Is it a Risk Factor for ROP?
*First Author: Angelica Aja **ALCOREZA***
*Co-Author(s): Sharlene **PRILE***

Retina (Medical)

A 12-week Phase 2/3 Double-masked, Randomized, Multicenter Study of OCS-01 OPTIREACH Technology Topical Dexamethasone Eye Drops in Subjects with Diabetic Macular Edema: Efficacy and Safety Findings
*First Author: Timothy **LAI***
*Co-Author(s): Arshad M. **KHANANI***

A Case of Occlusive Retinitis Following Intravitreal Faricimab-svoa Injection
*First Author: Ricko Wai Leung **WONG***
*Co-Author(s): Randolph **DOBSON**, Christopher **KENNEDY**, Xia Ni **WU***

A Review on Ocular Adverse Events Following SARS-CoV-2 Vaccination
*First Author: Ho Lam **WONG***

Aflibercept 8 mg for Diabetic Macular Edema: 96-week Results from the Phase 2/3 PHOTON Trial
*First Author: Andrew **CHANG***
*Co-Author(s): Diana **DO***

Assessing Visual Outcomes with Intravitreal Bevacizumab in Patients with Wet Age-related Macular Degeneration
*First Author: Pratik **BIKKANNAVAR***
*Co-Author(s): Malavika **SUBASH***

Association Between Mean Platelet Volume and Retinal Vein Occlusion in Adult Patients
*First Author: Tariq **ALI***

Changes in Subfoveal Choroidal Thickness and Choroidal Vascular Index After Intravitreal Injection of Anti-vascular Endothelial Growth Factor in Choroidal Neovascular Membrane
*First Author: Abu Faisal Md Jahangir **ALAM***
*Co-Author(s): Mohamed **AZZAM**, Niaz **KHAN**, Muhammad **MONIRUZZAMAN**, Farzana **MOU**, Mst **SAYEDATUNNESSA***

Changes to Macular Vascular Density and Central Retinal Thickness and Association with Functional Impact After Anti-VEGF Injections in Clinically Significant Macular Edema
*First Author: Muhammad **MONIRUZZAMAN***
*Co-Author(s): Md **AHMED**, Abrar **AHMED**, Abu Faisal Md Jahangir **ALAM**, Mohamed **AZZAM**, Md. **RAHMAN***

Clinical Features and Treatment Outcomes of Polypoidal Choroidal Vasculopathy in Patients Less than 55 Years
*First Author: Kiran **KEDARISETTI***
*Co-Author(s): Saarang **HANSRAJ**, Raja **NARAYANAN**, Niroj **KUMAR SAHOO***

Clinical Practice Pattern on Use of Ranibizumab Biosimilar in Indian Settings (Clariant Survey)
*First Author: Ashish **SHARMA***
*Co-Author(s): Maneesha **KHALSE**, Nilesh **KUMAR**, Nikula **PARACHURI**, Varsha **PAWAR***

Different Damage Between Superficial Capillary Plexus and Deep Capillary Plexus According to Diabetic Retinopathy Severity
*First Author: Hwa-young **YU***
*Co-Author(s): Jung-tae **KIM**, Min-woo **LEE**, Yong-yeon **SONG***

Effect of Anti-VEGF on Choroidal Vascular Index in Retinal Vein Occlusion
*First Author: Muhammad **MONIRUZZAMAN***
*Co-Author(s): Tariq **ALI**, Mohamed **AZZAM**, S. M. Baratul **ISLAM**, Mst **SAYEDATUNNESSA**, Md Abul Bashar **SHEIKH***

Effects of TGF-β2 and Hypoxia on Epithelial-mesenchymal Transition of Human Retinal Pigment Epithelium
*First Author: Soma **SUZUKI***
*Co-Author(s): Fumihito **HIKAGE**, Hiroshi **OHGURO**, Araya **UMETSU**, Megumi **WATANABE***

Efficacy of Pattern Electroretinogram to Detect Diabetic Retinopathy
*First Author: Roshija **KHANAL RIJAL***
*Co-Author(s): Deepesh **MOURYA***

Establishing the Pathogenicity of a Novel Variant in BBS5 in a Filipino Family
*First Author: Diego **RAMOS***
*Co-Author(s): Manuel Benjamin **IBANEZ**, Tamilyn Chelsea **LADDARAN***

Fatty Acid-binding Protein 4 is a New Pathological Indicator for Proliferative Diabetic Retinopathy
*First Author: Shohei **SUETAKE***
*Co-Author(s): Fumihito **HIKAGE**, Kaku **ITOH**, Hiroshi **OHGURO**, Araya **UMETSU**, Megumi **WATANABE***

Flecked Retina Disorder in an Adult Filipino Male: A Case of Fundus Albipunctatus Versus Retinitis Punctata Albescens
*First Author: Maria Giselle **DY***
*Co-Author(s): Karina **DE SAGUN***

Initial Patient Experience Switching to Faricimab for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy
*First Author: Farah **IBRAHIM***
*Co-Author(s): Gemmy **CHEUNG CHUI MING**, Kelvin **TEO***

Inner Choroidal Fibrosis: An Optical Coherence Tomography Biomarker of Severity in Chronic Central Serous Chorioretinopathy
*First Author: Saarang **HANSRAJ***
*Co-Author(s): Niroj **KUMAR SAHOO***

Intraretinal Cysts Associated with Pachychoroid Neovasculopathy: Choroidal Leak or Neovascular Leak?
*First Author: Moon Young **CHOI***
*Co-Author(s): Won Ki **LEE***

Intravitreal Brolucizumab Injections as Rescue Therapy for Neovascular Age-related Macular Degeneration
*First Author: Pik Sha **CHAN***
*Co-Author(s): Harvey **UY***

Late-onset Retinal Detachment in Untreated Retinopathy of Prematurity: A Review
*First Author: Seruni Hanna **ARDHIA***
*Co-Author(s): Ari **DJATIKUSUMO***

Long-term Efficacy and Safety of Pegcetacoplan in the GALE Open-label Extension of the Phase 3 OAKS and DERBY Trials
*First Author: Mark **GILLIES***
*Co-Author(s): Jeffrey **HEIER**, Daniel **JONES**, Chao **LI**, Charles **WYKOFF**, Felix **YEMANYI***

Management of Retinopathy of Prematurity: Are We Preferring Intravitreal Anti-VEGF Injection More Than Conventional Laser?
*First Author: Tariq **ALI***
*Co-Author(s): Nuzhat **CHOUDHURY**, Ferdous Akhter Jolly **JOLLY***

OCT Features in Patients Switching to Brolucizumab with Recalcitrant Age-related Macular Degeneration
*First Author: Christopher **GO***
*Co-Author(s): Rachel **CHEUNG**, Wai Yan **LAM**, Jeffrey **LO**, Chun Sum **PANG**, Stephanie **WU***

Optical Coherence Tomography Angiography Findings in Patients with Acute Non-arteritic Central Retinal Artery Occlusion Treated with Carbogen Inhalation
*First Author: Pongrapee **ATIPAS***
*Co-Author(s): Patama **BHURAYANONTACHAI**, Wantanee **DANGBOON**, Pichai **JIRARATTANASOPA**, Mansing **RATANASUKON**, Thada **TANTISARASART***

Outcomes of Neovascular Age-related Macular Degeneration Following COVID-19 Lockdown Treat-and-extend Regimen Discontinuation
*First Author: Jose Carlo **ARTIAGA***
*Co-Author(s): Pankaja **DHOBLE**, Swetha **KUMAR**, Deepthy **MENON**, Luke **NICHOLSON**, Shiao **WONG***

Preliminary Outcomes of Switching from Aflibercept to Faricimab for Refractory Age-related Macular Degeneration
*First Author: De-kuang **HWANG***
*Co-Author(s): Yu-bai **CHOU**, Tai-chi **LIN**, Chang-chi **WENG***

Presumed Choroidal Tuberculoma Masquerading as Central Serous Chorioretinopathy in a 37-year-old Filipino Male
*First Author: Maijann **PRECIA***
*Co-Author(s): Rodrigo **SENADOR**, John Philip **UY***

Presumed Unilateral Cancer-associated Retinopathy from Thymoma
*First Author: Oscar Jr **ACOPIADO***
*Co-Author(s): Jose Carlo **ARTIAGA***

Real-world Outcomes and Complications from India of Intravitreal Brolucizumab for Persistent Diabetic Macular Edema
*First Author: Saarang **HANSRAJ***
*Co-Author(s): Mudit **TYAGI***

Resolution of Persistent Pigment Epithelial Detachment Following Series and Switching of Intravitreal Injections of Anti-vascular Endothelial Growth Factor Agents
*First Author: Diandra **ASTARIDEWI***
*Co-Author(s): Wimbo **SASONO***

Retreatment with Faricimab in Prior Brolucizumab-related Intraocular Inflammation Eyes
*First Author: Tai-chi **LIN***
*Co-Author(s): Yu-bai **CHOU**, Yi-ming **HUANG**, De-kuang **HWANG**, Chang-chi **WENG***

Risk of Clinical and Subclinical Radiation-induced Retinopathy Following High-dose Irradiation in Chinese Patients with Nasopharyngeal Carcinoma: A Case-control Study
*First Author: Sophia Ling **LI***
*Co-Author(s): Noel **CHAN**, Mary **HO**, Ka Wai **KAM**, Ho Ming **WONG***

Severe Proliferative Retinopathy Following Pregnancy in a Young Female with Antiphospholipid Syndrome and Type 1 Diabetes Mellitus
*First Author: Oscar Jr **ACOPIADO***
*Co-Author(s): Jose Carlo **ARTIAGA***

Severe Visual Impairment Caused by Optic Neuropathy and Choroidopathy Following Radiation Therapy
*First Author: Kokoro **KONUMA***
*Co-Author(s): Kazusa **KUWANO**, Tadashi **NAKANO**, Akira **WATANABE**, Euido **NISHIJIMA**, Shumpei **OGAWA***

Significance of Pre-vitrectomy Intravitreal Bevacizumab for Preventing Recurrent Vitreous Hemorrhage: A Systematic Review and Meta-analysis
*First Author: Siddhi Putra **I GUSTI AGUNG***
*Co-Author(s): Firman **SETYAWARDHANA***

Single-cell Sequencing and Transcriptomic Analysis Reveal Key Genes and Regulatory Mechanisms in Diabetic Retinopathy
*First Author: Fei **LI***
*Co-Author(s): Yan **DAI**, Qingping **XIANG***

The Doppelganger of the Optic Nerve Head: A Unique Case of Tubercular Choroiditis
*First Author: Syifa **RAHMANI***
*Co-Author(s): Grimaldi **IHSAN**, Arief **KARTASASMITA**, Rova **VIRGANA**, Made Indra **WIDYANATHA**, Erwin **ISKANDAR***

The Microstructural Changes of Retina Between Different Types of Diabetic Macular Edema
*First Author: Zhengwei **GE***

Transient Acute Exacerbation of Subretinal Exudation Following Half-fluence Photodynamic Therapy for Bilateral Chronic Central Serous Chorioretinopathy: A Case Report
*First Author: Debbie **GOH***
*Co-Author(s): Thet **NAING**, George Naveen **THOMAS***

Treatment-naive and Refractory Diabetic Macular Edema Treated Using Intravitreal Brolucizumab: Short-term Outcomes
*First Author: Jia-kang **WANG***

Treatment-naive and Refractory Myopic Choroidal Neovascularization Treated Using Intravitreal Brolucizumab: Short-term Outcomes
*First Author: Jia-kang **WANG***

Vitreous FABP-5 is Involved in the Pathogenesis of Retinal Vascular Diseases
*First Author: Megumi **SUZUKI***
*Co-Author(s): Fumihito **HIKAGE**, Hiroshi **OHGURO**, Araya **UMETSU**, Megumi **WATANABE**, Masato **FURUHASHI***

Retina (Surgical)

A Case of Refractory Optic Disc Pit Macular Detachment Treated with a Novel Scleral Autograft Plug Technique
*First Author: Elaine Marie **TAN***
*Co-Author(s): Paolo Vicente **PALADIO**, Jocelyn **SY***

A Retrospective Study to Assess the Outcomes of Sequential Bilateral Rhegmatogenous Retinal Detachment
*First Author: Harshal **SAHARE***

Advanced Coats Disease in an Adult Filipino Male: A Case Report
*First Author: Maria Giselle **DY***
*Co-Author(s): Jazel **VERDE***

Analysis of Choroidal Thickness Changes in Recurrent Rhegmatogenous Retinal Detachment
*First Author: Gyu Chul **CHUNG***
*Co-Author(s): Kang Yeun **PAK***

Anatomical and Functional Outcomes After Vitrectomy for Macular Holes in Highly Myopic Eyes: Internal Limiting Peel Versus Flap
*First Author: Andrew **TSAI***
*Co-Author(s): Shu Yen **LEE**, Stanley **POH***

Assessment of Changes in Macular Microvasculature Using Optical Coherence Tomography Angiography in Idiopathic Epiretinal Membrane
*First Author: Nohae **PARK***
*Co-Author(s): Iksoo **BYON***

Burden of Gas Tamponades: A Targeted Literature Review
*First Author: Elizabeth **PERSAUD***
*Co-Author(s): Sandro **DI SIMPLICIO**, Omesh **GUPTA**, Jessica (Sun-ming) **PAN**, Wendy Zhi **WANG***

Clinical Factors and Predictors for Spontaneous Self-resolution of Idiopathic and Secondary Epiretinal Membranes
*First Author: Ju Seok **LEE***
*Co-Author(s): Hyun Goo **KANG**, Sung Soo **KIM***

Clinical Profile and Outcomes of Modified Internal Limiting Membrane Peeling Technique in Management of Macular Hole
*First Author: Sheetal **DIVATE***
*Co-Author(s): Pushpanjali **BADOLE**, Amit **NENE**, Smitesh **SHAH**, Pratik **SHENOY***

Clinical and Economic Burden of Sequential Vitrectomy and Phacoemulsification Compared with Phacovitrectomy: A Targeted Literature Review
*First Author: Sun-ming **PAN***
*Co-Author(s): Sandro **DI SIMPLICIO**, Carine C. W. **HSIAO**, Elizabeth **PERSAUD**, Wendy Zhi **WANG***

Comparative Evaluation of 10k/25G Beveled-tip Probe and 5k/23G Flat-tip Probe in MIVS in Day Surgery for the Treatment of PDR Patients with Fibrovascular Proliferation
*First Author: Yan Chun **ZHANG***

Comparison of Safety and Efficiency Between Different Forceps for Peeling Internal Limiting Membrane
*First Author: Yu-bai **CHOU***

Conventional and Modified Pneumatic Displacement with Anti-VEGF Injections in Management of Submacular Hemorrhage due to PCV
*First Author: Nishant **RADKE***
*Co-Author(s): Zhizhao **PENG**, Snehal **RADKE**, Kuang **ZHAOXIA***

Development of Severe Ocular Disorders Following Vaccination Against COVID-19: A Case Series
*First Author: Sanghamitra **KANUNGO***

Effect of Vitrectomy with or without Encircling Band on Choroidal Thickness and Mean Ocular Perfusion Pressure in Retinal Detachment: A Comparative Study
*First Author: Gaganjeet **GUJRAL***

Factors Predicting Late Redislocation or Suture Break in Eyes After Suture-fixated Intraocular Lens
*First Author: Ju Seok **LEE***
*Co-Author(s): Hyun Goo **KANG**, Sung Soo **KIM***

Focal Laser Photocoagulation for Central Serous Chorioretinopathy Impact on Subfoveal Choroidal Thickness and Choroidal Vascular Index
*First Author: Md. **RAHMAN***

*Co-Author(s): Abrar **AHMED**, Abu Faisal Md Jahangir **ALAM**, Mohamed **AZZAM**, Muhammad **MONIRUZZAMAN**, Mst **SAYEDATUNNESSA***

From Perforation to Clarity: Navigating Visual Recovery Post Globe Perforation in Cataract Surgery
*First Author: Neha **BIJLANI***
*Co-Author(s): Gajendra **CHAWLA***

From Retrobulbar to Intraocular: Using a Retrofitted 25G Needle in the Surgical Management of Retained Subretinal Perfluorocarbon Liquid
*First Author: Ruth Camille **ANTOLIN***
*Co-Author(s): Amadeo Jr **VELOSO***

Hemorrhagic Retinal or Macular Detachment Outcomes in PCV
*First Author: Nishant **RADKE***
*Co-Author(s): Lizhen **CHEN**, Snehal **RADKE**, Peng Zhi **ZHAO***

Lens Capsular Flap Transplantation in the Management of Macular Hole
*First Author: Liu **GUANGFENG***

Macular Hole Development After Vitrectomy for Rhegmatogenous Retinal Detachment
*First Author: Jong-uk **LEE***
*Co-Author(s): Young Joon **JO***

Nd:YAG Laser Membranotomy for Valsava Retinopathy Treatment in Pregnant Women
*First Author: Diandra **ASTARIDEWI***
*Co-Author(s): Sauli **ARI WIDJAJA**, Muhammad **FIRMANSJAH**, Ady **PRAKOSA**, Wimbo **SASONO**, Ima **YUSTIARINI***

Novel Morin-Devin T Macular Buckle Derived from 41 and 287WG Scleral Buckle Band
*First Author: Nitee **RATPRASATPORN***
*Co-Author(s): Chirat **SAOVAPRUT***

Outcome of the Management of Aggressive Retinopathy of Prematurity
*First Author: Tanzina **ISLAM***

Outcomes of Vitreoretinal Surgery in Eyes with Retinitis Pigmentosa Without Retinal Detachment
*First Author: Abhishek **UPADHYAYA***
*Co-Author(s): Deepika C **PARAMESWARAPPA**, Saarang **HANSRAJ**, Hardik **KIRI***

Pars Plana Vitrectomy with or without Internal Limiting Membrane Peel for Epiretinal Membrane: A Systematic Review and Meta-analysis
*First Author: Andrew **MIHALACHE***
*Co-Author(s): Ryan S. **HUANG**, Peter J. **KERTES**, Rajeev **MUNI**, Nikhil S. **PATIL**, Marko M. **POPOVIC***

Pars Plana Vitrectomy with or without Internal Limiting Membrane Peel for Macular Hole: A Systematic Review and Meta-analysis
*First Author: Andrew **MIHALACHE***
*Co-Author(s): Ryan S. **HUANG**, Peter J. **KERTES**, Rajeev **MUNI**, Nikhil S. **PATIL**, Marko M. **POPOVIC***

Results of Submacular Hemorrhage Treatment with Pneumatic Displacement and Intravitreal Anti-VEGF Injection with or without Intravitreal Tissue Plasminogen Activator Injection
*First Author: Patraramon **CHOTIKKAKAMTHORN***
*Co-Author(s): Patama **BHURAYANONTACHAI**, Wantanee **DANGBOON**, Pichai **JIRARATTANASOPA**, Mansing **RATANASUKON**, Thada **TANTISARASART***

Revolutionizing Vitrectomy: The 3A (Anyone, Anytime, Anywhere) Air Bubble Technique for Simplified and Effective Procedures
*First Author: Takahiro **MATSUOKA***

Self-induced Retinal Detachment and Redetachment in a Patient with Tourette Syndrome
*First Author: Ruth Camille **ANTOLIN***
*Co-Author(s): Amadeo Jr **VELOSO***

Sphingosine-1-phosphate Expression in Human Epiretinal Membranes
*First Author: Sohee **JEON***

Surgical Outcomes of Vitrectomy for Advanced Stages of Retinopathy of Prematurity: A Systematic Review
*First Author: Seruni Hanna **ARDHIA***
*Co-Author(s): Andini **RAHMAWATI***

The Ability of Artificial Intelligence Chatbots ChatGPT and Google Bard to Accurately Convey Preoperative Information for Patients Undergoing Ophthalmological Surgeries
*First Author: Nikhil S. **PATIL***
*Co-Author(s): Ryan **HUANG**, Peter **KERTES**, Eli **KISILEVSKY**, Jason **KWOK***

Translational Medicine

Assessing Eligibility for a Clinical Trial of Submacular Photoreceptor Stem Cell Therapy in a Prospective Cohort of Inherited Retinal Disease Patients
*First Author: Tien-en **TAN***
*Co-Author(s): Choi Mun **CHAN**, Beau **FENNER**, Ranjana **MATHUR**, Stephen **RUSSELL**, Rachael Wei Chao **TANG***

Mechanisms of Blue Light Retinopathy in the Cell and Mouse Models
*First Author: Yi-sheng **CHANG***

VIDEOS

Eye Trauma, Emergencies & Infections

Combined Cataract Extraction with Vitrectomy in Retained Intraocular Foreign Body
*First Author: Nawazish **SHAIKH***
*Co-Author(s): Shorya **AZAD**, Avilasha **MOHAPATRA***

Direct Extraction of Metallic Intraocular Foreign Bodies from Posterior Segment Though Clear Corneal Incision in Phacovitrectomy
*First Author: Haoyu **CHEN***

Early is Better: Vitrectomy Restores Vision in Early Endophthalmitis
*First Author: Mae-lynn **BASTION***
*Co-Author(s): Ainal **ADLIN NAFFI**, Lhacha **WANGDI***

In Hindsight: Iridodialysis Repair, Pars Plana Vitrectomy, and the Yamane Technique in an Eye with Previous Blunt Trauma
*First Author: Maria Giselle **DY***
*Co-Author(s): Erika Jean **SALVAME***

The Surprises Kept Coming: My Experience with a Case of Ocular Trauma
*First Author: Obuli **N***
*Co-Author(s): Soumya **JENA**, Anuja **PATIL**, Kritika **SINGH**, Gauri **KHARE***

Intraocular Inflammation, Uveitis & Scleritis

Gone Through a Rough Patch: Deroofing the Journey of a Case of *Mycobacterium leprae* Associated Scleritis and Intercalary Staphyloma
*First Author: Vishal **JADHAV***
*Co-Author(s): Soumyava **BASU**, Jyoti **GOYAL**, Anup **KELGAONKAR***

Ocular Oncology & Pathology

Intraoperative OCT-guided Subretinal Aspiration Biopsy for Primary Vitreoretinal Lymphoma
*First Author: Vishal **RAVAL***

Pediatric Retina

Contractile Morning Glory Syndrome in a Patient
*First Author: Jinghua **LIU***

Heads-up 3-dimensional Visualization System and Integrated Intraoperative Optical Coherence Tomography in Infantile Vitreoretinal Surgeries
*First Author: Akash **BELENJE***
*Co-Author(s): Subhadra **JALALI**, Brijesh **TAKKAR***

Retina (Surgical)

A Novel Sutureless T-shaped Haptic Scleral Fixated Intraocular Lens
*First Author: Sheetal **DIVATE***
*Co-Author(s): Pushpanjali **BADOLE**, Amit **NENE**, Smitesh **SHAH**, Pratik **SHENOY***

Aniridia Scleral Fixated Intraocular Lens in Traumatic Aniridia by 2 Different Techniques
*First Author: Sheetal **DIVATE***
*Co-Author(s): Pushpanjali **BADOLE**, Amit **NENE**, Smitesh **SHAH**, Pratik **SHENOY***

Autologous Scleral Graft Technique for Refractory Optic Disc Pit Maculopathy
*First Author: Paolo Vicente **PALADIO***
*Co-Author(s): Jocelyn **SY***

Buck to the Future: Revisiting Buckling Techniques
*First Author: Jose Timothy Martin **CHUA***
*Co-Author(s): Maria Cecilia **GARCIA-ARENAL**, Janice Marie **JORDAN-YU**, Carlo **NASOL***

Deflating but not Deflated: Surgical Management of Choroidal Detachment
*First Author: Adrian **FUNG***
*Co-Author(s): Eduardo **RODITI***

Double Trouble: Contemporaneous Management of Dislocated Lens and Retinal Detachment in Marfan Syndrome Brothers
*First Author: Harsh **JAIN***
*Co-Author(s): Mounika **BOLISETTY**, Subhasree **DUTTA**, Aditya **KELKAR***

Double Trouble: Recurrent Retinal Detachment with PVR and Macular Hole
*First Author: Shishir **VERGHESE***

Giant Retinal Tear with Severe Proliferative Vitreoretinopathy
*First Author: Bhuvan **CHANANA***

Low-cost Illuminated Scleral Indentor
*First Author: Wilson **WONG***

Macular Buckling Through Ab Externo Approach for Repair of Myopic Traction Maculopathy
*First Author: Joy Sheril **VILLAFLOR***

Management of Complicated Rhegmatogenous Retinal Detachment Associated with Choroidal Detachment, Hypotony, and Giant Retinal Tear
*First Author: Rajiv **GANDHI***

Management of Retinal Detachment in Pathologic Myopia and Nanophthalmos
*First Author: Vishal **AGRAWAL***

Membrane Dissection and Removal with PFCL Assistance in Diabetic Vitrectomy
*First Author: Bhuvan **CHANANA***

Modified Surgical Technique for Lamellar Macular Holes with Lamellar Hole–associated Epiretinal Proliferation
*First Author: Kshitiz **KUMAR***

Nightmare Alley
*First Author: Aditya **KELKAR***
*Co-Author(s): Mounika **BOLISETTY**, Apoorva **JADHAV**, Harsh **JAIN**, Sukanya **MONDAL***

Novel Indication for the Innovative Technique of Glue-assisted Retinopexy for Rhegmatogenous Retinal Detachment Surgery in Recurrent Detachment with Proliferative Vitreoretinopathy
*First Author: Anjali **MAHESHWARI***
*Co-Author(s): Subhadra **JALALI**, Mudit **TYAGI***

Pars Plana Vitrectomy for Live Vitreous Cysticercus Cyst with Retinal Detachment
*First Author: Ayushi **SINHA***
*Co-Author(s): Sushil **KUMAR***

Posterior Pole Rhegmatogenous Retinal Detachment in a Pathologic Myopic Patient
*First Author: Wilson **WONG***

SFIOL Implantation in Complicated Surgical Scenarios
*First Author: Gaurang **SEHGAL***
*Co-Author(s): Poornachandra **B**, Ayushi **CHOUDHARY**, Nikhil **GOPALAKRISHNAN**, Aishwarya **JOSHI***

Subfoveal Cysticercosis: The Curse of the White Pearl!
*First Author: Veer **SINGH***
*Co-Author(s): Arjan **SINGH**, Preetam **SINGH***

Subretinal Gliosis Removal: An Unconventional Surgical Approach
*First Author: Naresh **KANNAN***
*Co-Author(s): Avik **DEY SARKAR**, Muthukrishnan **VALLINAYAGAM***

Subretinal Hemorrhage Evacuation for Hemorrhagic Retinal Detachment Due to PCV
*First Author: Nishant **RADKE***
*Co-Author(s): Snehal **RADKE***

Surgical Approach to Bilateral Stage 4A Retinopathy of Prematurity
*First Author: Katrina Beatrize **MANAS-LIM***
*Co-Author(s): Gregory Francis **GERMAR***

Surgical Approach to a Combination of Tractional Retinal Detachment, Foveoschisis, and Lamellar Hole Secondary for Ocular Toxocariasis
*First Author: Peter Vincent **CO***

Surgical Nuances in Management of Intraocular Cysticercosis
*First Author: Nawazish **SHAIKH***
*Co-Author(s): Shorya **AZAD**, Akshaya **BALAJI***

Tale of a Stubborn Macular Hole
*First Author: Aditya **KELKAR***
*Co-Author(s): Mounika **BOLISETTY**, Subhasree **DUTTA**, Harsh **JAIN***

The Graft Craft for Macular Hole
*First Author: Gaurang **SEHGAL***
*Co-Author(s): Nagesha **CHOKKAHALLI**, Ayushi **CHOUDHARY**, Nikhil **GOPALAKRISHNAN**, Chaitra **JAYADEV***

The Rescue Needle
*First Author: Harshal **SAHARE***
*Co-Author(s): Ravi Shankar H **N***

Tractional Retinal Detachment: The Unveiling
*First Author: Harsh **JAIN***
*Co-Author(s): Subhasree **DUTTA**, Aditya **KELKAR***

Unraveling the Funnel: Tips on Managing Closed Funnel Retinal Detachment
*First Author: Ayushi **CHOUDHARY***
*Co-Author(s): Poornachandra **B**, Nikhil **GOPALAKRISHNAN**, Aishwarya **JOSHI**, Priyanka **GANDHI***

Visualizing the Obscure: Chromophore-assisted Retinal Break Detection
*First Author: Shishir **VERGHESE***

Vitrectomy in Retinopathy of Prematurity
*First Author: Rajiv **GANDHI***

When the Cornea Goes Brittle, Our Resolve Goes Hard
*First Author: Obuli **N***
*Co-Author(s): Soumya **JENA**, Mahipal **SACHDEV**, Pranita **SAHAY**, Gauri **KHARE***

"When you cannot eat it, bury it": An Unorthodox Surgical Approach for Fibrotic Subfoveal Choroidal Neovascular Membrane
*First Author: Naresh **KANNAN***
*Co-Author(s): Avik **DEY SARKAR**, Muthukrishnan **VALLINAYAGAM***

SPONSORSHIP

PACKAGE SPONSORS

Diamond Sponsors

BAYER

Roche

Platinum Sponsor

ZEISS

Seeing beyond

Silver Sponsors

Alcon

BAUSCH + LOMB
See better. Live better.

Nikon

optos

TOPCON Healthcare
SEEING EYE HEALTH DIFFERENTLY

Bronze Sponsors

康弘药业 KANGHONG PHARMACEUTICAL

NOVARTIS

EXHIBITION

The exhibition is held in Hall 5F, 5/F, Hong Kong Convention and Exhibition Centre. Please take the opportunity to visit our exhibitors who have supported the 16th APVRS in showcasing the latest products and services.

EXHIBITION OPENING TIMES

Dec 8, 2023 (Fri)	08:30 – 18:30
Dec 9, 2023 (Sat)	08:30 – 18:30
Dec 10, 2023 (Sun)	08:30 – 15:30

EXHIBITION FLOOR PLAN

EXHIBITOR DIRECTORY

	BOOTH NUMBER
DIAMOND SPONSORS	
Bayer	S2
Roche	S1
PLATINUM SPONSOR	
ZEISS	S8
SILVER SPONSORS	
Alcon	S3
Bausch + Lomb	S5
Nikon / Optos	S6
Topcon	S4
BRONZE SPONSORS	
Kanghong	Tea Break Stations
Novartis	S7
EXHIBITORS	
Affamed Therapeutics	B11
Arctic Vision	B05
Baishun Medical Instrument Factory	B16
BRUMABA	B36
ChongQing Sunkingdom Medical Instruments Co., Ltd	B02 B06
Clinico Instrument	B01
DORC	B41
Far Vision Technology	B33
Fubi	B20
Gauss Infomed	B23
Global Vision HongKong Limited	B15
Heidelberg Engineering	B04 B08 B12
Hong Kong Feat In Technology	B19
Hongda Medical Equipment	B43
iAlphaMed	B27
Intalight	B32 B37 B39
Leica Microsystems	B34
Loyal Tech	B28
Lumibird Medical	B31
MedOne Surgical	B30
Newtech	B38
OCULUS	B22

	BOOTH NUMBER
EXHIBITORS	
Olleyes	B42
Reich Pharm	B10 B18
RUMEX	B14
Santen	B35
Skyview	B13 B21 B29
Vita Company	B03 B07
ZP Therapeutics	B26
SOCIETIES	
APAO	B09
APVRS 2024 Singapore	B24
COHK HKOS	B40
MEDIA	
Media MICE	B17 B25

SPONSORED SESSIONS

Time	Company Name	Theme	Venue
Dec 8, 2023 (Fri)			
12:30 - 13:30	Bayer	Bayer Lunch Symposium 1: Aflibercept: Achieving Optimal Outcomes in Retinal Diseases	Hall 5G
	Roche	Roche Lunch Symposium 1: nAMD: Change in Treatment Paradigm for nAMD with faricimab: Evidence from Clinical Trials and Real World Practice	S421
	ZEISS	ZEISS Lunch Symposium: ZEISS Retina Workflow Lunch Symposium	S426 – S427
	Topcon	Topcon Lunch Symposium: Wider Applications of Retina Imaging and Treatment	S423 – S424
Dec 9, 2023 (Sat)			
12:30 - 13:30	Bayer	Bayer Lunch Symposium 2: Maximizing Patient Outcomes in nAMD, and Can We Go Further with Disease Control?	S421
	Roche	Roche Lunch Symposium 2: DME: Change in Treatment Paradigm for DME with faricimab: Evidence from Clinical Trials and Real World Practice	Hall 5G
	Alcon	Alcon Lunch Symposium 1: Modern Approach to Vitrectomy Surgery	S426 – S427
	Nikon/Optos	Nikon/Optos Lunch Symposium: Advances in Ultra-widefield Multimodal Retinal Imaging	S423 – S424
Dec 10, 2023 (Sun)			
12:30 - 13:30	Alcon	Alcon Lunch Symposium 2: Alcon Vision Suite: Complete, Connected Care for VR Surgeons	S426 – S427
	Novartis	Novartis Lunch Symposium: From Past to Present: The Evolution of Retinal Disease Therapy	S423 – S424

Visudyne®

verteporfin for injection

Name of the medicinal product: Visudyne 15 mg powder for solution for infusion
Qualitative and quantitative composition: Each vial contains 15 mg of verteporfin. After reconstitution, 1 ml contains 2 mg of verteporfin. 7.5 ml of reconstituted solution contains 15 mg of verteporfin. **Indications:** Visudyne is indicated for the treatment of • Adults (including the elderly [≥65 years old]) with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or • Adults (including the elderly [≥65 years old]) with subfoveal choroidal neovascularisation secondary to pathological myopia **Posology:** Visudyne photodynamic therapy (PDT) is a two-step process: • The first step is a 10-minute intravenous infusion of Visudyne at a dose of 6 mg/m² body surface area, diluted in 30 ml infusion solution • The second step is the light activation of Visudyne at 15 minutes after the start of the infusion. Patients should be re-evaluated every 3 months. In the event of recurrent CNV leakage, Visudyne therapy may be given up to 4 times per year. **Contraindications:** • Hypersensitivity to the active substance or to any of the excipients • Patients with porphyria and in patients with severe hepatic impairment **Precautions:** • Photosensitivity and exposure to light • Patients who receive Visudyne will become photosensitive for 48 hours after the infusion. • During that period, patients should avoid exposure of unprotected skin, eyes or other body organs to direct sunlight or bright indoor light such as tanning salons, bright halogen lighting, or high power lighting in surgery operating rooms or dental surgeries. Prolonged exposure to light from light-emitting medical devices such as pulse oximeters should also be avoided for 48 hours following Visudyne administration. Ambient indoor light is safe. Patients should not stay in the dark and should be encouraged to expose their skin to ambient indoor light. • Use in patients with moderate hepatic impairment or biliary obstruction. Visudyne therapy should be considered carefully in patients with moderate hepatic impairment or biliary obstruction since no experience has been gained in these patients. Since verteporfin is excreted primarily via the biliary (hepatic) route, increased verteporfin exposure is possible. • Risk of severe decrease of vision. Patients who experience a severe decrease of vision (equivalent to 4 lines or more) within one week after treatment should not be re-treated, at least until their vision has completely recovered to pre-treatment level and the potential benefits and risks of subsequent treatment have been carefully considered by the treating physician. • Extravasation of the solution for infusion. Extravasation of Visudyne, especially if the affected area is exposed to light, can cause severe pain, inflammation, swelling, blistering or discoloration at the injection site. The relief of pain may require analgesic treatment. If extravasation occurs, infusion should be stopped immediately. Protect the affected area thoroughly from bright direct light until swelling and discoloration have disappeared, and put cold compresses on the injection site. To avoid extravasation, a free-flowing intravenous line should be established before starting Visudyne infusion and the line should be monitored. The largest possible arm vein, preferably the antecubital, should be used for the infusion and small veins in the back of the hand should be avoided. • Hypersensitivity reactions. Chest pain, vasovagal reactions and hypersensitivity reactions related to Visudyne infusion have been reported. Both vasovagal and hypersensitivity reactions are associated with general symptoms such as syncope, sweating, dizziness, rash, dyspnoea, flushing, and changes in blood pressure and heart rate. On rare occasions these reactions may be severe, and potentially include convulsions. Patients should be under close medical supervision during the Visudyne infusion. • Anaesthesia. There are no clinical data on the use of Visudyne in anaesthetised patients. Patients should be under close medical supervision during the Visudyne infusion and caution should be exercised when Visudyne treatment under general anaesthesia is considered. **Adverse events:** The most frequently reported adverse reactions to Visudyne (verteporfin for infusion) are injection site reactions (including pain, oedema, inflammation, extravasation, rashes, haemorrhage, discolouration) and visual impairment (including blurred, fuzzy vision, photopsia, reduced visual acuity and visual field defects, including scotoma and black spots).
Before prescribing, please consult the full prescribing information.

HK-PM-CHEPLA-VISUDY-IDA-HCP-000003

ZP THERAPEUTICS
making healthcare more accessible

ZP Therapeutics, a division of Zuellig Pharma limited,
a company incorporated in Hong Kong with its registered address at
5/F, Berkshire House, 25 Westlands Road, Quarry Bay, Hong Kong
Tel: 852 28563632 Website: www.zuelligpharma.com

SAVE THE DATE

17th APVRS CONGRESS

Asia-Pacific Vitreo-Retina Society

22 - 24 November 2024

Suntec Singapore Convention and Exhibition Centre

TRANSFORMING RETINAL DISEASE MANAGEMENT WITH TECHNOLOGY

HOSTS:

apvrs

College of Ophthalmologists, Academy of Medicine, Singapore

Singapore Society of Ophthalmology

NW500

Robotic Fundus Imaging

Small Pupil Photography

ϕ2.0mm* or More

*Confirmed with model eyes

A.Cataract, Peripheral Drusen

B.Cataract, φ2mm Small Pupil

C.Retinal Hemorrhage

D.Diabetic Retinopathy (DR)

E.Glaucoma

Triton

Multimodal Swept-Source OCT

A New Frontier in OCT Imaging



F





G

Learn more at Topcon Booth S4

TOPCON Healthcare

IRIDEX®

A, B: Courtesy of Silicon Valley Eyecare Optometry and Contact Lenses in Santa Clara, CA.
C, D, E: Courtesy: Department of Technology and Design Thinking for Medicine, Hiroshima Univ. Endowed Chair, Hitoshi Tabuchi, M.D.,Ph.D., EMBA
F: Courtesy: Yuichiro Ogura, MD, Professor and Chairman, Department of Ophthalmology and Visual Science, Nagoya City University, Nagoya, Japan
G: Courtesy: Professor Jose Maria Ruiz Moreno, (Universidad de Castilla-La Mancha).